CN114502151A - 抗cd19抗体及其使用和制备方法 - Google Patents

抗cd19抗体及其使用和制备方法 Download PDF

Info

Publication number
CN114502151A
CN114502151A CN202180005432.XA CN202180005432A CN114502151A CN 114502151 A CN114502151 A CN 114502151A CN 202180005432 A CN202180005432 A CN 202180005432A CN 114502151 A CN114502151 A CN 114502151A
Authority
CN
China
Prior art keywords
ser
gly
leu
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180005432.XA
Other languages
English (en)
Other versions
CN114502151B (zh
Inventor
苏米里·查特吉
丹尼斯·R·古利特
安德鲁·韦特
麦雅丝
贾汉·哈利利
朱义
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Bailidote Biological Pharmaceutical Co ltd
Original Assignee
Sichuan Baili Pharmaceutical Co Ltd
Seattle Immunization Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Baili Pharmaceutical Co Ltd, Seattle Immunization Co filed Critical Sichuan Baili Pharmaceutical Co Ltd
Publication of CN114502151A publication Critical patent/CN114502151A/zh
Application granted granted Critical
Publication of CN114502151B publication Critical patent/CN114502151B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

一种对人CD19具有结合特异性的分离的单克隆抗体(mAb)或其抗原结合片段，其中分离的mAb或抗原结合片段包含与选自SEQ ID NO.1、3、5、7、9、11、13、15、17、19、21、23、91或93的序列具有同一性的氨基酸序列，其中同一性不小于95％。

Description

抗CD19抗体及其使用和制备方法
相关申请的交叉引用
根据35U.S.C.119(e)，本申请要求2020年3月3日提交的美国临时申请序列号62/984,731的优先权，其全部公开内容通过引用并入本文。
技术领域
本公开一般涉及生物治疗技术领域，更具体地涉及制备和使用多特异性抗体。
背景技术
淋巴瘤占美国每年诊断的所有癌症的4.3％，B细胞恶性肿瘤占所有淋巴瘤诊断的约90％。CD19是在不同分化阶段由B淋巴细胞表达的免疫球蛋白超家族的B淋巴细胞特异性成员，从V(D)J重排开始直到B细胞成熟为浆细胞，此时CD19的表面表达似乎丧失。虽然CD19广泛用作泛B细胞标志物，但发现CD19在许多形式的白血病和淋巴瘤中高度表达，具有B细胞起源的特征。30多年来，CD19一直是免疫疗法发展的焦点。制药公司正在积极地追求抗CD19策略，因为它们有希望直接靶向对应于早期B细胞分化阶段的那些B细胞恶性肿瘤。靶向CD19已被批准为一种优异的免疫治疗策略，特别是当靶向CD22(由B细胞恶性肿瘤表达的另一种泛B细胞标志物)的抗体治疗不成功时。
CD19是正常B细胞和B细胞起源癌症的重要细胞表面标志物。因此，非常希望有一种靶向CD19的抗体用于抗癌治疗。文献中的报道表明，难以鉴定也与食蟹猴中发现的CD19交叉反应的抗CD19抗体，这一特性极大地促进了治疗药理学和毒理学研究。历史抗体BU12已经显示具有对人CD19的高亲和力和对食蟹猴CD19的交叉反应性，然而该抗体是从小鼠杂交瘤中发现的并且不包含人框架序列。因此，BU12的人源化变体对于治疗用途是高度理想的。
发明内容
本申请提供了抗CD19肽、蛋白质、蛋白质复合物、抗体及其制备和使用方法。
在一个方面，本申请提供了对人CD19具有结合特异性的肽。在一个实施方案中，该肽具有与SEQ ID NO.1、3、5、7、9、11、13、15、17、19、21、23、91或93具有至少70％、80％、85％、90％、95％、97％、98％或99％的序列同一性的氨基酸序列。
在一个实施方案中，该肽为scFv肽。在一个实施方案中，scFv肽可具有对人CD19的结合亲和力，KD不大于1nM、2nM、3nM、5nM、10nM、15nM、20nM、30nM、40nM或50nM。
在一个方面，本申请提供了对人CD19具有结合特异性的抗体或其抗原结合片段。在一个实施方案中，分离的抗体或抗原结合片段包含与SEQ ID NO.1、3、5、7、9、11、13、15、17、19、21、23、91或93具有至少70％、80％、85％、90％、95％、97％、98％或99％的序列同一性的氨基酸序列。在一个实施方案中，抗体包括分离的单克隆抗体(mAb)。
在一个实施方案中，抗体为双特异性抗体。在一个实施方案中，抗体为多特异性抗体。在一个实施方案中，抗体为三特异性抗体、四特异性抗体、五特异性抗体或六特异性抗体。
在一个实施方案中，抗体包括scFv，其中scFv包含与SEQ ID NO.1、3、5、7、9、11、13、15、17、19、21、23、91或93具有至少70％、80％、85％、90％、95％、97％、98％或99％的序列同一性的氨基酸序列。
在一个实施方案中，抗体包括Fab，其中Fab包含与SEQ ID NO.1、3、5、7、9、11、13、15、17、19、21、23、91或93具有至少70％、80％、85％、90％、95％、97％、98％或99％的序列同一性的氨基酸序列。
在一个实施方案中，本申请提供了一种多特异性抗体样蛋白。在一个实施方案中，蛋白质包含肽，该肽具有与SEQ ID NO.1、3、5、7、9、11、13、15、17、19、21、23、91或93具有至少70％、80％、85％、90％、95％、97％、98％或99％的序列同一性的氨基酸序列。在一个实施方案中，多特异性抗体样蛋白具有N-末端和C-末端，从N-末端到C-末端依次包含N-末端的第一结合结构域(D1)、包含轻链部分的第二结合结构域(D2)、Fc区、第三结合结构域(D3)和C-末端的第四结合结构域(D4)。轻链部分包含共价连接到C-末端的第五结合结构域(D5)、共价连接到N-末端的第六结合结构域(D6)或两者，且D1、D2、D3、D4、D5和D6各自对肿瘤抗原、免疫信号传导抗原或其组合具有结合特异性。
在一个实施方案中，多特异性抗体样蛋白为五特异性的。在一个实施方案中，抗体样蛋白包含包括D1、D2、D3、D4和D6的结合结构域。
在一个实施方案中，多特异性抗体样蛋白为六特异性的。
在一个实施方案中，D1包含肽，该肽包含与SEQ ID NO.1、3、5、7、9、11、13、15、17、19、21、23、91或93具有至少70％、80％、85％、90％、95％、97％、98％或99％的序列同一性的氨基酸序列。
在一个实施方案中，D1包含肽，该肽具有与SEQ ID NO.7或19具有95％的序列同一性的氨基酸序列。
在一个实施方案中，D2包含肽，该肽具有与SEQ ID NO.1、3、5、7、9、11、13、15、17、19、21、23、91或93具有至少70％、80％、85％、90％、95％、97％、98％或99％的序列同一性的氨基酸序列。
在一个实施方案中，D2包含肽，该肽具有与SEQ ID NO.91或93具有95％的序列同一性的氨基酸序列的肽。
在一个实施方案中，D6包含肽，该肽具有与SEQ ID NO.1、3、5、7、9、11、13、15、17、19、21、23、91或93具有至少70％、80％、85％、90％、95％、97％、98％或99％的序列同一性的氨基酸序列。
在一个实施方案中，D6包含肽，该肽具有与SEQ ID NO.7或19具有95％的序列同一性的氨基酸序列。
在一个实施方案中，本申请提供了多特异性单克隆抗体，其包含如本文要求保护的多特异性抗体样蛋白。
在一个实施方案中，多特异性单克隆抗体可具有对人CD19的结合亲和力，Kd不大于1nM、5nM、10nM、20nM、30nM、40nM或50nM。
在一个实施方案中，抗体为人抗体。在一个实施方案中，多特异性单克隆抗体为IgG。
在一个实施方案中，本申请提供了分离的核酸，其编码分离的mAb或抗原结合片段、IgG1重链、κ轻链、可变轻链或可变重链，如本文所公开的。
在一个方面，本申请提供了编码本文公开的多特异性单克隆抗体的氨基酸序列的分离的核酸序列。
在一个实施方案中，本申请提供了包含如本文公开的分离的核酸序列的表达载体。
在一个实施方案中，本申请提供了包含如其公开的核酸序列的宿主细胞。在一个实施方案中，宿主细胞为原核细胞或真核细胞。
在一个方面，本申请提供了产生抗体的方法，包括培养宿主细胞以产生抗体。
在一个方面，本申请提供了免疫缀合物。在一个实施方案中，免疫缀合物包含分离的mAb或其抗原结合片段和药物单元，其中药物单元通过接头与分离的mAb或抗原结合片段连接，并且其中接头包含选自酯键、醚键、胺键、酰胺键、二硫键、酰亚胺键、砜键、磷酸酯键、磷酯键、肽键、腙键或其组合的共价键。
在一个实施方案中，药物单元包含细胞毒性剂、免疫调节试剂、显像剂或其组合。在一个实施方案中，细胞毒性剂选自生长抑制剂或来自一类微管蛋白结合剂、DNA嵌入剂、DNA烷化剂、酶抑制剂、免疫调节剂、抗代谢剂、放射性同位素或其组合的化学治疗剂。在一个实施方案中，细胞毒性剂选自卡奇霉素(calicheamicin)、喜树碱、奥唑米星(ozogamicin)、一甲基澳瑞他汀E(monomethyl auristatin E)、曲妥珠单抗(emtansine)、其衍生物或组合。
在一个实施方案中，免疫调节试剂激活或抑制免疫细胞、T细胞、NK细胞、B细胞、巨噬细胞或树突细胞。在一个实施方案中，显像剂可以是放射性核素、荧光剂、量子点或其组合。
在一个方面，本申请提供了药物组合物。在一个实施方案中，药物组合物包含分离的mAb或其抗原结合片段和药学上可接受的载体。在一个实施方案中，药物组合物还可包括化学治疗剂、生长抑制剂、来自一类卡奇霉素、抗有丝分裂剂、毒素、放射性同位素、治疗剂或其组合的细胞毒性剂。
在一个方面，本申请提供了药物组合物，其包含本文公开的免疫缀合物和药学上可接受的载体。
在一个方面，本申请提供了治疗患有癌症的受试者的方法。在一个实施方案中，该方法包括向受试者施用有效量的分离的mAb或其公开的抗原结合片段。在一个实施方案中，该方法还可包括共施用有效量的治疗剂，其中治疗剂包括抗体、化学治疗剂、酶或其组合。在一个实施方案中，受试者为人。
在另一个方面，本申请提供了包含有效浓度的如本文公开的多特异性单克隆抗体的溶液。在一个实施方案中，该溶液是受试者的血浆。
附图说明
结合附图，根据以下描述和所附权利要求，本公开的前述和其他特征将变得更加显而易见。应当理解的是，这些附图仅描绘了根据本公开布置的若干实施例并且因此不应被认为是对其范围的限制，将通过使用附图以附加的特征和细节来描述本公开，其中：
图1显示了人源化BU12、H4(1A中κ轻链的Vk、1B中重链的VH)和H5(1C中κ轻链的Vk、1D中重链的VH)的可变区中从小鼠序列(灰色线)到人源化框架(黑色线)的人性化评分(humanness scores)(Z评分)的增加；
图2显示了人源化小鼠BU12(H1-H6和H7)和人抗体(21D4)的可变区(2A中轻链的VL和2B中重链的VH)的序列比对；
图3显示了SI-63C1(BU12-嵌合)、SI-63C2(人源化BU12，H1)和SI-34C1(人抗体，21D4)的DLS热稳定性；
图4显示了描述SI-63C2抗体对人、食蟹猴和恒河猴CD20+B细胞(4A)和CD20-淋巴细胞(4B)的交叉反应性的直方图；
图5显示了与其亲本对照(SI-63C1)和小鼠抗人CD19抗体对照(SJ25C、LT19、HIB19和4G7)相比，SI-63C2抗体结合人(5A)、食蟹猴(5B)和恒河猴(5C)CD20+淋巴细胞的剂量-反应曲线；
图6显示了SI-63R1(H1)、蛋白A纯化的重组抗CD19 scFv-HIS蛋白(6A)和SI-63R1(H1)的DLS热稳定性的分析性SEC图，解折叠温度为约58.8℃(6B)；
图7显示了蛋白A纯化的重组抗CD19 scFv-单Fc蛋白(H1至H6)与90％目的蛋白(POI)的分析性SEC图；
图8描绘了包含核心Fab(D2)和Fc区的六特异性GNC抗体中的六个结合结构域(D1-D6)以及重链(HC)上的另外的D1、D3和D4和轻链上的D5和D6的示意图；
图9显示了三种六特异性GNC抗体SI-77H3、SI-77H6和SI-55H11的表达和纯化，它们的人源化抗CD19结构域分别为D1处的H4、D2处的H7(Fab)和D6处的H4；
图10显示了抗体(分别为SI-38E17、SI-55H11、SI-77H3和SI-77H6)对人(10A)或食蟹猴(10B)PBMC的直接细胞毒性(ADCC)的剂量-反应曲线；以及
图11显示了六特异性抗体如SI-77H、SI-77H6和SI-55H11的人源化CD19结合结构域介导仅表达CD19但不表达其他肿瘤抗原(11A)的Raji淋巴瘤细胞的细胞溶解，其具有与SI-38E17(人抗CD19抗体(21D4)(11B))相当的有效剂量-反应曲线。
具体实施方式
在下面的详细描述中，参考了构成其一部分的附图。在附图中，除非上下文另有规定，否则相似的符号通常标识相似的组件。在详细描述、附图和权利要求中描述的说明性实施方案并不意味着是限制性的。在不脱离本文所呈现的主题的精神或范围的情况下，可利用其他实施方案，且可作出其他改变。将容易理解的是，如本文中一般性描述的以及在附图中示出的本公开的方面可以以各种各样的不同配置来布置、替换、组合、分离和设计，所有这些在本文都是明确地预期的。
本公开尤其提供了分离的抗体；制备此类抗体的方法；由此类抗体或抗原结合片段组成的单克隆和/或重组单特异性抗体、多特异性抗体、抗体-药物缀合物和/或免疫缀合物、含有该抗体、单克隆和/或重组单特异性抗体、多特异性抗体、抗体-药物缀合物和/或免疫缀合物的药物组合物、制备抗体和组合物的方法；以及使用本文公开的抗体和组合物治疗癌症的方法。具体地，本公开提供了对人CD19具有结合特异性的分离的单克隆抗体(mAb)或其抗原结合片段(表1)，其中分离的mAb或抗原结合片段包含与选自SEQ ID NO.1、3、5、7、9、11、13、15、17、19、21、23、91或93的序列具有同一性的氨基酸序列。
除非上下文不合适，否则本文所用的术语“一”、“一个”和“该”被定义为意指“一个或多个”并且包括复数。
本文所用的术语“多肽”、“肽”和“蛋白质”是可互换的，并且定义为是指由通过肽键连接的氨基酸组成的生物分子。
术语“抗原”是指可以在生物体，特别是动物，更特别是包括人在内的哺乳动物中诱导免疫应答的实体或其片段。该术语包括免疫原及其负责抗原性或抗原决定簇的区域。
术语“抗原或表位结合部分或片段”、“可变区”、“可变区序列”或“结合结构域”是指能够结合抗原(如本申请中的CD19)的抗体片段。这些片段可具有完整抗体的抗原结合功能和其他功能。结合片段的实例包括但不限于单链Fv片段(scFv)，其由通过合成接头连接在单个多肽链中的抗体的单臂的可变轻链(VL)和可变重链(VH)结构域组成；或Fab片段，其为由VL、恒定轻链(CL)、VH和恒定重链1(CH1)结构域组成的单价片段。抗体片段可以是甚至更小的亚片段，并且可以由小至单个CDR结构域的结构域组成，特别是来自VL和/或VH结构域的CDR3区(例如参见Beiboer等人，J.Mol.Biol.296:833-49(2000))。使用本领域技术人员已知的常规方法产生抗体片段。可以使用与完整抗体所用的相同技术筛选抗体片段的效用。
“抗原或表位结合部分或片段”、“可变区”、“可变区序列”或“结合结构域”可通过许多本领域已知的技术衍生自本公开的抗体。例如，纯化的单克隆抗体可以用酶如胃蛋白酶裂解，并进行HPLC凝胶过滤。木瓜蛋白酶消化抗体产生两个相同的抗原结合片段，称为“Fab”片段，每个片段具有单一抗原结合位点，和残余的“Fc”片段，其名称反映了其容易结晶的能力。胃蛋白酶处理产生了具有两个抗原结合位点且仍能够交联抗原的F(ab′)2片段。然后收集含有Fab片段的适当级分并通过膜过滤等进行浓缩。关于分离抗体活性片段的一般技术的进一步描述，参见例如，Khaw,B.A.等人，J.Nucl.Med.23:1011-1019(1982)；Rousseaux等人，Methods Enzymology,121:663-69,Academic Press,1986。
术语“抗体”以最广泛的含义使用，并且具体地涵盖单一单克隆抗体和/或重组抗体(包括激动剂和拮抗剂抗体)、具有多表位特异性的抗体组合物、以及抗体片段如Fab、F(ab′)2和Fv，只要它们表现出所需的生物活性。在一些实施方案中，抗体可以为单克隆、多克隆、嵌合、单链、多特异性或多效、人和人源化抗体、以及其活性片段。结合已知抗原的活性片段分子的实例包括Fab、F(ab′)2、scFv和Fv片段，包括Fab免疫球蛋白表达文库的产物和任何上述抗体和片段的表位结合片段。
术语“Fv”是指含有完整抗原识别和结合位点的最小抗体片段。该区域由紧密、非共价结合的一个重链和一个轻链可变结构域的二聚体组成。正是在这种构型中，每个可变区的三个CDR相互作用以限定VH-VL二聚体表面上的抗原结合位点。这六个CDR共同赋予抗体抗原结合特异性。然而，即使单个可变结构域(或仅包含三个抗原特异性CDR的Fv的一半)也具有识别和结合抗原的能力，尽管亲和力低于整个结合位点。
在一些实施方案中，抗体可包括免疫球蛋白分子和免疫球蛋白分子的免疫活性部分，即含有结合位点并且免疫特异性结合抗原的分子。典型的抗体是指通常包含两条重(H)链和两条轻(L)链的异四聚体蛋白。每条重链由重链可变结构域(缩写为VH)和重链恒定结构域组成。每条轻链由轻链可变结构域(缩写为VL)和轻链恒定结构域组成。来自任何脊椎动物物种的抗体(免疫球蛋白)的轻链可以根据其恒定结构域的氨基酸序列归属于两种明显不同的类型中的一种，称为κ和λ。VH和VL区可进一步细分为高变互补决定区(CDR)的结构域和称为框架区(FR)的更保守的区域。每个可变结构域(VH或VL)通常由三个CDR和四个FR组成，按以下顺序排列：从氨基末端到羧基末端的FR1、CDR1、FR2、CDR2、FR3、CDR3、FR4。在轻链和重链的可变区内有与抗原相互作用的结合区。
根据其重链恒定结构域的氨基酸序列，免疫球蛋白可分为不同的类别。有五大类免疫球蛋白：IgA、IgD、IgE、IgG和IgM，以及其中的几种可以进一步分成亚类(同种型)，例如IgG-1、IgG-2、IgG-3和IgG-4；IgA-1和IgA-2。对应于不同类别免疫球蛋白的重链恒定区分别称为α、δ、ε、γ和μ。不同类型免疫球蛋白的亚单位结构和三维构型是众所周知的。
本文所用的术语“单克隆抗体”是指从基本上同质的抗体群体获得的抗体，即，包含该群体的个体抗体是相同的，除了可能以少量存在的可能天然发生的突变。单克隆抗体是高度特异性的，针对单一抗原位点。此外，与通常包括针对不同决定簇(表位)的不同抗体的常规(多克隆)抗体制剂相反，每种单克隆抗体针对抗原上的单一决定簇。除了它们的特异性之外，单克隆抗体的优点在于它们由杂交瘤培养物合成，不被其他免疫球蛋白污染。修饰语“单克隆”表示从基本上同质的抗体群体获得的抗体的特征，并且不应解释为需要通过任何特定方法产生抗体。例如，根据本公开使用的单克隆抗体可以通过Kohler&Milstein,Nature,256:495(1975)首次描述的杂交瘤方法制备，或者可以通过重组DNA方法制备(参见，例如，美国专利No.4,816,567)。“重组”是指使用重组核酸技术在外源宿主细胞中产生抗体。
单克隆抗体可使用各种方法产生，包括但不限于小鼠杂交瘤、噬菌体展示、重组DNA、直接来自原代B细胞的抗体的分子克隆和抗体发现方法(参见Siegel，Transfus.Clin.Biol.2002；Tiller，New Biotechnol.2011；Seeber等人，PLOS One.2014)。单克隆抗体可包括“嵌合”抗体(免疫球蛋白)，其中重链和/或轻链部分的一部分与衍生自特定物种或属于特定抗体类别或亚类的抗体中的相应序列相同或同源，而链的其余部分与衍生自另一物种或属于另一抗体类别或亚类的抗体中的相应序列以及此类抗体的片段(只要它们表现出所需的生物活性)相同或同源(美国专利No.4,816,567；和Morrison等人，Proc.Natl.Acad.Sci.USA,81:6851-6855[1984])。
如本文所用，术语“多特异性”抗体表示具有至少两个结合位点的抗体，每个结合位点对抗原的表位具有结合亲和力。如本文所用，术语“双特异性、三特异性、四特异性、五特异性或六特异性”抗体表示具有2个、3个、4个、5个或6个抗原结合位点的抗体。例如，本文公开的具有5个结合位点的抗体是五特异性的，具有6个结合位点的抗体是六特异性的。
术语“制导和导航控制(guidance and navigation control，GNC)”蛋白是指能够结合至少一种效应细胞(如免疫细胞)抗原和至少一种靶细胞(如肿瘤细胞、免疫细胞或微生物细胞)抗原的多特异性蛋白。GNC蛋白可以采用包括Fab区和Fc区的抗体核心结构，其中各种结合结构域附着于抗体核心，在这种情况下，GNC蛋白也称为GNC抗体。GNC蛋白可以采用抗体样结构，在这种情况下Fv片段可以用基于非抗体的结合结构域如NKG2D、4-1BBL(4-1BB受体配体)、4-1BB的4-1BBL三聚体或受体替代。
术语“GNC抗体”是指具有能够同时结合至少一种效应细胞(例如免疫细胞)和至少一种靶细胞(例如肿瘤细胞、免疫细胞或微生物细胞)的抗体结构的GNC蛋白。如本文所用，术语“双特异性GNC、三特异性GNC、四特异性GNC、五特异性GNC或六特异性GNC”抗体表示具有2个、3个、4个、5个或6个抗原结合位点的GNC抗体，其中至少一个抗原结合位点对免疫细胞具有结合亲和力并且至少一个抗原结合位点对肿瘤细胞具有结合亲和力。在一个实施方案中，本文公开的GNC抗体具有4-6个结合位点(或结合结构域)，并且分别为四特异性GNC、五特异性GNC和六特异性GNC抗体。在一些实施方案中，GNC抗体包括抗体结合结构域(例如Fab和scFv)，而不需要在Fc区进行额外的蛋白质工程。在一个实施方案中，GNC抗体还具有保留每种靶抗原的二价的优点。此外，在一个实施方案中，GNC抗体具有导致对抗原的更高亲和力和更低解离速率的亲合力效应的优点。每种抗原的这种双价与许多多特异性平台相反，该多特异性平台对于每种靶抗原是单价的，并且因此经常失去使抗体结合如此强的有益的亲合力作用。
术语“人源化抗体”是指具有衍生自非人供体免疫球蛋白的CDR的工程抗体类型，分子的其余免疫球蛋白衍生部分衍生自一种(或多种)人免疫球蛋白。此外，可以改变框架支持残基(framework support residue)以保持结合亲和力。获得“人源化抗体”的方法是本领域技术人员熟知的(参见，例如，Queen等人份，Proc.Natl Acad Sci USA,86:10029-10032(1989)；Hodgson等人，Bio/Technology,9:421(1991))。
术语“分离的”或“纯化的”是指生物分子不含其天然存在的至少一些组分。在用于描述本文公开的各种多肽时，“分离的”或“纯化的”是指已经从其表达的细胞或细胞培养物中鉴定和分离和/或回收的多肽。通常，纯化的多肽将通过至少一个纯化步骤制备。“分离的”或“纯化的”抗体是指基本上不含具有不同抗原结合特异性的其他抗体的抗体。
术语“免疫原性的(immunogenic)”是指在人或动物中引发或增强针对免疫原性剂的抗体、T细胞或其他反应性免疫细胞或动物中的免疫应答的物质。当个体针对所施用的本公开的免疫原性组合物产生足够的抗体、T细胞和其他反应性免疫细胞以缓和或减轻待治疗的病症时，发生免疫应答。尽管免疫原性应答通常包括免疫应答的细胞(T细胞)和体液(抗体)臂，但针对治疗性蛋白质的抗体(抗药物抗体，ADA)可由IgM、IgG、IgE和/或IgA同种型组成。
术语“特异性结合(specific binding或specifically binds to)”或“对特定抗原或表位具有特异性(is specific for a particular antigen or an epitope)”是指结合与非特异性相互作用明显不同。例如，特异性结合可通过测定分子的结合与对照分子的结合的比较来测量，该对照分子通常是不具有结合活性的类似结构的分子。例如，特异性结合可通过与类似于靶标的对照分子竞争来测定。
对特定抗原或表位的特异性结合可通过例如对抗原或表位的KD为至少约10-4M、至少约10-5M、至少约10-6M、至少约10-7M、至少约10-8M、至少约10-9、或者至少约10-10M、至少约10-11M、至少约10-12M或更大的抗体来展示，其中KD是指特定抗体-抗原相互作用的解离速率。通常，特异性结合抗原的多特异性抗体相对于抗原或表位的KD是对照分子的20、50、100、500、1000、5,000、10,000或更多倍。
此外，例如，对特定抗原或表位的特异性结合可通过对抗原或表位的KA或Ka为相对于对照的表位的至少20、50、100、500、1000、5,000、10,000或更多倍的抗体来展示，其中KA或Ka是指特定抗体-抗原相互作用的缔合速率。
通过参考本文包括的具体实施方案和实施例的以下详细描述，可以更容易地理解本公开。尽管已参考本公开的某些实施方案的特定细节描述了本公开，但并不打算将此类细节视为对本公开的范围的限制。
实施例
实施例1.设计人源化抗CD19序列.
所有计算步骤均在Discovery Studio软件包(Dassault Systemes)中执行。首先使用小鼠BU12序列产生结构模型(McDonagh等人，2009)。使用隐马尔可夫模型(HMM)鉴定输入序列中的抗体框架区并将其与抗体可变结构域的数据库进行比对，并使用MODELLER软件将该比对用于构建和评分模型。通过CDRL1、CDRL2、CDRL3、CDRH1和CDRH2区与已知规范类的结构作图进行CDR环建模，并与框架相似地构建环模型。
将小鼠BU12抗体的框架区与最接近的人种系序列比对并匹配，并将CDR区复制到人序列中，但重要的结构残基(Vernier残基[Almagro和Fransson，2008])除外。通过1000步最速下降法(1000steps of Steepest Descent)计算评价预测稳定先前构建的结构模型的突变，RMS梯度公差为3，随后是共轭梯度最小化，并且基于个体和组合ΔΔG对比初始模型选择匹配常见人残基的稳定化突变。以序列H1为参照，对发现工作室进行突变稳定能量分析。H2、H3和H4形式是突变变体，其具有负的突变能量值(ΔΔG分别为-0.8、-1.5和-1.1kCal)，并且假设比H1形式更稳定。基于Abhinandan和Martin(2007)的方法，使用Abysis网络服务器测试所得人源化序列(H1，SEQ ID NO.1和13)的人性化。如图1A和1B所示，使用H4作为其轻链(Vk)和重链(VH)的实例，人源化序列显示出比相应的小鼠序列(BU12)(SEQID NO.25和27)更高的人性化评分。
此外，使用直接CDR移植方法产生人源化形式H5。将参考抗体框架突变为类似的人种系残基，并将CDR直接移植到突变的框架中以产生H5。使用得到的人源化序列H5作为建立序列，在H5框架上进行更多的突变以提高产生人源化序列(H6)的框架稳定性。基于Abhinandan和Martin(2007)的方法，使用Abysis网络服务器测试人源化序列H5(SEQ IDNO.9和21)的人性化。人源化序列显示出比小鼠序列(BU12)(SEQ ID NO.25和27)更高的人性化评分(图1C和1D)。
H1是直接源自BU12的Fab序列的可变结构域的第一种人源化形式，在C-末端具有特征氨基酸序列LEIK。如图2所示，最后三个残基(EIK)主要存在于天然存在的可变κ链，并且当特异性地位于Fab结构域中时提供稳定性。在这种情况下，在Fab位置以VTVL为末端的H4对于抗体的稳定性可能不是理想的。H7形式是修饰的H4，假设其位于Fab结构域中时可提高蛋白质稳定性(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058631/)。H7通过还原EIK以及分别通过Q至C和G至C突变在H7VL和H7VH之间引入二硫化物钉(disulfidestaple)而产生。
如图2所示，为了比较和区分这些设计的序列的优先次序，将所有人源化可变区(H1、H2、H3、H4、H5、H6和H7)与来自人抗CD19抗体21D4(Rao-Naik等人,2009)的序列进行比对。与H1的百分比同一性对于H2、H3、H4和H7是98.1％VL和99.1-100％VH，对于H5和H6是85％VL和86％VH，对于21D4是70％VL和51％VH。这些发现暗示了在抗CD19结合结构域的一级序列中显著的灵活性。
为了预测人源化抗CD19序列的免疫原性，MixMHC2pred算法(Gfeller Lab,https://github.com/GfellerLab/MixMHC2pred)用于预测小鼠和人源化(VH/VL)序列中肽的主要组织相容性复合体-II(MHC-II)结合的程度。该算法检测了给定氨基酸序列中的“核心”肽的数量，其将以足够的亲和力结合MCHII以形成T细胞表位。序列中鉴定的MHCII结合肽的数量越高，该序列包含的潜在T细胞表位越多。大量的核心肽增加了含有一些免疫原性原肽的可能性。因此，减少抗体可变区中核心肽的数目可有助于通过消除潜在的T细胞表位来减少ADA。
抗CD19可变序列通过MixMHC2pred算法作为scFv(VH-(G4S)4-VL)运行。该算法包括对多个等位基因进行评分的选项。在这种情况下，“来自每种肽的得分被认为是其在所有等位基因中的最佳百分等级”。这种评分策略允许检查序列以发现MHCII的任何等位基因的最强配体。对于抗体可变结构域的序列分析，根据序列中可以与任何MHCII等位基因结合的肽的数量计算核心肽的数量，其中得分位于相互作用的前0.2％。如表1所示，大多数人源化序列比它们的亲代小鼠序列具有更低的得分，表明了更弱的MHCII结合肽和更低的免疫原性风险。在本文中，预测与MHCII强烈结合的可变区中核心肽的总得分从小鼠序列的9降至人源化序列的5(H1至H4和H7，H5和H6无变化)。使用人性化Z评分分析算法(Abhinandan&Andrew，2007)计算轻链和重链的人性化评分。对于VH序列，H1-H4形式具有与21D4相似的人性化，而H5和H6的人性化较高，H7的人性化较低。对于VK序列，H1-H7均具有相似的人性化，略低于21D4。值得注意的是，所有人源化序列(H1-H7、VH和Vk)比原始小鼠序列具有显著更高的人性化评分(表1)。考虑到人性化和MHC-II肽结合得分，H1-H4和H7是产生人源化抗CD19抗体的候选者。
实施例2.人源化抗CD19单克隆抗体的表达
为了表征人源化轻链CDR和重链CDR以及框架区，将编码H1和其它肽的DNA序列合成为重叠片段，并克隆到分别含有C-末端人κ序列或人IgG CH1和Fc区的线性化pTT5载体(NE Builder)中，以产生mAb形式(SEQ ID NO.37和39)。还合成了21D4和小鼠(BU12)可变区的DNA序列，并克隆到分别含有C-末端人κ序列或IgG CH1和Fc区的线性化pTT5载体中，以产生嵌合mAb形式(SEQ ID NO.33、35、83和85)。使用ExpiCHO表达系统(ThermoFisher)表达含有抗体序列的质粒DNA。三种重组抗体SI-63C1(具有BU12小鼠亲本抗CD19可变序列)、SI-63C2(具有H1人源化抗CD19可变序列，也称为SI-huCD19)和SI-34C1(具有21D4人抗CD19可变序列)通过使用蛋白A亲和色谱柱(mabSelect Resin,Ge healthcare)用PBS(5X Cv)洗涤，随后用20mM甘氨酸pH 3.5洗脱而从培养上清液中纯化。所得蛋白质用100X Tris pH8.5中和并在PDB缓冲液中透析过夜。为了检查稳定性和单分散性，将纯化的抗体浓缩至1mg/ml并注入到分析HPLC(waters,column waters BEH200A 300mm柱)上。纯化的抗CD19抗体显示具有1.8-2.5％聚集物的正确大小的尖锐单分散峰(表2)。
实施例3.SI-63C2的表征
使用生物膜层干涉测技术(ForteBio OctetRED 384)测试纯化的SI-63C1、SI-63C2和SI-34C1抗体的结合亲和力。抗体与抗人Fc生物传感器结合，人CD19蛋白(R&DBiosystems Cat#9269-CD-050)在4点系列的2倍稀释液中用作分析物，最高浓度为200nM。Octet分析的结果表明SI-63C3(也称为SI-huCD19)对人CD19和食蟹猴CD19的结合亲和力分别为3.8nM和3.6nM，与2.1nM和3.8nM的人抗CD19抗体(21D4)相当。此外，SI-63C2的人源化抗CD19可变序列不仅保留了对人和食蟹猴CD19的结合特异性，而且表现出与SI-63C1(具有BU12可变序列)和SI-34C1(具有21D4可变序列)相当的结合亲和力(KD)(表2)。
为了测试SI-63C2的热稳定性，使用动态光散射，同时温度以0.5℃/min从25℃升至75℃，并且通过使用Wyatt DynaPro酶标仪III监测蛋白质(1mg/ml)的半径。如图3和表2所示，结果表明SI-63C2和SI-63C1显示出类似的解折叠温度，如通过DLS Tm测量的，其高于SI-34C1的解折叠温度。
实施例4.SI-63C2的结合特异性
由于非人灵长类动物(NHP)如食蟹猴(cynomolgus)或恒河猴(rhesus macaque)与人的相似性、可预测的代谢稳定性和历史上建立的毒性特征，目前需要它们为抗体药物开发提供风险评估数据。为了最小化NHP的使用并提高效率，抗体药物候选物应该具有高靶标特异性和交叉反应性。在这种情况下，CD19是泛B细胞标志物，并且由大多数恶性B细胞表达。CD19比CD20对B细胞发育和分化的覆盖范围更广，CD20是来自人和NHP如食蟹猴和恒河猴的淋巴细胞的另一种泛B细胞标志物。在许多小鼠抗人CD19抗体中，BU12可与来源于自食蟹猴的B淋巴细胞以较低结合亲和力交叉反应(Liu等人，2016)。
为了确定人源化是否改变交叉反应性，进行了流式细胞术。SI-63C2抗体用于结合分别来自人、食蟹猴和恒河猴的外周血单核细胞。基于前向散射和侧向散射门控淋巴细胞，随后基于前向散射信号高度和面积的比率门控单细胞。基于膜渗透性胺活性染料的排除和CD20抗体的结合水平，对存活的CD20+B细胞和CD20-淋巴细胞进行门控(克隆2H7，Biolegend)。标记抗体的结合测定为荧光缀合物发射通道的细胞群体的几何平均荧光强度(gMFI)。如图4的直方图分析所示，SI-63C2抗体结合来自人、食蟹猴和恒河猴的CD20+B细胞(4A)，但不结合它们的CD20-淋巴细胞(4B)。当一组抗CD19抗体(即，SJ25C、LT19、HIB19和4G7)用于比较时，仅SI-63C2及其亲本抗体SI-63C1显示了对来自人、食蟹猴和恒河猴的CD20+B细胞的显著结合亲和力(图5)。这些数据证实保留了SI-63C2对人、食蟹猴和恒河猴B细胞的结合特异性，然而，如通过EC50测量的，其对食蟹猴的交叉反应性仍然低于其对人CD19的响应(表3)。
实施例5.His标记的人源化抗CD19 scFv蛋白
为了将人源化抗CD19结合结构域表征为scFv单位，将编码人源化抗CD19可变区(H1)的DNA序列克隆到His标记的scFv表达载体中，该载体在scFv的C-末端含有残基GSHHHHHH(SEQ ID NO.41)。使用ExpiCHO表达系统，表达人源化抗CD19scFv-His标记的蛋白，通过蛋白L亲和层析纯化，命名为SI-63R1。来自分析性SEC的数据表明SI-63R1具有70％的目的蛋白质，并且DLS热稳定性测试测量了在58.8℃下SI-63R1的解折叠温度(图6)。
为了评估SI-63R1的结合亲和力，使用Octet结合测定。通过共价偶联将SI-63R1蛋白以10μg/ml装载到AR2G传感器上，并与His标记的人CD19的系列稀释液(由最高浓度200nM开始的1∶2.5稀释液)结合。结果显示SI-63R1对人CD19具有低纳摩尔范围的结合亲和力(表2)。
实施例6.人源化抗CD19 scFv单体Fc融合蛋白.
为了进一步筛选和比较所有人源化肽，将编码人源化CD19结合变体(H1、H2、H3、H4、H5和H6)的DNA序列构建成scFv-单体Fc形式并克隆(Dimitrov等人，2012.)(SEQ IDNO.55、57、59、61、63、65)。使用ExpiCHO表达系统，表达6种人源化抗CD19 scFv单体Fc融合蛋白中的每一种，并通过蛋白A亲和层析纯化。它们被命名为SI-63SF1(H1)、SI-63SF2(H2)、SI-63SF4(H3)、SI-63SF5(H4)、SI-63SF6(H5)和SI-63SF7(H6)。在表达和纯化过程后，对所有6种蛋白的物理性质进行表征，包括产率(滴度)、纯度(％HMW和aSEC)、对人CD19的结合亲和力(KD、Kon和Kdis)和热稳定性。对于Octet测定，通过AHC传感器以10μg/ml装载scFv-单体Fc融合蛋白，并与His标记的人CD19的系列稀释液(由最高浓度200nM开始的1∶2.5的稀释液)结合，并将得到的整体拟合至1∶1结合模型。对于DLS分析，温度0.5℃/min从25℃升至75℃，同时通过Wyatt DynaPro酶标仪III监测scFv-单体Fc融合蛋白(1mg/ml)的半径。分析性SEC曲线示于图7中，且所有测量结果列于表4中。
数据显示SI-63SF5(H4)在51.8℃具有最高的DLS熔融温度(Tm)(表4)。由于其较高的热稳定性，选择具有H4肽的人源化抗CD19可变区用于在GNC抗体平台中进一步研究。
实施例7.GNC抗体中的人源化抗CD19 scFv或Fab结构域
制导和导航控制(GNC)抗体是指能够结合由至少一种靶细胞(包括但不限于肿瘤细胞、免疫细胞或微生物细胞)表达的抗原和由至少一种效应细胞(例如免疫细胞)表达的抗原的多特异性抗体(参见申请人的申请WO/2019/005642，其全文并入本文)。GNC抗体包含Fab和Fc区的抗体结构，其具有连接于抗体核心的各种另外的结合结构域，例如一个或多个单链片段可变结构域，也称为scFv。GNC抗体能够靶向肿瘤抗原、接合免疫激活受体，并以一小部分成本指导免疫效应细胞介导的肿瘤杀伤。例如，已经显示四特异性GNC(tetra-GNC)抗体发挥了理想的多方面效应，具有结构和功能多样但相对独立的结合结构域(参见申请人的申请WO/2019/191120，其全文并入本文)。在这种情况下，人源化抗CD19可变结构域可作为Fab或scFv结构域加入到任何GNC抗体中。
为了表征GNC抗体中的人源化CD19结合结构域，将编码H4和H7的DNA序列分别在5个scFv位点和Fab位点中的一个位点进行构建并克隆到GNC抗体形式中(图8显示了构建方案)。任选将突变R19S(Kabat编号)掺入GNC轻链上含VH3的scFv的人源化(H4)VH结构域的FR1区，例如SI-55H11。当含有VH3的scFv与轻链连接时，VH结构域可以在纯化过程中与蛋白A树脂结合，导致轻链单体和二聚体污染所需的重链-轻链异四聚体。为了合理地破坏VH3家族成员的蛋白A结合，采用结构方法来破坏结合界面。晶体结构1DEE(Graille M.等人，Proc.Nat.Acad.Sci.2000.)显示VH3中的残基R19(Kabat编号)与蛋白A结构域D的两个侧链直接接触。特别地，可以消除与Q32和D36的接触以显著削弱相互作用。因此，由于其较短的侧链，其不形成这些相互作用。另外，S19天然存在于其他VH家族成员中，表明它的免疫原性可能低于其他取代物。对于每条轻链可含有至多两个VVH3 scFv的六特异性GNC抗体，这种突变在允许有效纯化所需产物方面特别重要。
表5列出了在SI-77H3的D1(SEQ ID NO.67和69)、SI-77H6的D2(Fab)(SEQ IDNO.71、73)和SI-55H11的D6(SEQ ID NO.75和77)处具有人源化CD19结合结构域H4的六特异性GNC抗体；以及在SI-38P12的D6具有人源化CD19结合结构域H4的五特异性GNC抗体。将编码这些GNC抗体的表达载体转染并在ExpiCHO系统中表达，并通过蛋白A亲和层析纯化所有GNC抗体。通过滴度和aSEC测量的产率和纯度的结果表明，具有人源化CD19结合结构域的GNC抗体可以作为scFv或Fab被表达和纯化(图9和表6)。
为了测定六特异性和五特异性GNC抗体对人CD19的结合亲和力，使用Octet结合测定。GNC抗体通过AHC传感器以10μg/ml装载，并与系列稀释液(从最高浓度200nM开始的1∶2.5的稀释液)或单一100nM浓度的His标记的人CD19结合。由此产生的与1∶1结合模型的整体拟合证明这些GNC抗体以低纳摩尔范围的亲和力结合CD19(表6)。
实施例8.人源化CD19结合结构域在GNC抗体中的位置效应
为了评价人源化CD19结合结构域介导的抗体依赖性细胞毒性，使用来自人和食蟹猴的外周血单核细胞(PBMC)。将T细胞接合子加入人或食蟹猴PBMC中并培养5天。5天后，收集培养细胞，通过FACS计数存活和非存活CD20+B细胞。对存活的单个B细胞和存活的所有B细胞(门中的单细胞、双联体细胞或其他细胞)的分析独立地进行评价。使用加标的计数珠对照来定量相对总细胞计数。在该研究中，测试的六特异性GNC抗体包括SI-77H3(D1处的H4)、SI-77H6(D2处的H7，即Fab)、SI-55H11(D6处的H4)，而对照为四特异性GNC抗体SI-38E17(SEQ ID NO.79和81)，其在Fab区(D2)具有人CD19结合结构域(21D4)(表5)。
通过FACS进行的单细胞分析倾向于缺失T细胞接合子对非溶细胞复合物形成的影响，大多数似乎落在单细胞的门外。相反，包括双联体细胞的分析覆盖更多的事件，从而提供对细胞-细胞相互作用的更完整的理解。图10显示了在存活的所有B细胞上使用门控的ADCC分析的结果。对照抗体SI-38E17显示了对人CD19但不对食蟹猴CD19的结合特异性。作为比较，所有三种六特异性GNC抗体对人和食蟹猴PBMC均显示出相似的应答。出乎意料地，SI-77H6似乎不介导对人PBMC和食蟹猴PBMC的ADCC，尽管存在人源化CD19结合亲和力(表6)。如表5所示，在SI-77H6中，人源化CD19结合结构域是抗体核心结构的Fab区，而在SI-77H3和SI-55H11中，人源化CD19结合结构域是抗体核心结构的附加scFv结构域。六特异性GNC抗体具有至少6种结合特异性，因此能够在体内同时结合至少两种不同类型的细胞，这与评估单个结合结构域的亲和力的情况不同。这种观察到的位置和效应的相关性表明存在由人源化抗CD19 Fab结构域在GNC抗体中的位置效应介导的生物学上不同的结果，并且SI-77H6可能不能支持激活的T细胞和靶B细胞之间细胞溶解性免疫突触的正确形成。由于CD19由正常B细胞和肿瘤B细胞两者表达，当为治疗不同类型的癌症(即实体瘤对液体瘤)的益处指定每个结合结构域时，定位效应可能是有用的。例如，SI-77H6样GNC抗体仍可用于治疗对正常B细胞具有较高功效但细胞毒性较低的实体瘤。在另一个实施例中，SI-77H6样GNC抗体可用于在针对其他肿瘤相关抗原的细胞溶解相互作用中帮助B细胞接合T细胞。
实施例9.具有人源化CD19结合结构域的六特异性GNC抗体的RTCC
为了证明具有人源化CD19结合结构域的六特异性GNC抗体的细胞毒性作用，使用Raji细胞进行重定向T细胞细胞毒性(RTCC)分析。淋巴母细胞样细胞的Raji系来源于伯基特淋巴瘤。由于三种六特异性GNC抗体中的每一种都能结合CD19以外的多种肿瘤抗原，如EGFR、HER3和PD-L1(表5)，表达mKate2荧光蛋白的Raji细胞用针对各肿瘤抗原的标记单克隆抗体染色，并用FACS分析。直方图结果证实Raji细胞表达CD19，并且未检测到EGFR、HER3或PD-L1的表达(图11A)。
将表达mKate2荧光蛋白的Raji细胞与人CD8T细胞以5T细胞/Raji细胞的比例在浓度为10nM-1fM的T细胞接合蛋白存在下共培养81小时，一式三份。使用Graphpad Prism 8的5参数不对称S型非线性回归和最小二乘拟合法，通过定量显微镜和剂量反应曲线对靶细胞荧光信号进行评估，作为特异性细胞溶解的量度。如图11B所示，SI-55H11(EC50，2pM)、SI-77H3(EC50，8pM)和SI-77H6(EC50，30pM)各自的人源化CD19结合结构域介导肿瘤细胞的有效细胞溶解，并且SI-55H11的效力与SI-38E17(EC50，2pM)、人抗CD19抗体(21D4)的效力相同(表6)。SI-77H6表现出次优的细胞溶解作用，效力降低，这是一种与其在没有细胞溶解诱导的情况下CD19结合正常B细胞的效应平行的现象。SI-77H3能够完全杀死肿瘤细胞，但EC50降低。因此，利用优化的构型和处理条件(例如激活的T细胞与靶细胞的比率)，所公开的人源化CD19结合结构域可以发挥与多特异性GNC抗体中的人CD19结合结构域相同的效力，其具有对食蟹猴CD19的交叉反应性的附加特征。
虽然已经参考特定实施方案或示例描述了本公开，但是可以理解，实施方案是说明性的，并且本公开的范围不限于此。本公开的替代实施方案对于本公开所属领域的普通技术人员可能变得显而易见。这样的替代实施方案被认为包含在本公开的范围内。因此，本公开的范围由所附权利要求限定并由前述描述支持。本公开中引用或提及的所有参考文献通过引用以其整体并入本文。
参考文献：
1.Watkins MP,Bartlett NL.CD19-targeted immunotherapies for treatmentof patients with non-Hodgkin B-cell lymphomas.Expert Opin InvestigDrugs.2018；27(7):601–611.doi:10.1080/13543784.2018.1492549.
2.(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058631/.)
3.McDonagh,Charlotte et.Al.CD19 Binding agents and Uses Thereof.US20090136526A1.
4.Rao-Naik et.al.CD19 Antibodies and their uses.US 20090142349 A1.
5.Dimitrov et al.2012:https://www.frontiersin.org/articles/10.3389/ fimmu.2017.01545/full.
6.(Graille M.et al.Proc.Nat.Acad.Sci.2000.)2000.)
表格
表1.分别使用MixMHC2pred和Z评分分析算法计算人源化可变结构域的总MHCII结合评分和人性化评分。
Figure BDA0003555689090000151
表2.SI-63C1(具有小鼠亲本BU12可变序列)、SI-63C2(具有H1人源化抗CD19可变序列)、SI-34C1(具有21D4人抗CD19可变序列)和SI-63R1(人源化抗CD19 scFv-His标记蛋白)的纯度、结合亲和力和热稳定性。
Figure BDA0003555689090000152
表3.通过EC50测量的重组抗体(SI-63C1和SI-63C2)和小鼠抗人CD19抗体(SJ25C、LT19、HIB19和4G7)对人、食蟹猴和恒河猴来源的CD20+淋巴细胞的交叉反应性。
Figure BDA0003555689090000153
表4人源化抗CD19 scFv单体Fc融合蛋白SI-63SF1(H1)、SI-63SF2(H2)、SI-63SF4(H3)、SI-63SF5(H4)、SI-63SF6(H5)和SI-63SF7(H6)的纯度、结合亲和力和热稳定性。
Figure BDA0003555689090000154
Figure BDA0003555689090000161
表5.人源化CD19结合结构域和其他抗原结合结构域在GNC抗体中的位置。
Figure BDA0003555689090000162
表6.具有人源化抗CD19 scFv结构域或Fab区的GNC抗体的物理和功能特性。
Figure BDA0003555689090000163
序列表
Figure BDA0003555689090000171
Figure BDA0003555689090000181
>序列ID 1:人源化形式1(H1VH)氨基酸序列
QVTLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSS
>序列ID 2:人源化形式1(H1VH)核苷酸序列
CAGGTCACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCTTCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAAAGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAAAGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTGACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTATTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGT
>序列ID 3:人源化形式2(H2VH)氨基酸序列
QVTLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSS
>序列ID 4:人源化形式2(H2VH)核苷酸序列
CAGGTCACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCTTCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAAAGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAAAGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTGACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTATTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGT
>序列ID 5:人源化形式3(H3VH)氨基酸序列
QVTLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSS
>序列ID 6:人源化形式3(H3VH)核苷酸序列
CAGGTCACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCTTCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAAAGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAAAGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTGACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTATTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGT
>序列ID 7:人源化形式4(H4VH)氨基酸序列
QVTLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSS
>序列ID 8:人源化形式4(H4VH)核苷酸序列
CAGGTCACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCTTCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAAAGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAAAGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTGACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTATTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGT
>序列ID 9:人源化形式5(H5VH)氨基酸序列
EVQLVESGGGLVQPGGSLRLSCVFSGFSLSTSGMGVGWVRQAPGKGLEWVGHIWWDDDKRYNPALKSRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARMELWSYYFDYWGQGTLVTVSS
>序列ID 10:人源化形式5(H5VH)核苷酸序列
GAGGTGCAACTTGTGGAAAGCGGCGGCGGGTTGGTGCAACCTGGCGGTTCACTTCGGCTCTCATGTGTGTTCAGTGGTTTTTCCCTTAGCACAAGCGGGATGGGTGTCGGGTGGGTCCGCCAAGCGCCTGGCAAAGGTCTGGAATGGGTTGGTCACATTTGGTGGGATGATGACAAAAGGTATAATCCCGCGCTGAAATCTAGATTTACTATTAGTCGGGATACGAGTAAGAACACGGTGTATCTGCAAATGAACAGTCTCAGGGCAGAGGATACAGCGGTATATTATTGTGCTCGAATGGAGCTGTGGTCTTACTATTTTGATTACTGGGGCCAGGGCACGTTGGTAACGGTCTCGAGT
>序列ID 11:人源化形式6(H6VH)氨基酸序列
EVQLVESGGGLVQPGGSLRLSCSFSGFSLSTSGMGVGWVRQAPGKGLEWVGHIWWDDDKRYNPALKSRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARMELWSYYFDYWGQGTLVTVSS
>序列ID 12:人源化形式6(H6VH)核苷酸序列
GAGGTGCAACTTGTGGAAAGCGGCGGCGGGTTGGTGCAACCTGGCGGTTCACTTCGGCTCTCATGTAGCTTCAGTGGTTTTTCCCTTAGCACAAGCGGGATGGGTGTCGGGTGGGTCCGCCAAGCGCCTGGCAAAGGTCTGGAATGGGTTGGTCACATTTGGTGGGATGATGACAAAAGGTATAATCCCGCGCTGAAATCTAGATTTACTATTAGTCGGGATACGAGTAAGAACACGGTGTATCTGCAAATGAACAGTCTCAGGGCAGAGGATACAGCGGTATATTATTGTGCTCGAATGGAGCTGTGGTCTTACTATTTTGATTACTGGGGCCAGGGCACGTTGGTAACGGTCTCGAGT
>序列ID 13:人源化形式1(H1VL)氨基酸序列
ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGSGSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKLEIK
>序列ID 14:人源化形式1(H1VL)核苷酸序列
GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCACTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCCCAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCCGGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATTATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAATTGGAGATAAAG
>序列ID 15:人源化形式2(H2VL)氨基酸序列
ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGSGSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKITIL
>序列ID 16:人源化形式2(H2VL)核苷酸序列
GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCACTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCCCAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCCGGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATTATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAAATTACGATACTG
>序列ID 17:人源化形式3(H3VL)氨基酸序列
ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGSGSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKLTVL
>序列ID 18:人源化形式3(H3VL)核苷酸序列
GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCACTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCCCAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCCGGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATTATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAACTTACGGTACTG
>序列ID 19:人源化形式4(H4VL)氨基酸序列
ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGSGSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKVTVL
>序列ID 20:人源化形式4(H4VL)核苷酸序列
GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCACTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCCCAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCCGGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATTATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAAGTTACGGTACTG
>序列ID 21:人源化形式5(H5VL)氨基酸序列
EIVMTQSPSTLSASVGDRVIITCSASSSVSYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGAEFTLTISSLQPDDFATYYCFQGSVYPFTFGQGTKLTVL
>序列ID 22:人源化形式5(H5VL)核苷酸序列
GAAATAGTGATGACGCAGTCACCTAGCACCCTTAGTGCTTCTGTAGGAGACAGGGTTATAATTACCTGCAGTGCTAGTTCCTCAGTGTCATACATGCACTGGTATCAGCAGAAACCGGGAAAAGCTCCAAAGCTGCTTATATACGACACGTCCAAATTGGCATCAGGTGTCCCCAGTCGATTTAGTGGCTCTGGCTCAGGGGCTGAATTTACGCTCACAATCTCCAGCCTCCAACCAGATGACTTCGCCACATACTACTGTTTTCAGGGCTCAGTGTATCCGTTTACTTTCGGCCAGGGGACAAAGTTGACTGTACTT
>序列ID 23:人源化形式6(H6VL)氨基酸序列
EIVMTQSPSTLSASVGDRVIITCSASSSVSYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGAEFTLTISSLQPDDFATYYCFQGSVYPFTFGQGTKLTVL
>序列ID 24:人源化形式6(H6VL)核苷酸序列
GAAATAGTGATGACGCAGTCACCTAGCACCCTTAGTGCTTCTGTAGGAGACAGGGTTATAATTACCTGCAGTGCTAGTTCCTCAGTGTCATACATGCACTGGTATCAGCAGAAACCGGGAAAAGCTCCAAAGCTGCTTATATACGACACGTCCAAATTGGCATCAGGTGTCCCCAGTCGATTTAGTGGCTCTGGCTCAGGGGCTGAATTTACGCTCACAATCTCCAGCCTCCAACCAGATGACTTCGCCACATACTACTGTTTTCAGGGCTCAGTGTATCCGTTTACTTTCGGCCAGGGGACAAAGTTGACTGTACTT
>序列ID 25:BU12 VH:小鼠抗CD19VH氨基酸序列
QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSSNQVFLKIASVDTADTAAYYCARMELWSYYFDYWGQGTTLTVSS
>序列ID 26:BU12 VH:小鼠抗CD19 VH核苷酸序列
CAGGTGACCCTGAAAGAAAGCGGCCCGGGCATTCTGCAGCCGAGCCAGACCCTGAGCCTGACCTGCAGCTTTAGCGGCTTTAGCCTGAGCACCAGCGGCATGGGCGTGGGCTGGATTCGCCAGCCGAGCGGCAAAGGCCTGGAATGGCTGGCGCATATTTGGTGGGATGATGATAAACGCTATAACCCGGCGCTGAAAAGCCGCCTGACCATTAGCAAAGATACCAGCAGCAACCAGGTGTTTCTGAAAATTGCGAGCGTGGATACCGCGGATACCGCGGCGTATTATTGCGCGCGCATGGAACTGTGGAGCTATTATTTTGATTATTGGGGCCAGGGCACCACCCTGACCGTGAGCAGC
>序列ID 27:BU12 VL:小鼠抗CD19 VL氨基酸序列
ENVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSSTSPKLWIYDTSKLASGVPGRFSGSGSGNSHFLTISSMEAEDVATYYCFQGSVYPFTFGSGTKLEIK
>序列ID 28:BU12 VL:小鼠抗CD19 VL核苷酸序列
GAAAACGTGCTGACCCAGAGCCCGGCGATTATGAGCGCGAGCCCGGGCGAAAAAGTGACCATGACCTGCAGCGCGAGCAGCAGCGTGAGCTATATGCATTGGTATCAGCAGAAAAGCAGCACCAGCCCGAAACTGTGGATTTATGATACCAGCAAACTGGCGAGCGGCGTGCCGGGCCGCTTTAGCGGCAGCGGCAGCGGCAACAGCCATTTTCTGACCATTAGCAGCATGGAAGCGGAAGATGTGGCGACCTATTATTGCTTTCAGGGCAGCGTGTATCCGTTTACCTTTGGCAGCGGCACCAAACTGGAAATTAAA
>序列ID 29:21D4人抗体VH氨基酸序列
EVQLVQSGAEVKKPGESLKISCKGSGYSFSSSWIGWVRQAPGKGLEWMGIIYPDDSDTRYSPSFQGQVTISADKSIRTAYLQWSSLKASDTAMYYCARHVTMIWGVIIDFWGQGTLVTVSS
>序列ID 30:21D4人抗体VH核苷酸序列
GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAGAAACCAGGAGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTAGCAGTTCATGGATCGGCTGGGTGCGCCAGGCACCTGGGAAAGGCCTGGAATGGATGGGGATCATCTATCCTGATGACTCTGATACCAGATACAGTCCATCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGGACTGCCTACCTGCAGTGGAGTAGCCTGAAGGCCTCGGACACCGCTATGTATTACTGTGCGAGACATGTTACTATGATTTGGGGAGTTATTATTGACTTCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA
>序列ID 31:21D4人抗体VL氨基酸序列
AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPFTFGPGTKVDIK
>序列ID 32:21D4人抗体VL核苷酸序列
GCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAA
>序列ID 33:SI-63C1重链氨基酸序列
QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSSNQVFLKIASVDTADTAAYYCARMELWSYYFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
>序列ID 34:SI-63C1重链核苷酸序列
CAGGTGACCCTGAAAGAAAGCGGCCCGGGCATTCTGCAGCCGAGCCAGACCCTGAGCCTGACCTGCAGCTTTAGCGGCTTTAGCCTGAGCACCAGCGGCATGGGCGTGGGCTGGATTCGCCAGCCGAGCGGCAAAGGCCTGGAATGGCTGGCGCATATTTGGTGGGATGATGATAAACGCTATAACCCGGCGCTGAAAAGCCGCCTGACCATTAGCAAAGATACCAGCAGCAACCAGGTGTTTCTGAAAATTGCGAGCGTGGATACCGCGGATACCGCGGCGTATTATTGCGCGCGCATGGAACTGTGGAGCTATTATTTTGATTATTGGGGCCAGGGCACCACCCTGACCGTGAGCAGCGCTAGCACCAAGGGCCCATCTGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCTGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCTGAACCTGTGACAGTGTCCTGGAACTCAGGAGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTCCTGTAGCAGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACGCCAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCCGGGCAAA
>序列ID 35:SI-63C1轻链氨基酸序列
ENVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSSTSPKLWIYDTSKLASGVPGRFSGSGSGNSHFLTISSMEAEDVATYYCFQGSVYPFTFGSGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
>序列ID 36:SI-63C1轻链核苷酸序列
GAAAACGTGCTGACCCAGAGCCCGGCGATTATGAGCGCGAGCCCGGGCGAAAAAGTGACCATGACCTGCAGCGCGAGCAGCAGCGTGAGCTATATGCATTGGTATCAGCAGAAAAGCAGCACCAGCCCGAAACTGTGGATTTATGATACCAGCAAACTGGCGAGCGGCGTGCCGGGCCGCTTTAGCGGCAGCGGCAGCGGCAACAGCCATTTTCTGACCATTAGCAGCATGGAAGCGGAAGATGTGGCGACCTATTATTGCTTTCAGGGCAGCGTGTATCCGTTTACCTTTGGCAGCGGCACCAAACTGGAAATTAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
>序列ID 37:SI-63C2重链氨基酸序列
QVTLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
>序列ID 38:SI-63C2重链核苷酸序列
CAGGTCACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCTTCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAAAGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAAAGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTGACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTATTGGGGGCAGGGGACTCTCGTCACGGTGTCCTCTGCTAGCACCAAGGGCCCATCTGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCTGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCTGAACCTGTGACAGTGTCCTGGAACTCAGGAGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTCCTGTAGCAGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACGCCAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCCGGGCAAA
>序列ID 39:SI-63C2轻链氨基酸序列
ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGSGSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
>序列ID 40:SI-63C2轻链核苷酸序列
GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCACTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCCCAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCCGGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATTATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAATTGGAGATAAAGCGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
>序列ID 41:SI-63R1(H1 ScFv-His)氨基酸序列ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGSGSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKLEIKGGGGSGGGGSGGGGSGGGGSQVTLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGSHHHHHH
>序列ID 42:SI-63R1(H1 ScFv-His)核苷酸序列
GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCACTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCCCAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCCGGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATTATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAATTGGAGATAAAGGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAGGTCACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCTTCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAAAGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAAAGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTGACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTATTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGTGGATCCCATCATCACCATCACCATTGA
>序列ID 43:SI-63SV1氨基酸序列
ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGSGSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKLEIKGGGGSGGGGSGGGGSGGGGSQVTLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSS
>序列ID 44:SI-63SV1核酸序列
GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCACTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCCCAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCCGGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATTATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAATTGGAGATAAAGGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAGGTCACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCTTCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAAAGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAAAGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTGACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTATTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGT
>序列ID 45:SI-63SV2氨基酸序列
ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGSGSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKITILGGGGSGGGGSGGGGSGGGGSQVTLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSS
>序列ID 46:SI-63SV2核酸序列
GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCACTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCCCAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCCGGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATTATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAAATTACGATACTGGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAGGTCACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCTTCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAAAGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAAAGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTGACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTATTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGT
>序列ID 47:SI-63SV3氨基酸序列
ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGSGSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKLTVLGGGGSGGGGSGGGGSGGGGSQVTLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSS
>序列ID 48:SI-63SV3核酸序列
GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCACTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCCCAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCCGGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATTATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAATTGACGGTACTGGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAGGTCACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCTTCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAAAGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAAAGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTGACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTATTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGT
>序列ID 49:SI-63SV4氨基酸序列
ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGSGSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKVTVLGGGGSGGGGSGGGGSGGGGSQVTLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSS
>序列ID 50:SI-63SV4核酸序列
GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCACTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCCCAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCCGGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATTATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAAGTTACGGTACTGGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAGGTCACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCTTCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAAAGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAAAGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTGACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTATTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGT
>序列ID 51:SI-63SV5氨基酸序列
EIVMTQSPSTLSASVGDRVIITCSASSSVSYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGAEFTLTISSLQPDDFATYYCFQGSVYPFTFGQGTKLTVLGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCVFSGFSLSTSGMGVGWVRQAPGKGLEWVGHIWWDDDKRYNPALKSRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARMELWSYYFDYWGQGTLVTVSS
>序列ID 52:SI-63SV5核酸序列
GAAATAGTGATGACGCAGTCACCTAGCACCCTTAGTGCTTCTGTAGGAGACAGGGTTATAATTACCTGCAGTGCTAGTTCCTCAGTGTCATACATGCACTGGTATCAGCAGAAACCGGGAAAAGCTCCAAAGCTGCTTATATACGACACGTCCAAATTGGCATCAGGTGTCCCCAGTCGATTTAGTGGCTCTGGCTCAGGGGCTGAATTTACGCTCACAATCTCCAGCCTCCAACCAGATGACTTCGCCACATACTACTGTTTTCAGGGCTCAGTGTATCCGTTTACTTTCGGCCAGGGGACAAAGTTGACTGTACTTGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCAGAGGTGCAACTTGTGGAAAGCGGCGGCGGGTTGGTGCAACCTGGCGGTTCACTTCGGCTCTCATGTGTGTTCAGTGGTTTTTCCCTTAGCACAAGCGGGATGGGTGTCGGGTGGGTCCGCCAAGCGCCTGGCAAAGGTCTGGAATGGGTTGGTCACATTTGGTGGGATGATGACAAAAGGTATAATCCCGCGCTGAAATCTAGATTTACTATTAGTCGGGATACGAGTAAGAACACGGTGTATCTGCAAATGAACAGTCTCAGGGCAGAGGATACAGCGGTATATTATTGTGCTCGAATGGAGCTGTGGTCTTACTATTTTGATTACTGGGGCCAGGGCACGTTGGTAACGGTCTCGAGT
>序列ID 53:SI-63SV6氨基酸序列
EIVMTQSPSTLSASVGDRVIITCSASSSVSYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGAEFTLTISSLQPDDFATYYCFQGSVYPFTFGQGTKLTVLGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCSFSGFSLSTSGMGVGWVRQAPGKGLEWVGHIWWDDDKRYNPALKSRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARMELWSYYFDYWGQGTLVTVSS
>序列ID 54:SI-63SV6核酸序列
GAAATAGTGATGACGCAGTCACCTAGCACCCTTAGTGCTTCTGTAGGAGACAGGGTTATAATTACCTGCAGTGCTAGTTCCTCAGTGTCATACATGCACTGGTATCAGCAGAAACCGGGAAAAGCTCCAAAGCTGCTTATATACGACACGTCCAAATTGGCATCAGGTGTCCCCAGTCGATTTAGTGGCTCTGGCTCAGGGGCTGAATTTACGCTCACAATCTCCAGCCTCCAACCAGATGACTTCGCCACATACTACTGTTTTCAGGGCTCAGTGTATCCGTTTACTTTCGGCCAGGGGACAAAGTTGACTGTACTTGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCAGAGGTGCAACTTGTGGAAAGCGGCGGCGGGTTGGTGCAACCTGGCGGTTCACTTCGGCTCTCATGTAGCTTCAGTGGTTTTTCCCTTAGCACAAGCGGGATGGGTGTCGGGTGGGTCCGCCAAGCGCCTGGCAAAGGTCTGGAATGGGTTGGTCACATTTGGTGGGATGATGACAAAAGGTATAATCCCGCGCTGAAATCTAGATTTACTATTAGTCGGGATACGAGTAAGAACACGGTGTATCTGCAAATGAACAGTCTCAGGGCAGAGGATACAGCGGTATATTATTGTGCTCGAATGGAGCTGTGGTCTTACTATTTTGATTACTGGGGCCAGGGCACGTTGGTAACGGTCTCGAGT
>序列ID 55:SI-63SF1(H1 ScFv-单体Fc)氨基酸序列
ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGSGSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKLEIKGGGGSGGGGSGGGGSGGGGSQVTLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGGSSGSGSGSTGLVPRGSTSSSGTGTSAGTPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLRCHVKGFYPSDIAVEWESNGQPENNYKTTKPVLDSDGSFFLYSTLTVDKSRWQQGNVFSCSVLHEALHNHYTQKSLSLSPGKGSGLNDIFEAQKIEWHE
>序列ID 56:SI-63SF1(H1 ScFv-单体Fc)核苷酸序列
GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCACTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCCCAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCCGGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATTATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAATTGGAGATAAAGGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAGGTCACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCTTCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAAAGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAAAGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTGACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTATTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGTGGGGGATCCTCTGGAAGTGGCTCCGGCAGCACTGGGCTCGTACCAAGGGGGTCCACATCCAGTAGCGGTACTGGCACATCCGCGGGAACCCCCGTCGCTGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACGCTAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGAGATGCCACGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGAAGCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCACCCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGCTCCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCCGGGCAAAGGTTCAGGCCTGAACGATATTTTTGAAGCGCAGAAAATTGAATGGCATGAA
>序列ID 57:SI-63SF2(H2 ScFv-单体Fc)氨基酸序列
ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGSGSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKITILGGGGSGGGGSGGGGSGGGGSQVTLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGGSSGSGSGSTGLVPRGSTSSSGTGTSAGTPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLRCHVKGFYPSDIAVEWESNGQPENNYKTTKPVLDSDGSFFLYSTLTVDKSRWQQGNVFSCSVLHEALHNHYTQKSLSLSPGKGSGLNDIFEAQKIEWHE
>序列ID 58:SI-63SF2(H2 ScFv-单体Fc)核苷酸序列
GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCACTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCCCAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCCGGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATTATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAAATTACGATACTGGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAGGTCACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCTTCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAAAGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAAAGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTGACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTATTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGTGGGGGATCCTCTGGAAGTGGCTCCGGCAGCACTGGGCTCGTACCAAGGGGGTCCACATCCAGTAGCGGTACTGGCACATCCGCGGGAACCCCCGTCGCTGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACGCTAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGAGATGCCACGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGAAGCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCACCCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGCTCCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCCGGGCAAAGGTTCAGGCCTGAACGATATTTTTGAAGCGCAGAAAATTGAATGGCATGAA
>序列ID 59:SI-63SF4(H3 ScFv-单体Fc)氨基酸序列
ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGSGSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKLTVLGGGGSGGGGSGGGGSGGGGSQVTLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGGSSGSGSGSTGLVPRGSTSSSGTGTSAGTPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLRCHVKGFYPSDIAVEWESNGQPENNYKTTKPVLDSDGSFFLYSTLTVDKSRWQQGNVFSCSVLHEALHNHYTQKSLSLSPGKGSGLNDIFEAQKIEWHE
>序列ID 60:SI-63SF4(H3 ScFv-单体Fc)核苷酸序列
GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCACTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCCCAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCCGGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATTATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAACTTACGGTACTGGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAGGTCACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCTTCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAAAGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAAAGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTGACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTATTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGTGGGGGATCCTCTGGAAGTGGCTCCGGCAGCACTGGGCTCGTACCAAGGGGGTCCACATCCAGTAGCGGTACTGGCACATCCGCGGGAACCCCCGTCGCTGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACGCTAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGAGATGCCACGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGAAGCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCACCCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGCTCCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCCGGGCAAAGGTTCAGGCCTGAACGATATTTTTGAAGCGCAGAAAATTGAATGGCATGAA
>序列ID 61:SI-63SF5(H4 ScFv-单体Fc)氨基酸序列
ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGSGSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKVTVLGGGGSGGGGSGGGGSGGGGSQVTLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGGSSGSGSGSTGLVPRGSTSSSGTGTSAGTPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLRCHVKGFYPSDIAVEWESNGQPENNYKTTKPVLDSDGSFFLYSTLTVDKSRWQQGNVFSCSVLHEALHNHYTQKSLSLSPGKGSGLNDIFEAQKIEWHE
>序列ID 62:SI-63SF5(H4 ScFv-单体Fc)核苷酸序列
GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCACTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCCCAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCCGGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATTATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAAGTTACGGTACTGGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAGGTCACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCTTCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAAAGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAAAGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTGACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTATTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGTGGGGGATCCTCTGGAAGTGGCTCCGGCAGCACTGGGCTCGTACCAAGGGGGTCCACATCCAGTAGCGGTACTGGCACATCCGCGGGAACCCCCGTCGCTGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACGCTAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGAGATGCCACGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGAAGCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCACCCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGCTCCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCCGGGCAAAGGTTCAGGCCTGAACGATATTTTTGAAGCGCAGAAAATTGAATGGCATGAA
>序列ID 63:SI-63SF6(H5 ScFv-单体Fc)氨基酸序列
EIVMTQSPSTLSASVGDRVIITCSASSSVSYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGAEFTLTISSLQPDDFATYYCFQGSVYPFTFGQGTKLTVLGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCVFSGFSLSTSGMGVGWVRQAPGKGLEWVGHIWWDDDKRYNPALKSRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGSSGSGSGSTGLVPRGSTSSSGTGTSAGTPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLRCHVKGFYPSDIAVEWESNGQPENNYKTTKPVLDSDGSFFLYSTLTVDKSRWQQGNVFSCSVLHEALHNHYTQKSLSLSPGKGSGLNDIFEAQKIEWHE
>序列ID 64:SI-63SF6(H5 ScFv-单体Fc)核苷酸序列
GAAATAGTGATGACGCAGTCACCTAGCACCCTTAGTGCTTCTGTAGGAGACAGGGTTATAATTACCTGCAGTGCTAGTTCCTCAGTGTCATACATGCACTGGTATCAGCAGAAACCGGGAAAAGCTCCAAAGCTGCTTATATACGACACGTCCAAATTGGCATCAGGTGTCCCCAGTCGATTTAGTGGCTCTGGCTCAGGGGCTGAATTTACGCTCACAATCTCCAGCCTCCAACCAGATGACTTCGCCACATACTACTGTTTTCAGGGCTCAGTGTATCCGTTTACTTTCGGCCAGGGGACAAAGTTGACTGTACTTGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCAGAGGTGCAACTTGTGGAAAGCGGCGGCGGGTTGGTGCAACCTGGCGGTTCACTTCGGCTCTCATGTGTGTTCAGTGGTTTTTCCCTTAGCACAAGCGGGATGGGTGTCGGGTGGGTCCGCCAAGCGCCTGGCAAAGGTCTGGAATGGGTTGGTCACATTTGGTGGGATGATGACAAAAGGTATAATCCCGCGCTGAAATCTAGATTTACTATTAGTCGGGATACGAGTAAGAACACGGTGTATCTGCAAATGAACAGTCTCAGGGCAGAGGATACAGCGGTATATTATTGTGCTCGAATGGAGCTGTGGTCTTACTATTTTGATTACTGGGGCCAGGGCACGTTGGTAACGGTCTCGAGTGGATCCTCTGGAAGTGGCTCCGGCAGCACTGGGCTCGTACCAAGGGGGTCCACATCCAGTAGCGGTACTGGCACATCCGCGGGAACCCCCGTCGCTGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACGCTAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGAGATGCCACGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGAAGCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCACCCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGCTCCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCCGGGCAAAGGTTCAGGCCTGAACGATATTTTTGAAGCGCAGAAAATTGAATGGCATGAA
>序列ID 65:SI-63SF7(H6 ScFv-单体Fc)氨基酸序列
EIVMTQSPSTLSASVGDRVIITCSASSSVSYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGAEFTLTISSLQPDDFATYYCFQGSVYPFTFGQGTKLTVLGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCSFSGFSLSTSGMGVGWVRQAPGKGLEWVGHIWWDDDKRYNPALKSRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGSSGSGSGSTGLVPRGSTSSSGTGTSAGTPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLRCHVKGFYPSDIAVEWESNGQPENNYKTTKPVLDSDGSFFLYSTLTVDKSRWQQGNVFSCSVLHEALHNHYTQKSLSLSPGKGSGLNDIFEAQKIEWHE
>序列ID 66:SI-63SF7(H6 ScFv-单体Fc)核苷酸序列
GAAATAGTGATGACGCAGTCACCTAGCACCCTTAGTGCTTCTGTAGGAGACAGGGTTATAATTACCTGCAGTGCTAGTTCCTCAGTGTCATACATGCACTGGTATCAGCAGAAACCGGGAAAAGCTCCAAAGCTGCTTATATACGACACGTCCAAATTGGCATCAGGTGTCCCCAGTCGATTTAGTGGCTCTGGCTCAGGGGCTGAATTTACGCTCACAATCTCCAGCCTCCAACCAGATGACTTCGCCACATACTACTGTTTTCAGGGCTCAGTGTATCCGTTTACTTTCGGCCAGGGGACAAAGTTGACTGTACTTGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCAGAGGTGCAACTTGTGGAAAGCGGCGGCGGGTTGGTGCAACCTGGCGGTTCACTTCGGCTCTCATGTAGCTTCAGTGGTTTTTCCCTTAGCACAAGCGGGATGGGTGTCGGGTGGGTCCGCCAAGCGCCTGGCAAAGGTCTGGAATGGGTTGGTCACATTTGGTGGGATGATGACAAAAGGTATAATCCCGCGCTGAAATCTAGATTTACTATTAGTCGGGATACGAGTAAGAACACGGTGTATCTGCAAATGAACAGTCTCAGGGCAGAGGATACAGCGGTATATTATTGTGCTCGAATGGAGCTGTGGTCTTACTATTTTGATTACTGGGGCCAGGGCACGTTGGTAACGGTCTCGAGTGGATCCTCTGGAAGTGGCTCCGGCAGCACTGGGCTCGTACCAAGGGGGTCCACATCCAGTAGCGGTACTGGCACATCCGCGGGAACCCCCGTCGCTGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACGCTAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGAGATGCCACGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGAAGCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCACCCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGCTCCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCCGGGCAAAGGTTCAGGCCTGAACGATATTTTTGAAGCGCAGAAAATTGAATGGCATGAA
>序列ID 67:SI-77H3重链氨基酸序列
ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGSGSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKVTVLGGGGSGGGGSGGGGSGGGGSQVTLKESGPGLVQPGQTLSLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGGGGSGGGGSQVQLQQSGPGLVKPSETLSITCTVSGFSLTNYGVHWIRQAPGKCLEWLGVIWSGGNTDYNTPFTSRFTITKDNSKNQVYFKLRSVRADDTAIYYCARALTYYDYEFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKGLEWIACIAAGSAGITYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDLWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITCQASQSISSHLNWYQQKPGKAPKLLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVDNVFGGGTKVEIKGGGGSGGGGSGRSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWVRQAPGKGLEYIGTISSGGNVYYASSARGRFTISRPSSKNTVDLQMNSLRAEDTAVYYCARDSGYSDPMWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPSSVSASVGDRVTITCQASQNIRTYLSWYQQKPGKAPKLLIYAAANLASGVPSRFSGSGSGTDFTLTISDLEPGDAATYYCQSTYLGTDYVGGAFGGGTKVEIK
>序列ID 68:SI-77H3重链核酸序列
GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCACTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCCCAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCCGGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATTATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAAGTGACCGTCCTAGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAGGTCACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGCCTCACCTGTGCCTTCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAAAGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAAAGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTGACGCCGAGGATACGGCTGTATATTATTGCGCTCGGATGGAACTCTGGTCTTACTACTTTGATTATTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCACAAGTACAGTTGCAGCAATCCGGTCCCGGTCTCGTCAAACCGAGTGAGACGCTTAGTATAACGTGTACTGTTTCAGGCTTTAGCCTTACGAACTATGGAGTTCACTGGATTCGGCAGGCACCCGGCAAATGTTTGGAATGGCTGGGTGTTATTTGGTCAGGTGGAAATACAGACTATAACACCCCCTTTACAAGTCGGTTCACAATTACGAAAGATAATTCCAAAAATCAAGTTTATTTCAAGTTGAGATCCGTCCGCGCGGACGACACTGCGATCTACTATTGTGCGAGGGCACTGACCTACTACGATTACGAATTTGCGTATTGGGGGCAAGGGACTCTTGTAACAGTCTCCAGTGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCTCCTTCAGTAGCGGGTACGACATGTGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGCATGCATTGCTGCTGGTAGTGCTGGTATCACTTACGACGCGAACTGGGCGAAAGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAGATCGGCGTTTTCGTTCGACTACGCCATGGACCTCTGGGGCCAGGGAACCCTGGTCACCGTGTCGAGCGGTGGAGGCGGATCTGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGCCAGTCAGAGCATTAGTTCCCACTTAAACTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAGGCATCCACTCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAACAGGGTTATAGTTGGGGTAATGTTGATAATGTTTTCGGCGGAGGGACCAAGGTGGAGATCAAAGGCGGTGGAGGGTCCGGCGGTGGTGGCTCCGGACGGTCGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTACTGCCTCTGGATTCACCATCAGTAGCTACCACATGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTACATCGGAACCATTAGTAGTGGTGGTAATGTATACTACGCAAGCTCCGCTAGAGGCAGATTCACCATCTCCAGACCCTCGTCCAAGAACACGGTGGATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACTCTGGTTATAGTGATCCTATGTGGGGCCAGGGAACCCTGGTCACCGTCTCTTCAGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCAGACGTTGTGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACCTGTCAGGCCAGTCAGAACATTAGGACTTACTTATCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCAGCCAATCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCGACCTGGAGCCTGGCGATGCTGCAACTTACTATTGTCAGTCTACCTATCTTGGTACTGATTATGTTGGCGGTGCTTTCGGCGGAGGGACCAAGGTGGAGATCAAATGA
>序列ID 69:SI-77H3轻链氨基酸序列
EIVMTQSPSTLSASVGDRVIITCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSGSGSGAEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGQGTKLTVLGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLSLSCAASGFTISTNAMSWVRQAPGKGLEWVGVITGRDITYYASWAKGRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSSGGGGSGGGGSEIVLTQSPSTLSVSPGERATFSCRASQSIGTNIHWYQQKPGKPPRLLIKYASESISGIPDRFSGSGSGTEFTLTISSVQSEDFAVYYCQQNNNWPTTFGCGTKLTVLRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECGGGGSGGGGSGGGGSQSALTQPASVSGSPGQSITISCTGTSSDVGGYNFVSWYQQHPGKAPKLMIYDVSDRPSGVSDRFSGSKSGNTASLIISGLQADDEADYYCSSYGSSSTHVIFGGGTKVTVLGGGGSGGGGSGGGGSGGGGSQVQLQESGGGLVKPGGSLSLSCAASGFTFSSYWMSWVRQAPGKGLEWVANINRDGSASYYVDSVKGRFTISRDDAKNSLYLQMNSLRAEDTAVYYCARDRGVGYFDLWGRGTLVTVSS
>序列ID 70:SI-77H3轻链核苷酸序列
GAAATCGTTATGACGCAGAGTCCCTCCACGCTCTCCGCTAGTGTCGGGGATCGCGTCATTATCACATGCCAGGCCTCCGAGTCAATCAGCAGCTGGCTTGCATGGTATCAACAGAAGCCGGGAAAAGCTCCTAAATTGCTGATCTATGAAGCGTCAAAATTGGCGTCTGGTGTCCCATCTAGGTTCTCCGGCTCTGGGTCTGGTGCGGAATTTACTTTGACAATCTCCAGTCTTCAACCAGACGATTTCGCTACCTACTACTGCCAAGGGTATTTCTATTTTATAAGCCGGACATATGTAAACTCCTTCGGCCAAGGAACAAAGTTGACTGTTCTTGGTGGCGGAGGCAGTGGTGGCGGGGGCAGCGGAGGTGGTGGTTCAGGGGGTGGTGGGAGCGAAGTCCAATTGGTAGAAAGTGGCGGTGGTCTGGTGCAACCTGGTGGATCTCTTAGCCTCTCATGCGCCGCTAGTGGCTTTACTATTTCAACTAATGCGATGAGCTGGGTTCGCCAGGCCCCCGGCAAAGGACTTGAGTGGGTCGGCGTCATCACCGGCAGGGACATTACATACTATGCGAGTTGGGCAAAGGGCAGGTTCACGATTAGCCGCGATACTTCAAAGAATACCGTTTACCTTCAAATGAATAGCTTGAGGGCGGAAGACACAGCTGTGTATTACTGCGCGAGGGATGGAGGTAGTTCCGCCATAACTTCCAACAACATATGGGGACAAGGCACGCTGGTTACTGTCTCGAGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCAGAAATCGTCCTTACACAATCTCCTAGCACACTGAGTGTGAGCCCCGGCGAACGCGCGACTTTCTCTTGCAGGGCAAGTCAATCCATAGGGACTAATATACATTGGTATCAACAAAAGCCAGGTAAACCACCCAGGCTTTTGATTAAGTATGCAAGTGAGTCTATTTCCGGTATCCCTGACCGCTTCTCTGGATCAGGCAGTGGCACAGAGTTCACACTCACCATATCTAGTGTGCAATCAGAGGACTTCGCCGTGTATTACTGCCAACAGAATAATAACTGGCCGACTACCTTCGGATGCGGTACAAAGCTGACCGTTTTACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTGGCGGTGGCGGTAGCGGTGGCGGCGGAAGTGGTGGCGGAGGATCCCAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAGCAGTGACGTTGGTGGTTATAACTTTGTCTCCTGGTACCAACAACACCCAGGCAAAGCCCCCAAACTCATGATCTATGATGTCAGTGATCGGCCCTCAGGGGTGTCTGATCGCTTCTCCGGCTCCAAGTCTGGCAACACGGCCTCCCTGATCATCTCTGGCCTCCAGGCTGACGACGAGGCTGATTATTACTGCAGCTCATATGGGAGCAGCAGCACTCATGTGATTTTCGGCGGAGGGACCAAGGTGACCGTCCTAGGTGGAGGCGGTTCAGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTCAGGTGCAATTGCAGGAGTCGGGGGGAGGCCTGGTCAAGCCTGGAGGGTCCCTGAGTCTCTCCTGTGCAGCCTCTGGATTCACCTTTAGTAGTTATTGGATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCGCGATGGAAGTGCGAGTTACTATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACGACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGATCGTGGGGTGGGCTACTTCGATCTCTGGGGCCGTGGCACCCTGGTCACCGTCTCTAGC
>序列ID 71:SI-77H6重链氨基酸序列
EIVLTQSPSTLSVSPGERATFSCRASQSIGTNIHWYQQKPGKPPRLLIKYASESISGIPDRFSGSGSGTEFTLTISSVQSEDFAVYYCQQNNNWPTTFGPGTKLTVLGGGGSGGGGSGGGGSGGGGSQVQLQQSGPGLVKPSETLSITCTVSGFSLTNYGVHWIRQAPGKGLEWLGVIWSGGNTDYNTPFTSRFTITKDNSKNQVYFKLRSVRADDTAIYYCARALTYYDYEFAYWGQGTLVTVSSGGGGSGGGGSQVTLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKCLEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKGLEWIACIAAGSAGITYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDLWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITCQASQSISSHLNWYQQKPGKAPKLLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVDNVFGGGTKVEIKGGGGSGGGGSGRSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWVRQAPGKGLEYIGTISSGGNVYYASSARGRFTISRPSSKNTVDLQMNSLRAEDTAVYYCARDSGYSDPMWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPSSVSASVGDRVTITCQASQNIRTYLSWYQQKPGKAPKLLIYAAANLASGVPSRFSGSGSGTDFTLTISDLEPGDAATYYCQSTYLGTDYVGGAFGGGTKVEIK
>序列ID 72:SI-77H6重链核苷酸序列
GAAATCGTCCTTACACAATCTCCTAGCACACTGAGTGTGAGCCCCGGCGAACGCGCGACTTTCTCTTGCAGGGCAAGTCAATCCATAGGGACTAATATACATTGGTATCAACAAAAGCCAGGTAAACCACCCAGGCTTTTGATTAAGTATGCAAGTGAGTCTATTTCCGGTATCCCTGACCGCTTCTCTGGATCAGGCAGTGGCACAGAGTTCACACTCACCATATCTAGTGTGCAATCAGAGGACTTCGCCGTGTATTACTGCCAACAGAATAATAACTGGCCGACTACCTTCGGACCCGGTACAAAGCTGACCGTTTTAGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAAGTACAGTTGCAGCAATCCGGTCCCGGTCTCGTCAAACCGAGTGAGACGCTTAGTATAACGTGTACTGTTTCAGGCTTTAGCCTTACGAACTATGGAGTTCACTGGATTCGGCAGGCACCCGGCAAAGGTTTGGAATGGCTGGGTGTTATTTGGTCAGGTGGAAATACAGACTATAACACCCCCTTTACAAGTCGGTTCACAATTACGAAAGATAATTCCAAAAATCAAGTTTATTTCAAGTTGAGATCCGTCCGCGCGGACGACACTGCGATCTACTATTGTGCGAGGGCACTGACCTACTACGATTACGAATTTGCGTATTGGGGGCAAGGGACTCTTGTAACAGTCTCGAGCGGCGGTGGAGGGTCCGGCGGTGGTGGATCACAGGTCACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCTTCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAAATGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAAAGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTGACGCCGAGGATACGGCTGTATATTATTGCGCTCGGATGGAACTCTGGTCTTACTACTTTGATTATTGGGGGCAGGGGACTCTCGTCACGGTGTCGAGTGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCTCCTTCAGTAGCGGGTACGACATGTGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGCATGCATTGCTGCTGGTAGTGCTGGTATCACTTACGACGCGAACTGGGCGAAAGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAGATCGGCGTTTTCGTTCGACTACGCCATGGACCTCTGGGGCCAGGGAACCCTGGTCACCGTGTCGAGCGGTGGAGGCGGATCTGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGCCAGTCAGAGCATTAGTTCCCACTTAAACTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAGGCATCCACTCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAACAGGGTTATAGTTGGGGTAATGTTGATAATGTTTTCGGCGGAGGGACCAAGGTGGAGATCAAAGGCGGTGGAGGGTCCGGCGGTGGTGGCTCCGGACGGTCGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTACTGCCTCTGGATTCACCATCAGTAGCTACCACATGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTACATCGGAACCATTAGTAGTGGTGGTAATGTATACTACGCAAGCTCCGCTAGAGGCAGATTCACCATCTCCAGACCCTCGTCCAAGAACACGGTGGATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACTCTGGTTATAGTGATCCTATGTGGGGCCAGGGAACCCTGGTCACCGTCTCTTCAGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCAGACGTTGTGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACCTGTCAGGCCAGTCAGAACATTAGGACTTACTTATCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCAGCCAATCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCGACCTGGAGCCTGGCGATGCTGCAACTTACTATTGTCAGTCTACCTATCTTGGTACTGATTATGTTGGCGGTGCTTTCGGCGGAGGGACCAAGGTGGAGATCAAA
>序列ID 73:SI-77H6轻链氨基酸序列
EIVMTQSPSTLSASVGDRVIITCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSGSGSGAEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGQGTKLTVLGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLSLSCAASGFTISTNAMSWVRQAPGKGLEWVGVITGRDITYYASWAKGRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSSGGGGSGGGGSENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGSGSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGCGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECGGGGSGGGGSGGGGSQSALTQPASVSGSPGQSITISCTGTSSDVGGYNFVSWYQQHPGKAPKLMIYDVSDRPSGVSDRFSGSKSGNTASLIISGLQADDEADYYCSSYGSSSTHVIFGGGTKVTVLGGGGSGGGGSGGGGSGGGGSQVQLQESGGGLVKPGGSLSLSCAASGFTFSSYWMSWVRQAPGKGLEWVANINRDGSASYYVDSVKGRFTISRDDAKNSLYLQMNSLRAEDTAVYYCARDRGVGYFDLWGRGTLVTVSS
>序列ID 74:SI-77H6轻链核苷酸序列
GAAATCGTTATGACGCAGAGTCCCTCCACGCTCTCCGCTAGTGTCGGGGATCGCGTCATTATCACATGCCAGGCCTCCGAGTCAATCAGCAGCTGGCTTGCATGGTATCAACAGAAGCCGGGAAAAGCTCCTAAATTGCTGATCTATGAAGCGTCAAAATTGGCGTCTGGTGTCCCATCTAGGTTCTCCGGCTCTGGGTCTGGTGCGGAATTTACTTTGACAATCTCCAGTCTTCAACCAGACGATTTCGCTACCTACTACTGCCAAGGGTATTTCTATTTTATAAGCCGGACATATGTAAACTCCTTCGGCCAAGGAACAAAGTTGACTGTTCTTGGTGGCGGAGGCAGTGGTGGCGGGGGCAGCGGAGGTGGTGGTTCAGGGGGTGGTGGGAGCGAAGTCCAATTGGTAGAAAGTGGCGGTGGTCTGGTGCAACCTGGTGGATCTCTTAGCCTCTCATGCGCCGCTAGTGGCTTTACTATTTCAACTAATGCGATGAGCTGGGTTCGCCAGGCCCCCGGCAAAGGACTTGAGTGGGTCGGCGTCATCACCGGCAGGGACATTACATACTATGCGAGTTGGGCAAAGGGCAGGTTCACGATTAGCCGCGATACTTCAAAGAATACCGTTTACCTTCAAATGAATAGCTTGAGGGCGGAAGACACAGCTGTGTATTACTGCGCGAGGGATGGAGGTAGTTCCGCCATAACTTCCAACAACATATGGGGACAAGGCACGCTGGTTACTGTCTCGAGCGGCGGTGGAGGGTCCGGCGGTGGTGGATCAGAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCACTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCCCAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCCGGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATTATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGTGTGGGACAAAAGTGGAGATCAAGCGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTGGCGGTGGCGGTAGCGGTGGCGGCGGAAGTGGTGGCGGAGGATCCCAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAGCAGTGACGTTGGTGGTTATAACTTTGTCTCCTGGTACCAACAACACCCAGGCAAAGCCCCCAAACTCATGATCTATGATGTCAGTGATCGGCCCTCAGGGGTGTCTGATCGCTTCTCCGGCTCCAAGTCTGGCAACACGGCCTCCCTGATCATCTCTGGCCTCCAGGCTGACGACGAGGCTGATTATTACTGCAGCTCATATGGGAGCAGCAGCACTCATGTGATTTTCGGCGGAGGGACCAAGGTGACCGTCCTAGGTGGAGGCGGTTCAGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTCAGGTGCAATTGCAGGAGTCGGGGGGAGGCCTGGTCAAGCCTGGAGGGTCCCTGAGTCTCTCCTGTGCAGCCTCTGGATTCACCTTTAGTAGTTATTGGATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCGCGATGGAAGTGCGAGTTACTATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACGACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGATCGTGGGGTGGGCTACTTCGATCTCTGGGGCCGTGGCACCCTGGTCACCGTCTCTAGC
>序列ID 75:SI-55H11重链氨基酸序列
EIVLTQSPSTLSVSPGERATFSCRASQSIGTNIHWYQQKPGKPPRLLIKYASESISGIPDRFSGSGSGTEFTLTISSVQSEDFAVYYCQQNNNWPTTFGPGTKLTVLGGGGSGGGGSGGGGSGGGGSQVQLQQSGPGLVKPSETLSITCTVSGFSLTNYGVHWIRQAPGKGLEWLGVIWSGGNTDYNTPFTSRFTITKDNSKNQVYFKLRSVRADDTAIYYCARALTYYDYEFAYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVRQAPGKCLEWIGVITGRDITYYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKGLEWIACIAAGSAGITYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDLWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITCQASQSISSHLNWYQQKPGKAPKLLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVDNVFGGGTKVEIKGGGGSGGGGSGRSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWVRQAPGKGLEYIGTISSGGNVYYASSARGRFTISRPSSKNTVDLQMNSLRAEDTAVYYCARDSGYSDPMWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPSSVSASVGDRVTITCQASQNIRTYLSWYQQKPGKAPKLLIYAAANLASGVPSRFSGSGSGTDFTLTISDLEPGDAATYYCQSTYLGTDYVGGAFGGGTKVEIK
>序列ID 76:SI-55H11重链核苷酸序列
GAAATCGTCCTTACACAATCTCCTAGCACACTGAGTGTGAGCCCCGGCGAACGCGCGACTTTCTCTTGCAGGGCAAGTCAATCCATAGGGACTAATATACATTGGTATCAACAAAAGCCAGGTAAACCACCCAGGCTTTTGATTAAGTATGCAAGTGAGTCTATTTCCGGTATCCCTGACCGCTTCTCTGGATCAGGCAGTGGCACAGAGTTCACACTCACCATATCTAGTGTGCAATCAGAGGACTTCGCCGTGTATTACTGCCAACAGAATAATAACTGGCCGACTACCTTCGGACCCGGTACAAAGCTGACCGTTTTAGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAAGTACAGTTGCAGCAATCCGGTCCCGGTCTCGTCAAACCGAGTGAGACGCTTAGTATAACGTGTACTGTTTCAGGCTTTAGCCTTACGAACTATGGAGTTCACTGGATTCGGCAGGCACCCGGCAAAGGTTTGGAATGGCTGGGTGTTATTTGGTCAGGTGGAAATACAGACTATAACACCCCCTTTACAAGTCGGTTCACAATTACGAAAGATAATTCCAAAAATCAAGTTTATTTCAAGTTGAGATCCGTCCGCGCGGACGACACTGCGATCTACTATTGTGCGAGGGCACTGACCTACTACGATTACGAATTTGCGTATTGGGGGCAAGGGACTCTTGTAACAGTCTCGAGCGGTGGAGGCGGATCTGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCATCAGTACCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGTGTCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCGAGCTGGGCGAAAGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACGGTGGTTCTTCTGCTATTACTAGTAACAACATTTGGGGCCAGGGAACCCTGGTCACCGTGTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCTCCTTCAGTAGCGGGTACGACATGTGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGCATGCATTGCTGCTGGTAGTGCTGGTATCACTTACGACGCGAACTGGGCGAAAGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAGATCGGCGTTTTCGTTCGACTACGCCATGGACCTCTGGGGCCAGGGAACCCTGGTCACCGTGTCGAGCGGTGGAGGCGGATCTGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGCCAGTCAGAGCATTAGTTCCCACTTAAACTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAGGCATCCACTCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAACAGGGTTATAGTTGGGGTAATGTTGATAATGTTTTCGGCGGAGGGACCAAGGTGGAGATCAAAGGCGGTGGAGGGTCCGGCGGTGGTGGCTCCGGACGGTCGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTACTGCCTCTGGATTCACCATCAGTAGCTACCACATGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTACATCGGAACCATTAGTAGTGGTGGTAATGTATACTACGCAAGCTCCGCTAGAGGCAGATTCACCATCTCCAGACCCTCGTCCAAGAACACGGTGGATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACTCTGGTTATAGTGATCCTATGTGGGGCCAGGGAACCCTGGTCACCGTCTCTTCAGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCAGACGTTGTGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACCTGTCAGGCCAGTCAGAACATTAGGACTTACTTATCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCAGCCAATCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCGACCTGGAGCCTGGCGATGCTGCAACTTACTATTGTCAGTCTACCTATCTTGGTACTGATTATGTTGGCGGTGCTTTCGGCGGAGGGACCAAGGTGGAGATCAAA
>序列ID 77:SI-55H11轻链氨基酸序列
ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGSGSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKVTVLGGGGSGGGGSGGGGSGGGGSQVTLKESGPGLVQPGQTLSLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGGGGSGGGGSDVVMTQSPSTLSASVGDRVTINCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGCGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECGGGGSGGGGSGGGGSQSALTQPASVSGSPGQSITISCTGTSSDVGGYNFVSWYQQHPGKAPKLMIYDVSDRPSGVSDRFSGSKSGNTASLIISGLQADDEADYYCSSYGSSSTHVIFGGGTKVTVLGGGGSGGGGSGGGGSGGGGSQVQLQESGGGLVKPGGSLSLSCAASGFTFSSYWMSWVRQAPGKGLEWVANINRDGSASYYVDSVKGRFTISRDDAKNSLYLQMNSLRAEDTAVYYCARDRGVGYFDLWGRGTLVTVSS
>序列ID 78:SI-55H11轻链核苷酸序列
GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCACTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCCCAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCCGGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATTATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAAGTGACCGTCCTAGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAGGTCACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGCCTCACCTGTGCCTTCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAAAGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAAAGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTGACGCCGAGGATACGGCTGTATATTATTGCGCTCGGATGGAACTCTGGTCTTACTACTTTGATTATTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCAGACGTCGTGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCAATTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAAGCATCCAAACTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAAGGCTATTTTTATTTTATTAGTCGTACTTATGTAAATTCTTTCGGCTGTGGGACCAAGGTGGAGATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTGGCGGTGGCGGTAGCGGTGGCGGCGGAAGTGGTGGCGGAGGATCCCAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAGCAGTGACGTTGGTGGTTATAACTTTGTCTCCTGGTACCAACAACACCCAGGCAAAGCCCCCAAACTCATGATCTATGATGTCAGTGATCGGCCCTCAGGGGTGTCTGATCGCTTCTCCGGCTCCAAGTCTGGCAACACGGCCTCCCTGATCATCTCTGGCCTCCAGGCTGACGACGAGGCTGATTATTACTGCAGCTCATATGGGAGCAGCAGCACTCATGTGATTTTCGGCGGAGGGACCAAGGTGACCGTCCTAGGTGGAGGCGGTTCAGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTCAGGTGCAATTGCAGGAGTCGGGGGGAGGCCTGGTCAAGCCTGGAGGGTCCCTGAGTCTCTCCTGTGCAGCCTCTGGATTCACCTTTAGTAGTTATTGGATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCGCGATGGAAGTGCGAGTTACTATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACGACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGATCGTGGGGTGGGCTACTTCGATCTCTGGGGCCGTGGCACCCTGGTCACCGTCTCTAGCTGA
>序列ID 79:SI-38E17重链氨基酸序列
DVVMTQSPSTLSASVGDRVTINCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVRQAPGKGLEWIGVITGRDITYYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSSGGGGSGGGGSEVQLVQSGAEVKKPGESLKISCKGSGYSFSSSWIGWVRQAPGKGLEWMGIIYPDDSDTRYSPSFQGQVTISADKSIRTAYLQWSSLKASDTAMYYCARHVTMIWGVIIDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKGLEWIACIAAGSAGITYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDLWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITCQASQSISSHLNWYQQKPGKAPKLLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVDNVFGGGTKVEIKGGGGSGGGGSRSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWVRQAPGKGLEYIGTISSGGNVYYASSARGRFTISRPSSKNTVDLQMNSLRAEDTAVYYCARDSGYSDPMWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPSSVSASVGDRVTITCQASQNIRTYLSWYQQKPGKAPKLLIYAAANLASGVPSRFSGSGSGTDFTLTISDLEPGDAATYYCQSTYLGTDYVGGAFGGGTKVEIK
>序列ID 80:SI-38E17重链氨基酸序列
GACGTCGTGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCAATTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAAGCATCCAAACTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAAGGCTATTTTTATTTTATTAGTCGTACTTATGTAAATTCTTTCGGCGGAGGGACCAAGGTGGAGATCAAAGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCAGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCATCAGTACCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCGAGCTGGGCGAAAGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGCGCGACGGTGGATCATCTGCTATTACTAGTAACAACATTTGGGGCCAAGGAACTCTGGTCACCGTTTCTTCAGGCGGTGGAGGGTCCGGCGGTGGTGGATCCGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAGAAACCAGGAGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTAGCAGTTCATGGATCGGCTGGGTGCGCCAGGCACCTGGGAAAGGCCTGGAATGGATGGGGATCATCTATCCTGATGACTCTGATACCAGATACAGTCCATCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGGACTGCCTACCTGCAGTGGAGTAGCCTGAAGGCCTCGGACACCGCTATGTATTACTGTGCGAGACATGTTACTATGATTTGGGGAGTTATTATTGACTTCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTATACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCTCCTTCAGTAGCGGGTACGACATGTGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGCATGCATTGCTGCTGGTAGTGCTGGTATCACTTACGACGCGAACTGGGCGAAAGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAGATCGGCGTTTTCGTTCGACTACGCCATGGACCTCTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGCGGTGGAGGCGGATCTGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGCCAGTCAGAGCATTAGTTCCCACTTAAACTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAGGCATCCACTCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAACAGGGTTATAGTTGGGGTAATGTTGATAATGTTTTCGGCGGAGGGACCAAGGTGGAGATCAAAGGCGGTGGAGGGTCCGGCGGTGGTGGATCCCGGTCGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTACAGCCTCTGGATTCACCATCAGTAGCTACCACATGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTACATCGGAACCATTAGTAGTGGTGGTAATGTATACTACGCGAGCTCCGCGAGAGGCAGATTCACCATCTCCAGACCCTCGTCCAAGAACACGGTGGATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACTCTGGTTATAGTGATCCTATGTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGCGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCAGACGTTGTGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACCTGTCAGGCCAGTCAGAACATTAGGACTTACTTATCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCAGCCAATCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCGACCTGGAGCCTGGCGATGCTGCAACTTACTATTGTCAGTCTACCTATCTTGGTACTGATTATGTTGGCGGTGCTTTCGGCGGAGGGACCAAGGTGGAGATCAAA
>序列ID 81:SI-38E17轻链氨基酸序列
AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
>序列ID 82:SI-38E17轻链核苷酸序列
GCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
>序列ID 83:SI-34C1重链氨基酸序列
EVQLVQSGAEVKKPGESLKISCKGSGYSFSSSWIGWVRQAPGKGLEWMGIIYPDDSDTRYSPSFQGQVTISADKSIRTAYLQWSSLKASDTAMYYCARHVTMIWGVIIDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
>序列ID 84:SI-34C1重链核苷酸序列
GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAGAAACCAGGAGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTAGCAGTTCATGGATCGGCTGGGTGCGCCAGGCACCTGGGAAAGGCCTGGAATGGATGGGGATCATCTATCCTGATGACTCTGATACCAGATACAGTCCATCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGGACTGCCTACCTGCAGTGGAGTAGCCTGAAGGCCTCGGACACCGCTATGTATTACTGTGCGAGACATGTTACTATGATTTGGGGAGTTATTATTGACTTCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT
>序列ID 85:SI-34C1轻链氨基酸序列
AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
>序列ID 86:SI-34C1轻链核苷酸序列
GCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
>序列ID 87:SI-38P12重链氨基酸序列
QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLTVLGGGGSGGGGSGGGGSGGGGSQVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVRQAPGKGLEWIGVITGRDITYYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKGLEWIACIAAGSAGITYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDLWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITCQASQSISSHLNWYQQKPGKAPKLLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVDNVFGGGTKVEIKGGGGSGGGGSGRSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWVRQAPGKGLEYIGTISSGGNVYYASSARGRFTISRPSSKNTVDLQMNSLRAEDTAVYYCARDSGYSDPMWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPSSVSASVGDRVTITCQASQNIRTYLSWYQQKPGKAPKLLIYAAANLASGVPSRFSGSGSGTDFTLTISDLEPGDAATYYCQSTYLGTDYVGGAFGGGTKVEIK
>序列ID 88:SI-38P12重链核苷酸序列
CAGATCGTGCTGAGCCAGAGCCCCGCCATCCTGAGCGCCAGCCCCGGCGAGAAGGTGACCATGACCTGCCGGGCCAGCAGCAGCGTGAGCTACATCCACTGGTTCCAGCAGAAGCCCGGCAGCAGCCCCAAGCCCTGGATCTACGCCACCAGCAACCTGGCCAGCGGCGTGCCCGTGCGGTTCAGCGGCAGCGGCAGCGGCACCAGCTACAGCCTGACCATCAGCCGGGTGGAGGCCGAGGACGCCGCCACCTACTACTGCCAGCAGTGGACCAGCAACCCCCCCACCTTCGGCGGCGGCACCAAGCTGACCGTGCTGGGTGGTGGTGGCTCTGGAGGAGGCGGGAGCGGGGGTGGTGGCTCAGGTGGTGGAGGTTCCCAGGTGCAGCTGCAGCAGCCCGGCGCCGAGCTGGTGAAGCCCGGCGCCAGCGTGAAGATGAGCTGCAAGGCCAGCGGCTACACCTTCACCAGCTACAACATGCACTGGGTGAAGCAGACCCCCGGCCGGGGCCTGGAGTGGATCGGCGCCATCTACCCCGGCAACGGCGACACCAGCTACAACCAGAAGTTCAAGGGCAAGGCCACCCTGACCGCCGACAAGAGCAGCAGCACCGCCTACATGCAGCTGAGCAGCCTGACCAGCGAGGACAGCGCCGTGTACTACTGCGCCCGGAGCACCTACTACGGCGGCGACTGGTACTTCAACGTGTGGGGCGCCGGCACCACCGTGACCGTCTCGAGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCAGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCATCAGTACCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCGAGCTGGGCGAAAGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACGGTGGTTCTTCTGCTATTACTAGTAACAACATTTGGGGCCAGGGAACCCTGGTCACCGTGTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCTCCTTCAGTAGCGGGTACGACATGTGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGCATGCATTGCTGCTGGTAGTGCTGGTATCACTTACGACGCGAACTGGGCGAAAGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAGATCGGCGTTTTCGTTCGACTACGCCATGGACCTCTGGGGCCAGGGAACCCTGGTCACCGTGTCGAGCGGTGGAGGCGGATCTGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGCCAGTCAGAGCATTAGTTCCCACTTAAACTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAGGCATCCACTCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAACAGGGTTATAGTTGGGGTAATGTTGATAATGTTTTCGGCGGAGGGACCAAGGTGGAGATCAAAGGCGGTGGAGGGTCCGGCGGTGGTGGCTCCGGACGGTCGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTACTGCCTCTGGATTCACCATCAGTAGCTACCACATGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTACATCGGAACCATTAGTAGTGGTGGTAATGTATACTACGCAAGCTCCGCTAGAGGCAGATTCACCATCTCCAGACCCTCGTCCAAGAACACGGTGGATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACTCTGGTTATAGTGATCCTATGTGGGGCCAGGGAACCCTGGTCACCGTCTCTTCAGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCAGACGTTGTGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACCTGTCAGGCCAGTCAGAACATTAGGACTTACTTATCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCAGCCAATCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCGACCTGGAGCCTGGCGATGCTGCAACTTACTATTGTCAGTCTACCTATCTTGGTACTGATTATGTTGGCGGTGCTTTCGGCGGAGGGACCAAGGTGGAGATCAAATGA
>序列ID 89:SI-38P12轻链氨基酸序列
ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGSGSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKVTVLGGGGSGGGGSGGGGSGGGGSQVTLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGGGGSGGGGSDVVMTQSPSTLSASVGDRVTINCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
>序列ID 90:SI-38P12轻链核苷酸序列
GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCACTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCCCAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCCGGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATTATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAAGTGACGGTACTGGGTGGAGGCGGTTCAGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTCAGGTCACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCTTCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAAAGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAAAGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTGACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTATTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGCGGCGGTGGAGGGTCCGGCGGTGGTGGATCAGACGTCGTGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCAATTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAAGCATCCAAACTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAAGGCTATTTTTATTTTATTAGTCGTACTTATGTAAATTCTTTCGGCGGAGGGACCAAGGTGGAGATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
>序列ID 91:人源化形式7(H7VH)氨基酸序列
QVTLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKCLEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSS
>序列ID 92:人源化形式7(H7VH)核苷酸序列
CAGGTCACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCTTCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAAATGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAAAGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTGACGCCGAGGATACGGCTGTATATTATTGCGCTCGGATGGAACTCTGGTCTTACTACTTTGATTATTGGGGGCAGGGGACTCTCGTCACGGTGTCGAGT
>序列ID 93:人源化形式7(H7VL)氨基酸序列
ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGSGSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGCGTKVEIK
>序列ID 94:人源化形式7(H7VL)核苷酸序列
GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCACTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCCCAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCCGGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATTATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGTGTGGGACAAAAGTGGAGATCAAG
>序列ID 95:SI-63SV7氨基酸序列
ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGSGSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGCGTKVEIKGGGGSGGGGSGGGGSGGGGSQVTLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKCLEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSS
>序列ID 96:SI-63SV7核酸序列
GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCACTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCCCAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCCGGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATTATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGTGTGGGACAAAAGTGGAGATCAAGGGTGGCGGAGGCAGTGGTGGCGGGGGCAGCGGAGGTGGTGGTTCAGGGGGTGGTGGGAGCCAGGTCACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCTTCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAAATGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAAAGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTGACGCCGAGGATACGGCTGTATATTATTGCGCTCGGATGGAACTCTGGTCTTACTACTTTGATTATTGGGGGCAGGGGACTCTCGTCACGGTGTCGAGT
序列表
<110> 西雅图免疫公司
四川百利药业有限责任公司
<120> 抗CD19抗体及其使用和制备方法
<130> SIBA063PCT
<141> 2021-02-27
<150> 62/984,731
<151> 2020-03-03
<160> 96
<170> SIPOSequenceListing 1.0
<210> 1
<211> 120
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 1
Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln
1 5 10 15
Thr Leu Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80
Tyr Leu Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 2
<211> 360
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 2
caggtcacat tgaaggaatc tggccccggc cttgttcagc caggacagac ccttaggctc 60
acctgtgcct tcagtggttt ttctcttagc actagcggta tgggggtcgg ctggattcgg 120
cagcctcccg gcaaaggtct tgagtggttg gctcacattt ggtgggacga cgacaaacgg 180
tataatcctg ccttgaaaag tcggctgacc attagtaagg atacctcaaa aaatcaagtg 240
tacttgcaaa tgaatagcct tgacgccgag gatacggctg tatattattg cgcgcggatg 300
gaactctggt cttactactt tgattattgg gggcagggga ctctcgtcac ggtctcgagt 360
<210> 3
<211> 120
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 3
Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln
1 5 10 15
Thr Leu Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80
Tyr Leu Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 4
<211> 360
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 4
caggtcacat tgaaggaatc tggccccggc cttgttcagc caggacagac ccttaggctc 60
acctgtgcct tcagtggttt ttctcttagc actagcggta tgggggtcgg ctggattcgg 120
cagcctcccg gcaaaggtct tgagtggttg gctcacattt ggtgggacga cgacaaacgg 180
tataatcctg ccttgaaaag tcggctgacc attagtaagg atacctcaaa aaatcaagtg 240
tacttgcaaa tgaatagcct tgacgccgag gatacggctg tatattattg cgcgcggatg 300
gaactctggt cttactactt tgattattgg gggcagggga ctctcgtcac ggtctcgagt 360
<210> 5
<211> 120
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 5
Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln
1 5 10 15
Thr Leu Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80
Tyr Leu Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 6
<211> 360
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 6
caggtcacat tgaaggaatc tggccccggc cttgttcagc caggacagac ccttaggctc 60
acctgtgcct tcagtggttt ttctcttagc actagcggta tgggggtcgg ctggattcgg 120
cagcctcccg gcaaaggtct tgagtggttg gctcacattt ggtgggacga cgacaaacgg 180
tataatcctg ccttgaaaag tcggctgacc attagtaagg atacctcaaa aaatcaagtg 240
tacttgcaaa tgaatagcct tgacgccgag gatacggctg tatattattg cgcgcggatg 300
gaactctggt cttactactt tgattattgg gggcagggga ctctcgtcac ggtctcgagt 360
<210> 7
<211> 120
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 7
Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln
1 5 10 15
Thr Leu Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80
Tyr Leu Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 8
<211> 360
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 8
caggtcacat tgaaggaatc tggccccggc cttgttcagc caggacagac ccttaggctc 60
acctgtgcct tcagtggttt ttctcttagc actagcggta tgggggtcgg ctggattcgg 120
cagcctcccg gcaaaggtct tgagtggttg gctcacattt ggtgggacga cgacaaacgg 180
tataatcctg ccttgaaaag tcggctgacc attagtaagg atacctcaaa aaatcaagtg 240
tacttgcaaa tgaatagcct tgacgccgag gatacggctg tatattattg cgcgcggatg 300
gaactctggt cttactactt tgattattgg gggcagggga ctctcgtcac ggtctcgagt 360
<210> 9
<211> 120
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 9
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Val Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
35 40 45
Trp Val Gly His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala
50 55 60
Leu Lys Ser Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn Thr Val
65 70 75 80
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 10
<211> 360
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 10
gaggtgcaac ttgtggaaag cggcggcggg ttggtgcaac ctggcggttc acttcggctc 60
tcatgtgtgt tcagtggttt ttcccttagc acaagcggga tgggtgtcgg gtgggtccgc 120
caagcgcctg gcaaaggtct ggaatgggtt ggtcacattt ggtgggatga tgacaaaagg 180
tataatcccg cgctgaaatc tagatttact attagtcggg atacgagtaa gaacacggtg 240
tatctgcaaa tgaacagtct cagggcagag gatacagcgg tatattattg tgctcgaatg 300
gagctgtggt cttactattt tgattactgg ggccagggca cgttggtaac ggtctcgagt 360
<210> 11
<211> 120
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 11
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
35 40 45
Trp Val Gly His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala
50 55 60
Leu Lys Ser Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn Thr Val
65 70 75 80
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 12
<211> 360
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 12
gaggtgcaac ttgtggaaag cggcggcggg ttggtgcaac ctggcggttc acttcggctc 60
tcatgtagct tcagtggttt ttcccttagc acaagcggga tgggtgtcgg gtgggtccgc 120
caagcgcctg gcaaaggtct ggaatgggtt ggtcacattt ggtgggatga tgacaaaagg 180
tataatcccg cgctgaaatc tagatttact attagtcggg atacgagtaa gaacacggtg 240
tatctgcaaa tgaacagtct cagggcagag gatacagcgg tatattattg tgctcgaatg 300
gagctgtggt cttactattt tgattactgg ggccagggca cgttggtaac ggtctcgagt 360
<210> 13
<211> 106
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 13
Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly
1 5 10 15
Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 14
<211> 318
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 14
gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact 60
atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga 120
caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc 180
ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa 240
gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg 300
acaaaattgg agataaag 318
<210> 15
<211> 106
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 15
Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly
1 5 10 15
Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Gln Gly Thr Lys Ile Thr Ile Leu
100 105
<210> 16
<211> 318
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 16
gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact 60
atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga 120
caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc 180
ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa 240
gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg 300
acaaaaatta cgatactg 318
<210> 17
<211> 106
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 17
Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly
1 5 10 15
Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Thr Val Leu
100 105
<210> 18
<211> 318
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 18
gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact 60
atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga 120
caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc 180
ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa 240
gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg 300
acaaaactta cggtactg 318
<210> 19
<211> 106
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 19
Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly
1 5 10 15
Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Gln Gly Thr Lys Val Thr Val Leu
100 105
<210> 20
<211> 318
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 20
gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact 60
atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga 120
caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc 180
ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa 240
gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg 300
acaaaagtta cggtactg 318
<210> 21
<211> 106
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 21
Glu Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Ile Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Thr Val Leu
100 105
<210> 22
<211> 318
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 22
gaaatagtga tgacgcagtc acctagcacc cttagtgctt ctgtaggaga cagggttata 60
attacctgca gtgctagttc ctcagtgtca tacatgcact ggtatcagca gaaaccggga 120
aaagctccaa agctgcttat atacgacacg tccaaattgg catcaggtgt ccccagtcga 180
tttagtggct ctggctcagg ggctgaattt acgctcacaa tctccagcct ccaaccagat 240
gacttcgcca catactactg ttttcagggc tcagtgtatc cgtttacttt cggccagggg 300
acaaagttga ctgtactt 318
<210> 23
<211> 106
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 23
Glu Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Ile Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Thr Val Leu
100 105
<210> 24
<211> 318
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 24
gaaatagtga tgacgcagtc acctagcacc cttagtgctt ctgtaggaga cagggttata 60
attacctgca gtgctagttc ctcagtgtca tacatgcact ggtatcagca gaaaccggga 120
aaagctccaa agctgcttat atacgacacg tccaaattgg catcaggtgt ccccagtcga 180
tttagtggct ctggctcagg ggctgaattt acgctcacaa tctccagcct ccaaccagat 240
gacttcgcca catactactg ttttcagggc tcagtgtatc cgtttacttt cggccagggg 300
acaaagttga ctgtactt 318
<210> 25
<211> 120
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 25
Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Gly Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Ser Asn Gln Val
65 70 75 80
Phe Leu Lys Ile Ala Ser Val Asp Thr Ala Asp Thr Ala Ala Tyr Tyr
85 90 95
Cys Ala Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Thr Leu Thr Val Ser Ser
115 120
<210> 26
<211> 360
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 26
caggtgaccc tgaaagaaag cggcccgggc attctgcagc cgagccagac cctgagcctg 60
acctgcagct ttagcggctt tagcctgagc accagcggca tgggcgtggg ctggattcgc 120
cagccgagcg gcaaaggcct ggaatggctg gcgcatattt ggtgggatga tgataaacgc 180
tataacccgg cgctgaaaag ccgcctgacc attagcaaag ataccagcag caaccaggtg 240
tttctgaaaa ttgcgagcgt ggataccgcg gataccgcgg cgtattattg cgcgcgcatg 300
gaactgtgga gctattattt tgattattgg ggccagggca ccaccctgac cgtgagcagc 360
<210> 27
<211> 106
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 27
Glu Asn Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly
1 5 10 15
Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Ser Ser Thr Ser Pro Lys Leu Trp Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Gly Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Asn Ser His Phe Leu Thr Ile Ser Ser Met Glu Ala Glu
65 70 75 80
Asp Val Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 28
<211> 318
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 28
gaaaacgtgc tgacccagag cccggcgatt atgagcgcga gcccgggcga aaaagtgacc 60
atgacctgca gcgcgagcag cagcgtgagc tatatgcatt ggtatcagca gaaaagcagc 120
accagcccga aactgtggat ttatgatacc agcaaactgg cgagcggcgt gccgggccgc 180
tttagcggca gcggcagcgg caacagccat tttctgacca ttagcagcat ggaagcggaa 240
gatgtggcga cctattattg ctttcagggc agcgtgtatc cgtttacctt tggcagcggc 300
accaaactgg aaattaaa 318
<210> 29
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 29
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ser Ser Ser
20 25 30
Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Tyr Pro Asp Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
50 55 60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Arg Thr Ala Tyr
65 70 75 80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg His Val Thr Met Ile Trp Gly Val Ile Ile Asp Phe Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 30
<211> 363
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 30
gaggtgcagc tggtgcagtc tggagcagag gtgaagaaac caggagagtc tctgaagatc 60
tcctgtaagg gttctggata cagctttagc agttcatgga tcggctgggt gcgccaggca 120
cctgggaaag gcctggaatg gatggggatc atctatcctg atgactctga taccagatac 180
agtccatcct tccaaggcca ggtcaccatc tcagccgaca agtccatcag gactgcctac 240
ctgcagtgga gtagcctgaa ggcctcggac accgctatgt attactgtgc gagacatgtt 300
actatgattt ggggagttat tattgacttc tggggccagg gaaccctggt caccgtctcc 360
tca 363
<210> 31
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 31
Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Ala
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
<210> 32
<211> 321
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 32
gccatccagt tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggcaagtca gggcattagc agtgctttag cctggtatca gcagaaacca 120
gggaaagctc ctaagctcct gatctatgat gcctccagtt tggaaagtgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcagcct 240
gaagattttg caacttatta ctgtcaacag tttaatagtt acccattcac tttcggccct 300
gggaccaaag tggatatcaa a 321
<210> 33
<211> 449
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 33
Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Gly Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Ser Asn Gln Val
65 70 75 80
Phe Leu Lys Ile Ala Ser Val Asp Thr Ala Asp Thr Ala Ala Tyr Tyr
85 90 95
Cys Ala Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Thr Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp
210 215 220
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro
225 230 235 240
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
260 265 270
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
275 280 285
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val
290 295 300
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305 310 315 320
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
325 330 335
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
340 345 350
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
355 360 365
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
405 410 415
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
Lys
<210> 34
<211> 1347
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 34
caggtgaccc tgaaagaaag cggcccgggc attctgcagc cgagccagac cctgagcctg 60
acctgcagct ttagcggctt tagcctgagc accagcggca tgggcgtggg ctggattcgc 120
cagccgagcg gcaaaggcct ggaatggctg gcgcatattt ggtgggatga tgataaacgc 180
tataacccgg cgctgaaaag ccgcctgacc attagcaaag ataccagcag caaccaggtg 240
tttctgaaaa ttgcgagcgt ggataccgcg gataccgcgg cgtattattg cgcgcgcatg 300
gaactgtgga gctattattt tgattattgg ggccagggca ccaccctgac cgtgagcagc 360
gctagcacca agggcccatc tgtcttcccc ctggcaccct cctccaagag cacctctggg 420
ggcacagctg ccctgggctg cctggtcaag gactacttcc ctgaacctgt gacagtgtcc 480
tggaactcag gagccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca 540
ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacccagacc 600
tacatctgca acgtgaatca caagcccagc aacaccaagg tggacaagaa agttgagccc 660
aaatcttgtg acaaaactca cacatgccca ccgtgcccag cacctcctgt agcaggaccg 720
tcagtcttcc tcttcccccc aaaacccaag gacaccctca tgatctcccg gacccctgag 780
gtcacatgcg tggtggtgga cgtgagccac gaagaccctg aggtcaagtt caactggtac 840
gtggacggcg tggaggtgca taatgccaag acaaagccgc gggaggagca gtacgccagc 900
acgtaccgtg tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa tggcaaggag 960
tacaagtgca aggtctccaa caaagccctc ccagccccca tcgagaaaac catctccaaa 1020
gccaaagggc agccccgaga accacaggtg tacaccctgc ccccatcccg ggatgagctg 1080
accaagaacc aggtcagcct gacctgcctg gtcaaaggct tctatcccag cgacatcgcc 1140
gtggagtggg agagcaatgg gcagccggag aacaactaca agaccacgcc tcccgtgctg 1200
gactccgacg gctccttctt cctctacagc aagctcaccg tggacaagag caggtggcag 1260
caggggaacg tcttctcatg ctccgtgatg catgaggctc tgcacaacca ctacacacag 1320
aagagcctct ccctgtctcc gggcaaa 1347
<210> 35
<211> 213
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 35
Glu Asn Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly
1 5 10 15
Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Ser Ser Thr Ser Pro Lys Leu Trp Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Gly Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Asn Ser His Phe Leu Thr Ile Ser Ser Met Glu Ala Glu
65 70 75 80
Asp Val Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro
100 105 110
Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr
115 120 125
Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys
130 135 140
Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu
145 150 155 160
Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser
165 170 175
Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala
180 185 190
Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe
195 200 205
Asn Arg Gly Glu Cys
210
<210> 36
<211> 639
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 36
gaaaacgtgc tgacccagag cccggcgatt atgagcgcga gcccgggcga aaaagtgacc 60
atgacctgca gcgcgagcag cagcgtgagc tatatgcatt ggtatcagca gaaaagcagc 120
accagcccga aactgtggat ttatgatacc agcaaactgg cgagcggcgt gccgggccgc 180
tttagcggca gcggcagcgg caacagccat tttctgacca ttagcagcat ggaagcggaa 240
gatgtggcga cctattattg ctttcagggc agcgtgtatc cgtttacctt tggcagcggc 300
accaaactgg aaattaaacg tacggtggct gcaccatctg tcttcatctt cccgccatct 360
gatgagcagt tgaaatctgg aactgcctct gttgtgtgcc tgctgaataa cttctatccc 420
agagaggcca aagtacagtg gaaggtggat aacgccctcc aatcgggtaa ctcccaggag 480
agtgtcacag agcaggacag caaggacagc acctacagcc tcagcagcac cctgacgctg 540
agcaaagcag actacgagaa acacaaagtc tacgcctgcg aagtcaccca tcagggcctg 600
agctcgcccg tcacaaagag cttcaacagg ggagagtgt 639
<210> 37
<211> 449
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 37
Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln
1 5 10 15
Thr Leu Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80
Tyr Leu Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp
210 215 220
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro
225 230 235 240
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
260 265 270
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
275 280 285
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val
290 295 300
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305 310 315 320
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
325 330 335
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
340 345 350
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
355 360 365
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
405 410 415
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
Lys
<210> 38
<211> 1347
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 38
caggtcacat tgaaggaatc tggccccggc cttgttcagc caggacagac ccttaggctc 60
acctgtgcct tcagtggttt ttctcttagc actagcggta tgggggtcgg ctggattcgg 120
cagcctcccg gcaaaggtct tgagtggttg gctcacattt ggtgggacga cgacaaacgg 180
tataatcctg ccttgaaaag tcggctgacc attagtaagg atacctcaaa aaatcaagtg 240
tacttgcaaa tgaatagcct tgacgccgag gatacggctg tatattattg cgcgcggatg 300
gaactctggt cttactactt tgattattgg gggcagggga ctctcgtcac ggtgtcctct 360
gctagcacca agggcccatc tgtcttcccc ctggcaccct cctccaagag cacctctggg 420
ggcacagctg ccctgggctg cctggtcaag gactacttcc ctgaacctgt gacagtgtcc 480
tggaactcag gagccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca 540
ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacccagacc 600
tacatctgca acgtgaatca caagcccagc aacaccaagg tggacaagaa agttgagccc 660
aaatcttgtg acaaaactca cacatgccca ccgtgcccag cacctcctgt agcaggaccg 720
tcagtcttcc tcttcccccc aaaacccaag gacaccctca tgatctcccg gacccctgag 780
gtcacatgcg tggtggtgga cgtgagccac gaagaccctg aggtcaagtt caactggtac 840
gtggacggcg tggaggtgca taatgccaag acaaagccgc gggaggagca gtacgccagc 900
acgtaccgtg tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa tggcaaggag 960
tacaagtgca aggtctccaa caaagccctc ccagccccca tcgagaaaac catctccaaa 1020
gccaaagggc agccccgaga accacaggtg tacaccctgc ccccatcccg ggatgagctg 1080
accaagaacc aggtcagcct gacctgcctg gtcaaaggct tctatcccag cgacatcgcc 1140
gtggagtggg agagcaatgg gcagccggag aacaactaca agaccacgcc tcccgtgctg 1200
gactccgacg gctccttctt cctctacagc aagctcaccg tggacaagag caggtggcag 1260
caggggaacg tcttctcatg ctccgtgatg catgaggctc tgcacaacca ctacacacag 1320
aagagcctct ccctgtctcc gggcaaa 1347
<210> 39
<211> 213
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 39
Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly
1 5 10 15
Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro
100 105 110
Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr
115 120 125
Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys
130 135 140
Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu
145 150 155 160
Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser
165 170 175
Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala
180 185 190
Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe
195 200 205
Asn Arg Gly Glu Cys
210
<210> 40
<211> 639
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 40
gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact 60
atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga 120
caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc 180
ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa 240
gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg 300
acaaaattgg agataaagcg tacggtggct gcaccatctg tcttcatctt cccgccatct 360
gatgagcagt tgaaatctgg aactgcctct gttgtgtgcc tgctgaataa cttctatccc 420
agagaggcca aagtacagtg gaaggtggat aacgccctcc aatcgggtaa ctcccaggag 480
agtgtcacag agcaggacag caaggacagc acctacagcc tcagcagcac cctgacgctg 540
agcaaagcag actacgagaa acacaaagtc tacgcctgcg aagtcaccca tcagggcctg 600
agctcgcccg tcacaaagag cttcaacagg ggagagtgt 639
<210> 41
<211> 254
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 41
Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly
1 5 10 15
Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Gly Gly Gly Gly Ser Gly
100 105 110
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
115 120 125
Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu
130 135 140
Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met
145 150 155 160
Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
165 170 175
Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys
180 185 190
Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu
195 200 205
Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
210 215 220
Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
225 230 235 240
Leu Val Thr Val Ser Ser Gly Ser His His His His His His
245 250
<210> 42
<211> 765
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 42
gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact 60
atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga 120
caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc 180
ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa 240
gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg 300
acaaaattgg agataaaggg cggtggcggt agtgggggag gcggttctgg cggcggaggg 360
tccggcggtg gaggatcaca ggtcacattg aaggaatctg gccccggcct tgttcagcca 420
ggacagaccc ttaggctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg 480
ggggtcggct ggattcggca gcctcccggc aaaggtcttg agtggttggc tcacatttgg 540
tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat 600
acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta 660
tattattgcg cgcggatgga actctggtct tactactttg attattgggg gcaggggact 720
ctcgtcacgg tctcgagtgg atcccatcat caccatcacc attga 765
<210> 43
<211> 246
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 43
Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly
1 5 10 15
Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Gly Gly Gly Gly Ser Gly
100 105 110
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
115 120 125
Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu
130 135 140
Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met
145 150 155 160
Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
165 170 175
Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys
180 185 190
Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu
195 200 205
Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
210 215 220
Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
225 230 235 240
Leu Val Thr Val Ser Ser
245
<210> 44
<211> 738
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 44
gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact 60
atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga 120
caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc 180
ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa 240
gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg 300
acaaaattgg agataaaggg cggtggcggt agtgggggag gcggttctgg cggcggaggg 360
tccggcggtg gaggatcaca ggtcacattg aaggaatctg gccccggcct tgttcagcca 420
ggacagaccc ttaggctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg 480
ggggtcggct ggattcggca gcctcccggc aaaggtcttg agtggttggc tcacatttgg 540
tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat 600
acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta 660
tattattgcg cgcggatgga actctggtct tactactttg attattgggg gcaggggact 720
ctcgtcacgg tctcgagt 738
<210> 45
<211> 246
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 45
Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly
1 5 10 15
Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Gln Gly Thr Lys Ile Thr Ile Leu Gly Gly Gly Gly Ser Gly
100 105 110
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
115 120 125
Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu
130 135 140
Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met
145 150 155 160
Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
165 170 175
Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys
180 185 190
Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu
195 200 205
Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
210 215 220
Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
225 230 235 240
Leu Val Thr Val Ser Ser
245
<210> 46
<211> 738
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 46
gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact 60
atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga 120
caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc 180
ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa 240
gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg 300
acaaaaatta cgatactggg cggtggcggt agtgggggag gcggttctgg cggcggaggg 360
tccggcggtg gaggatcaca ggtcacattg aaggaatctg gccccggcct tgttcagcca 420
ggacagaccc ttaggctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg 480
ggggtcggct ggattcggca gcctcccggc aaaggtcttg agtggttggc tcacatttgg 540
tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat 600
acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta 660
tattattgcg cgcggatgga actctggtct tactactttg attattgggg gcaggggact 720
ctcgtcacgg tctcgagt 738
<210> 47
<211> 246
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 47
Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly
1 5 10 15
Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Ser Gly
100 105 110
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
115 120 125
Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu
130 135 140
Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met
145 150 155 160
Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
165 170 175
Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys
180 185 190
Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu
195 200 205
Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
210 215 220
Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
225 230 235 240
Leu Val Thr Val Ser Ser
245
<210> 48
<211> 738
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 48
gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact 60
atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga 120
caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc 180
ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa 240
gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg 300
acaaaattga cggtactggg cggtggcggt agtgggggag gcggttctgg cggcggaggg 360
tccggcggtg gaggatcaca ggtcacattg aaggaatctg gccccggcct tgttcagcca 420
ggacagaccc ttaggctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg 480
ggggtcggct ggattcggca gcctcccggc aaaggtcttg agtggttggc tcacatttgg 540
tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat 600
acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta 660
tattattgcg cgcggatgga actctggtct tactactttg attattgggg gcaggggact 720
ctcgtcacgg tctcgagt 738
<210> 49
<211> 246
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 49
Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly
1 5 10 15
Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Gln Gly Thr Lys Val Thr Val Leu Gly Gly Gly Gly Ser Gly
100 105 110
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
115 120 125
Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu
130 135 140
Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met
145 150 155 160
Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
165 170 175
Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys
180 185 190
Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu
195 200 205
Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
210 215 220
Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
225 230 235 240
Leu Val Thr Val Ser Ser
245
<210> 50
<211> 738
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 50
gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact 60
atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga 120
caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc 180
ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa 240
gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg 300
acaaaagtta cggtactggg cggtggcggt agtgggggag gcggttctgg cggcggaggg 360
tccggcggtg gaggatcaca ggtcacattg aaggaatctg gccccggcct tgttcagcca 420
ggacagaccc ttaggctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg 480
ggggtcggct ggattcggca gcctcccggc aaaggtcttg agtggttggc tcacatttgg 540
tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat 600
acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta 660
tattattgcg cgcggatgga actctggtct tactactttg attattgggg gcaggggact 720
ctcgtcacgg tctcgagt 738
<210> 51
<211> 246
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 51
Glu Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Ile Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Ser Gly
100 105 110
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val
115 120 125
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
130 135 140
Arg Leu Ser Cys Val Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met
145 150 155 160
Gly Val Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
165 170 175
Gly His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys
180 185 190
Ser Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn Thr Val Tyr Leu
195 200 205
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
210 215 220
Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
225 230 235 240
Leu Val Thr Val Ser Ser
245
<210> 52
<211> 738
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 52
gaaatagtga tgacgcagtc acctagcacc cttagtgctt ctgtaggaga cagggttata 60
attacctgca gtgctagttc ctcagtgtca tacatgcact ggtatcagca gaaaccggga 120
aaagctccaa agctgcttat atacgacacg tccaaattgg catcaggtgt ccccagtcga 180
tttagtggct ctggctcagg ggctgaattt acgctcacaa tctccagcct ccaaccagat 240
gacttcgcca catactactg ttttcagggc tcagtgtatc cgtttacttt cggccagggg 300
acaaagttga ctgtacttgg cggtggcggt agtgggggag gcggttctgg cggcggaggg 360
tccggcggtg gaggatcaga ggtgcaactt gtggaaagcg gcggcgggtt ggtgcaacct 420
ggcggttcac ttcggctctc atgtgtgttc agtggttttt cccttagcac aagcgggatg 480
ggtgtcgggt gggtccgcca agcgcctggc aaaggtctgg aatgggttgg tcacatttgg 540
tgggatgatg acaaaaggta taatcccgcg ctgaaatcta gatttactat tagtcgggat 600
acgagtaaga acacggtgta tctgcaaatg aacagtctca gggcagagga tacagcggta 660
tattattgtg ctcgaatgga gctgtggtct tactattttg attactgggg ccagggcacg 720
ttggtaacgg tctcgagt 738
<210> 53
<211> 246
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 53
Glu Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Ile Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Ser Gly
100 105 110
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val
115 120 125
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
130 135 140
Arg Leu Ser Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met
145 150 155 160
Gly Val Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
165 170 175
Gly His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys
180 185 190
Ser Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn Thr Val Tyr Leu
195 200 205
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
210 215 220
Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
225 230 235 240
Leu Val Thr Val Ser Ser
245
<210> 54
<211> 738
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 54
gaaatagtga tgacgcagtc acctagcacc cttagtgctt ctgtaggaga cagggttata 60
attacctgca gtgctagttc ctcagtgtca tacatgcact ggtatcagca gaaaccggga 120
aaagctccaa agctgcttat atacgacacg tccaaattgg catcaggtgt ccccagtcga 180
tttagtggct ctggctcagg ggctgaattt acgctcacaa tctccagcct ccaaccagat 240
gacttcgcca catactactg ttttcagggc tcagtgtatc cgtttacttt cggccagggg 300
acaaagttga ctgtacttgg cggtggcggt agtgggggag gcggttctgg cggcggaggg 360
tccggcggtg gaggatcaga ggtgcaactt gtggaaagcg gcggcgggtt ggtgcaacct 420
ggcggttcac ttcggctctc atgtagcttc agtggttttt cccttagcac aagcgggatg 480
ggtgtcgggt gggtccgcca agcgcctggc aaaggtctgg aatgggttgg tcacatttgg 540
tgggatgatg acaaaaggta taatcccgcg ctgaaatcta gatttactat tagtcgggat 600
acgagtaaga acacggtgta tctgcaaatg aacagtctca gggcagagga tacagcggta 660
tattattgtg ctcgaatgga gctgtggtct tactattttg attactgggg ccagggcacg 720
ttggtaacgg tctcgagt 738
<210> 55
<211> 507
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 55
Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly
1 5 10 15
Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Gly Gly Gly Gly Ser Gly
100 105 110
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
115 120 125
Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu
130 135 140
Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met
145 150 155 160
Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
165 170 175
Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys
180 185 190
Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu
195 200 205
Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
210 215 220
Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
225 230 235 240
Leu Val Thr Val Ser Ser Gly Gly Ser Ser Gly Ser Gly Ser Gly Ser
245 250 255
Thr Gly Leu Val Pro Arg Gly Ser Thr Ser Ser Ser Gly Thr Gly Thr
260 265 270
Ser Ala Gly Thr Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro
275 280 285
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
290 295 300
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
305 310 315 320
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
325 330 335
Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
340 345 350
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
355 360 365
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
370 375 380
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
385 390 395 400
Leu Thr Lys Asn Gln Val Ser Leu Arg Cys His Val Lys Gly Phe Tyr
405 410 415
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
420 425 430
Asn Tyr Lys Thr Thr Lys Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
435 440 445
Leu Tyr Ser Thr Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
450 455 460
Val Phe Ser Cys Ser Val Leu His Glu Ala Leu His Asn His Tyr Thr
465 470 475 480
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Ser Gly Leu Asn Asp
485 490 495
Ile Phe Glu Ala Gln Lys Ile Glu Trp His Glu
500 505
<210> 56
<211> 1521
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 56
gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact 60
atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga 120
caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc 180
ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa 240
gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg 300
acaaaattgg agataaaggg cggtggcggt agtgggggag gcggttctgg cggcggaggg 360
tccggcggtg gaggatcaca ggtcacattg aaggaatctg gccccggcct tgttcagcca 420
ggacagaccc ttaggctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg 480
ggggtcggct ggattcggca gcctcccggc aaaggtcttg agtggttggc tcacatttgg 540
tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat 600
acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta 660
tattattgcg cgcggatgga actctggtct tactactttg attattgggg gcaggggact 720
ctcgtcacgg tctcgagtgg gggatcctct ggaagtggct ccggcagcac tgggctcgta 780
ccaagggggt ccacatccag tagcggtact ggcacatccg cgggaacccc cgtcgctgga 840
ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggacccct 900
gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg 960
tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacgct 1020
agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag 1080
gagtacaagt gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc 1140
aaagccaaag ggcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggatgag 1200
ctgaccaaga accaggtcag cctgagatgc cacgtcaaag gcttctatcc cagcgacatc 1260
gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gaagcccgtg 1320
ctggactccg acggctcctt cttcctctac agcaccctca ccgtggacaa gagcaggtgg 1380
cagcagggga acgtcttctc atgctccgtg ctccatgagg ctctgcacaa ccactacaca 1440
cagaagagcc tctccctgtc tccgggcaaa ggttcaggcc tgaacgatat ttttgaagcg 1500
cagaaaattg aatggcatga a 1521
<210> 57
<211> 507
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 57
Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly
1 5 10 15
Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Gln Gly Thr Lys Ile Thr Ile Leu Gly Gly Gly Gly Ser Gly
100 105 110
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
115 120 125
Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu
130 135 140
Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met
145 150 155 160
Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
165 170 175
Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys
180 185 190
Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu
195 200 205
Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
210 215 220
Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
225 230 235 240
Leu Val Thr Val Ser Ser Gly Gly Ser Ser Gly Ser Gly Ser Gly Ser
245 250 255
Thr Gly Leu Val Pro Arg Gly Ser Thr Ser Ser Ser Gly Thr Gly Thr
260 265 270
Ser Ala Gly Thr Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro
275 280 285
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
290 295 300
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
305 310 315 320
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
325 330 335
Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
340 345 350
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
355 360 365
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
370 375 380
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
385 390 395 400
Leu Thr Lys Asn Gln Val Ser Leu Arg Cys His Val Lys Gly Phe Tyr
405 410 415
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
420 425 430
Asn Tyr Lys Thr Thr Lys Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
435 440 445
Leu Tyr Ser Thr Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
450 455 460
Val Phe Ser Cys Ser Val Leu His Glu Ala Leu His Asn His Tyr Thr
465 470 475 480
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Ser Gly Leu Asn Asp
485 490 495
Ile Phe Glu Ala Gln Lys Ile Glu Trp His Glu
500 505
<210> 58
<211> 1521
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 58
gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact 60
atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga 120
caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc 180
ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa 240
gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg 300
acaaaaatta cgatactggg cggtggcggt agtgggggag gcggttctgg cggcggaggg 360
tccggcggtg gaggatcaca ggtcacattg aaggaatctg gccccggcct tgttcagcca 420
ggacagaccc ttaggctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg 480
ggggtcggct ggattcggca gcctcccggc aaaggtcttg agtggttggc tcacatttgg 540
tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat 600
acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta 660
tattattgcg cgcggatgga actctggtct tactactttg attattgggg gcaggggact 720
ctcgtcacgg tctcgagtgg gggatcctct ggaagtggct ccggcagcac tgggctcgta 780
ccaagggggt ccacatccag tagcggtact ggcacatccg cgggaacccc cgtcgctgga 840
ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggacccct 900
gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg 960
tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacgct 1020
agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag 1080
gagtacaagt gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc 1140
aaagccaaag ggcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggatgag 1200
ctgaccaaga accaggtcag cctgagatgc cacgtcaaag gcttctatcc cagcgacatc 1260
gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gaagcccgtg 1320
ctggactccg acggctcctt cttcctctac agcaccctca ccgtggacaa gagcaggtgg 1380
cagcagggga acgtcttctc atgctccgtg ctccatgagg ctctgcacaa ccactacaca 1440
cagaagagcc tctccctgtc tccgggcaaa ggttcaggcc tgaacgatat ttttgaagcg 1500
cagaaaattg aatggcatga a 1521
<210> 59
<211> 507
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 59
Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly
1 5 10 15
Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Ser Gly
100 105 110
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
115 120 125
Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu
130 135 140
Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met
145 150 155 160
Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
165 170 175
Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys
180 185 190
Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu
195 200 205
Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
210 215 220
Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
225 230 235 240
Leu Val Thr Val Ser Ser Gly Gly Ser Ser Gly Ser Gly Ser Gly Ser
245 250 255
Thr Gly Leu Val Pro Arg Gly Ser Thr Ser Ser Ser Gly Thr Gly Thr
260 265 270
Ser Ala Gly Thr Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro
275 280 285
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
290 295 300
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
305 310 315 320
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
325 330 335
Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
340 345 350
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
355 360 365
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
370 375 380
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
385 390 395 400
Leu Thr Lys Asn Gln Val Ser Leu Arg Cys His Val Lys Gly Phe Tyr
405 410 415
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
420 425 430
Asn Tyr Lys Thr Thr Lys Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
435 440 445
Leu Tyr Ser Thr Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
450 455 460
Val Phe Ser Cys Ser Val Leu His Glu Ala Leu His Asn His Tyr Thr
465 470 475 480
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Ser Gly Leu Asn Asp
485 490 495
Ile Phe Glu Ala Gln Lys Ile Glu Trp His Glu
500 505
<210> 60
<211> 1521
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 60
gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact 60
atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga 120
caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc 180
ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa 240
gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg 300
acaaaactta cggtactggg cggtggcggt agtgggggag gcggttctgg cggcggaggg 360
tccggcggtg gaggatcaca ggtcacattg aaggaatctg gccccggcct tgttcagcca 420
ggacagaccc ttaggctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg 480
ggggtcggct ggattcggca gcctcccggc aaaggtcttg agtggttggc tcacatttgg 540
tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat 600
acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta 660
tattattgcg cgcggatgga actctggtct tactactttg attattgggg gcaggggact 720
ctcgtcacgg tctcgagtgg gggatcctct ggaagtggct ccggcagcac tgggctcgta 780
ccaagggggt ccacatccag tagcggtact ggcacatccg cgggaacccc cgtcgctgga 840
ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggacccct 900
gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg 960
tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacgct 1020
agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag 1080
gagtacaagt gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc 1140
aaagccaaag ggcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggatgag 1200
ctgaccaaga accaggtcag cctgagatgc cacgtcaaag gcttctatcc cagcgacatc 1260
gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gaagcccgtg 1320
ctggactccg acggctcctt cttcctctac agcaccctca ccgtggacaa gagcaggtgg 1380
cagcagggga acgtcttctc atgctccgtg ctccatgagg ctctgcacaa ccactacaca 1440
cagaagagcc tctccctgtc tccgggcaaa ggttcaggcc tgaacgatat ttttgaagcg 1500
cagaaaattg aatggcatga a 1521
<210> 61
<211> 507
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 61
Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly
1 5 10 15
Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Gln Gly Thr Lys Val Thr Val Leu Gly Gly Gly Gly Ser Gly
100 105 110
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
115 120 125
Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu
130 135 140
Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met
145 150 155 160
Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
165 170 175
Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys
180 185 190
Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu
195 200 205
Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
210 215 220
Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
225 230 235 240
Leu Val Thr Val Ser Ser Gly Gly Ser Ser Gly Ser Gly Ser Gly Ser
245 250 255
Thr Gly Leu Val Pro Arg Gly Ser Thr Ser Ser Ser Gly Thr Gly Thr
260 265 270
Ser Ala Gly Thr Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro
275 280 285
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
290 295 300
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
305 310 315 320
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
325 330 335
Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
340 345 350
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
355 360 365
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
370 375 380
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
385 390 395 400
Leu Thr Lys Asn Gln Val Ser Leu Arg Cys His Val Lys Gly Phe Tyr
405 410 415
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
420 425 430
Asn Tyr Lys Thr Thr Lys Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
435 440 445
Leu Tyr Ser Thr Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
450 455 460
Val Phe Ser Cys Ser Val Leu His Glu Ala Leu His Asn His Tyr Thr
465 470 475 480
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Ser Gly Leu Asn Asp
485 490 495
Ile Phe Glu Ala Gln Lys Ile Glu Trp His Glu
500 505
<210> 62
<211> 1521
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 62
gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact 60
atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga 120
caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc 180
ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa 240
gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg 300
acaaaagtta cggtactggg cggtggcggt agtgggggag gcggttctgg cggcggaggg 360
tccggcggtg gaggatcaca ggtcacattg aaggaatctg gccccggcct tgttcagcca 420
ggacagaccc ttaggctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg 480
ggggtcggct ggattcggca gcctcccggc aaaggtcttg agtggttggc tcacatttgg 540
tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat 600
acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta 660
tattattgcg cgcggatgga actctggtct tactactttg attattgggg gcaggggact 720
ctcgtcacgg tctcgagtgg gggatcctct ggaagtggct ccggcagcac tgggctcgta 780
ccaagggggt ccacatccag tagcggtact ggcacatccg cgggaacccc cgtcgctgga 840
ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggacccct 900
gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg 960
tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacgct 1020
agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag 1080
gagtacaagt gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc 1140
aaagccaaag ggcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggatgag 1200
ctgaccaaga accaggtcag cctgagatgc cacgtcaaag gcttctatcc cagcgacatc 1260
gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gaagcccgtg 1320
ctggactccg acggctcctt cttcctctac agcaccctca ccgtggacaa gagcaggtgg 1380
cagcagggga acgtcttctc atgctccgtg ctccatgagg ctctgcacaa ccactacaca 1440
cagaagagcc tctccctgtc tccgggcaaa ggttcaggcc tgaacgatat ttttgaagcg 1500
cagaaaattg aatggcatga a 1521
<210> 63
<211> 506
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 63
Glu Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Ile Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Ser Gly
100 105 110
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val
115 120 125
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
130 135 140
Arg Leu Ser Cys Val Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met
145 150 155 160
Gly Val Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
165 170 175
Gly His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys
180 185 190
Ser Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn Thr Val Tyr Leu
195 200 205
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
210 215 220
Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
225 230 235 240
Leu Val Thr Val Ser Ser Gly Ser Ser Gly Ser Gly Ser Gly Ser Thr
245 250 255
Gly Leu Val Pro Arg Gly Ser Thr Ser Ser Ser Gly Thr Gly Thr Ser
260 265 270
Ala Gly Thr Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
275 280 285
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
290 295 300
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
305 310 315 320
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
325 330 335
Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
340 345 350
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
355 360 365
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
370 375 380
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
385 390 395 400
Thr Lys Asn Gln Val Ser Leu Arg Cys His Val Lys Gly Phe Tyr Pro
405 410 415
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
420 425 430
Tyr Lys Thr Thr Lys Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
435 440 445
Tyr Ser Thr Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
450 455 460
Phe Ser Cys Ser Val Leu His Glu Ala Leu His Asn His Tyr Thr Gln
465 470 475 480
Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Ser Gly Leu Asn Asp Ile
485 490 495
Phe Glu Ala Gln Lys Ile Glu Trp His Glu
500 505
<210> 64
<211> 1518
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 64
gaaatagtga tgacgcagtc acctagcacc cttagtgctt ctgtaggaga cagggttata 60
attacctgca gtgctagttc ctcagtgtca tacatgcact ggtatcagca gaaaccggga 120
aaagctccaa agctgcttat atacgacacg tccaaattgg catcaggtgt ccccagtcga 180
tttagtggct ctggctcagg ggctgaattt acgctcacaa tctccagcct ccaaccagat 240
gacttcgcca catactactg ttttcagggc tcagtgtatc cgtttacttt cggccagggg 300
acaaagttga ctgtacttgg cggtggcggt agtgggggag gcggttctgg cggcggaggg 360
tccggcggtg gaggatcaga ggtgcaactt gtggaaagcg gcggcgggtt ggtgcaacct 420
ggcggttcac ttcggctctc atgtgtgttc agtggttttt cccttagcac aagcgggatg 480
ggtgtcgggt gggtccgcca agcgcctggc aaaggtctgg aatgggttgg tcacatttgg 540
tgggatgatg acaaaaggta taatcccgcg ctgaaatcta gatttactat tagtcgggat 600
acgagtaaga acacggtgta tctgcaaatg aacagtctca gggcagagga tacagcggta 660
tattattgtg ctcgaatgga gctgtggtct tactattttg attactgggg ccagggcacg 720
ttggtaacgg tctcgagtgg atcctctgga agtggctccg gcagcactgg gctcgtacca 780
agggggtcca catccagtag cggtactggc acatccgcgg gaacccccgt cgctggaccg 840
tcagtcttcc tcttcccccc aaaacccaag gacaccctca tgatctcccg gacccctgag 900
gtcacatgcg tggtggtgga cgtgagccac gaagaccctg aggtcaagtt caactggtac 960
gtggacggcg tggaggtgca taatgccaag acaaagccgc gggaggagca gtacgctagc 1020
acgtaccgtg tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa tggcaaggag 1080
tacaagtgca aggtctccaa caaagccctc ccagccccca tcgagaaaac catctccaaa 1140
gccaaagggc agccccgaga accacaggtg tacaccctgc ccccatcccg ggatgagctg 1200
accaagaacc aggtcagcct gagatgccac gtcaaaggct tctatcccag cgacatcgcc 1260
gtggagtggg agagcaatgg gcagccggag aacaactaca agaccacgaa gcccgtgctg 1320
gactccgacg gctccttctt cctctacagc accctcaccg tggacaagag caggtggcag 1380
caggggaacg tcttctcatg ctccgtgctc catgaggctc tgcacaacca ctacacacag 1440
aagagcctct ccctgtctcc gggcaaaggt tcaggcctga acgatatttt tgaagcgcag 1500
aaaattgaat ggcatgaa 1518
<210> 65
<211> 506
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 65
Glu Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Ile Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Ser Gly
100 105 110
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val
115 120 125
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
130 135 140
Arg Leu Ser Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met
145 150 155 160
Gly Val Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
165 170 175
Gly His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys
180 185 190
Ser Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn Thr Val Tyr Leu
195 200 205
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
210 215 220
Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
225 230 235 240
Leu Val Thr Val Ser Ser Gly Ser Ser Gly Ser Gly Ser Gly Ser Thr
245 250 255
Gly Leu Val Pro Arg Gly Ser Thr Ser Ser Ser Gly Thr Gly Thr Ser
260 265 270
Ala Gly Thr Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
275 280 285
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
290 295 300
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
305 310 315 320
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
325 330 335
Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
340 345 350
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
355 360 365
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
370 375 380
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
385 390 395 400
Thr Lys Asn Gln Val Ser Leu Arg Cys His Val Lys Gly Phe Tyr Pro
405 410 415
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
420 425 430
Tyr Lys Thr Thr Lys Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
435 440 445
Tyr Ser Thr Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
450 455 460
Phe Ser Cys Ser Val Leu His Glu Ala Leu His Asn His Tyr Thr Gln
465 470 475 480
Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Ser Gly Leu Asn Asp Ile
485 490 495
Phe Glu Ala Gln Lys Ile Glu Trp His Glu
500 505
<210> 66
<211> 1518
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 66
gaaatagtga tgacgcagtc acctagcacc cttagtgctt ctgtaggaga cagggttata 60
attacctgca gtgctagttc ctcagtgtca tacatgcact ggtatcagca gaaaccggga 120
aaagctccaa agctgcttat atacgacacg tccaaattgg catcaggtgt ccccagtcga 180
tttagtggct ctggctcagg ggctgaattt acgctcacaa tctccagcct ccaaccagat 240
gacttcgcca catactactg ttttcagggc tcagtgtatc cgtttacttt cggccagggg 300
acaaagttga ctgtacttgg cggtggcggt agtgggggag gcggttctgg cggcggaggg 360
tccggcggtg gaggatcaga ggtgcaactt gtggaaagcg gcggcgggtt ggtgcaacct 420
ggcggttcac ttcggctctc atgtagcttc agtggttttt cccttagcac aagcgggatg 480
ggtgtcgggt gggtccgcca agcgcctggc aaaggtctgg aatgggttgg tcacatttgg 540
tgggatgatg acaaaaggta taatcccgcg ctgaaatcta gatttactat tagtcgggat 600
acgagtaaga acacggtgta tctgcaaatg aacagtctca gggcagagga tacagcggta 660
tattattgtg ctcgaatgga gctgtggtct tactattttg attactgggg ccagggcacg 720
ttggtaacgg tctcgagtgg atcctctgga agtggctccg gcagcactgg gctcgtacca 780
agggggtcca catccagtag cggtactggc acatccgcgg gaacccccgt cgctggaccg 840
tcagtcttcc tcttcccccc aaaacccaag gacaccctca tgatctcccg gacccctgag 900
gtcacatgcg tggtggtgga cgtgagccac gaagaccctg aggtcaagtt caactggtac 960
gtggacggcg tggaggtgca taatgccaag acaaagccgc gggaggagca gtacgctagc 1020
acgtaccgtg tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa tggcaaggag 1080
tacaagtgca aggtctccaa caaagccctc ccagccccca tcgagaaaac catctccaaa 1140
gccaaagggc agccccgaga accacaggtg tacaccctgc ccccatcccg ggatgagctg 1200
accaagaacc aggtcagcct gagatgccac gtcaaaggct tctatcccag cgacatcgcc 1260
gtggagtggg agagcaatgg gcagccggag aacaactaca agaccacgaa gcccgtgctg 1320
gactccgacg gctccttctt cctctacagc accctcaccg tggacaagag caggtggcag 1380
caggggaacg tcttctcatg ctccgtgctc catgaggctc tgcacaacca ctacacacag 1440
aagagcctct ccctgtctcc gggcaaaggt tcaggcctga acgatatttt tgaagcgcag 1500
aaaattgaat ggcatgaa 1518
<210> 67
<211> 1223
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 67
Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly
1 5 10 15
Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Gln Gly Thr Lys Val Thr Val Leu Gly Gly Gly Gly Ser Gly
100 105 110
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
115 120 125
Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu
130 135 140
Ser Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met
145 150 155 160
Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
165 170 175
Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys
180 185 190
Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu
195 200 205
Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
210 215 220
Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
225 230 235 240
Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
245 250 255
Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
260 265 270
Thr Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr
275 280 285
Gly Val His Trp Ile Arg Gln Ala Pro Gly Lys Cys Leu Glu Trp Leu
290 295 300
Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr
305 310 315 320
Ser Arg Phe Thr Ile Thr Lys Asp Asn Ser Lys Asn Gln Val Tyr Phe
325 330 335
Lys Leu Arg Ser Val Arg Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala
340 345 350
Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly
355 360 365
Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
370 375 380
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
385 390 395 400
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
405 410 415
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
420 425 430
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
435 440 445
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
450 455 460
Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys
465 470 475 480
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala Pro
485 490 495
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
500 505 510
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
515 520 525
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
530 535 540
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
545 550 555 560
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
565 570 575
Tyr Lys Cys Ala Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
580 585 590
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
595 600 605
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
610 615 620
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
625 630 635 640
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
645 650 655
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
660 665 670
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
675 680 685
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
690 695 700
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Leu Glu
705 710 715 720
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys
725 730 735
Ala Ala Ser Gly Phe Ser Phe Ser Ser Gly Tyr Asp Met Cys Trp Val
740 745 750
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala Cys Ile Ala Ala
755 760 765
Gly Ser Ala Gly Ile Thr Tyr Asp Ala Asn Trp Ala Lys Gly Arg Phe
770 775 780
Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn
785 790 795 800
Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Ala
805 810 815
Phe Ser Phe Asp Tyr Ala Met Asp Leu Trp Gly Gln Gly Thr Leu Val
820 825 830
Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
835 840 845
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
850 855 860
Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln
865 870 875 880
Ala Ser Gln Ser Ile Ser Ser His Leu Asn Trp Tyr Gln Gln Lys Pro
885 890 895
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Thr Leu Ala Ser
900 905 910
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr
915 920 925
Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys
930 935 940
Gln Gln Gly Tyr Ser Trp Gly Asn Val Asp Asn Val Phe Gly Gly Gly
945 950 955 960
Thr Lys Val Glu Ile Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
965 970 975
Gly Arg Ser Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
980 985 990
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Ile Ser Ser Tyr
995 1000 1005
His Met Gln Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Ile
1010 1015 1020
Gly Thr Ile Ser Ser Gly Gly Asn Val Tyr Tyr Ala Ser Ser Ala Arg
1025 1030 1035 1040
Gly Arg Phe Thr Ile Ser Arg Pro Ser Ser Lys Asn Thr Val Asp Leu
1045 1050 1055
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
1060 1065 1070
Arg Asp Ser Gly Tyr Ser Asp Pro Met Trp Gly Gln Gly Thr Leu Val
1075 1080 1085
Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
1090 1095 1100
Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser Pro
1105 1110 1115 1120
Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln
1125 1130 1135
Ala Ser Gln Asn Ile Arg Thr Tyr Leu Ser Trp Tyr Gln Gln Lys Pro
1140 1145 1150
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ala Asn Leu Ala Ser
1155 1160 1165
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
1170 1175 1180
Leu Thr Ile Ser Asp Leu Glu Pro Gly Asp Ala Ala Thr Tyr Tyr Cys
1185 1190 1195 1200
Gln Ser Thr Tyr Leu Gly Thr Asp Tyr Val Gly Gly Ala Phe Gly Gly
1205 1210 1215
Gly Thr Lys Val Glu Ile Lys
1220
<210> 68
<211> 3672
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 68
gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact 60
atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga 120
caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc 180
ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa 240
gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg 300
acaaaagtga ccgtcctagg cggtggcggt agtgggggag gcggttctgg cggcggaggg 360
tccggcggtg gaggatcaca ggtcacattg aaggaatctg gccccggcct tgttcagcca 420
ggacagaccc ttagcctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg 480
ggggtcggct ggattcggca gcctcccggc aaaggtcttg agtggttggc tcacatttgg 540
tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat 600
acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta 660
tattattgcg ctcggatgga actctggtct tactactttg attattgggg gcaggggact 720
ctcgtcacgg tctcgagtgg cggtggaggg tccggcggtg gtggatcaca agtacagttg 780
cagcaatccg gtcccggtct cgtcaaaccg agtgagacgc ttagtataac gtgtactgtt 840
tcaggcttta gccttacgaa ctatggagtt cactggattc ggcaggcacc cggcaaatgt 900
ttggaatggc tgggtgttat ttggtcaggt ggaaatacag actataacac cccctttaca 960
agtcggttca caattacgaa agataattcc aaaaatcaag tttatttcaa gttgagatcc 1020
gtccgcgcgg acgacactgc gatctactat tgtgcgaggg cactgaccta ctacgattac 1080
gaatttgcgt attgggggca agggactctt gtaacagtct ccagtgctag caccaagggc 1140
ccatcggtct tccccctggc accctcctcc aagagcacct ctgggggcac agcggccctg 1200
ggctgcctgg tcaaggacta cttccccgaa ccggtgacgg tgtcgtggaa ctcaggcgcc 1260
ctgaccagcg gcgtgcacac cttcccggct gtcctacagt cctcaggact ctactccctc 1320
agcagcgtgg tgaccgtgcc ctccagcagc ttgggcaccc agacctacat ctgcaacgtg 1380
aatcacaagc ccagcaacac caaggtggac aagagagttg agcccaaatc ttgtgacaaa 1440
actcacacat gcccaccgtg cccagcacct gaagccgcgg gggcaccgtc agtcttcctc 1500
ttccccccaa aacccaagga caccctcatg atctcccgga cccctgaggt cacatgcgtg 1560
gtggtggacg tgagccacga agaccctgag gtcaagttca actggtacgt ggacggcgtg 1620
gaggtgcata atgccaagac aaagccgcgg gaggagcagt acaacagcac gtaccgtgtg 1680
gtcagcgtcc tcaccgtcct gcaccaggac tggctgaatg gcaaggagta caagtgcgcg 1740
gtctccaaca aagccctccc agcccccatc gagaaaacca tctccaaagc caaagggcag 1800
ccccgagaac cacaggtgta caccctgccc ccatcccggg atgagctgac caagaaccag 1860
gtcagcctga cctgcctggt caaaggcttc tatcccagcg acatcgccgt ggagtgggag 1920
agcaatgggc agccggagaa caactacaag accacgcctc ccgtgctgga ctccgacggc 1980
tccttcttcc tctatagcaa gctcaccgtg gacaagagca ggtggcagca ggggaacgtc 2040
ttctcatgct ccgtgatgca tgaggctctg cacaaccact acacgcagaa gagcctctcc 2100
ctgtctccgg gtggcggtgg agggtccggc ggtggtggat ccgaggtgca gctgttggag 2160
tctgggggag gcttggtaca gcctgggggg tccctgagac tctcctgtgc agcctctgga 2220
ttctccttca gtagcgggta cgacatgtgc tgggtccgcc aggctccagg gaaggggctg 2280
gagtggatcg catgcattgc tgctggtagt gctggtatca cttacgacgc gaactgggcg 2340
aaaggccggt tcaccatctc cagagacaat tccaagaaca cgctgtatct gcaaatgaac 2400
agcctgagag ccgaggacac ggccgtatat tactgtgcga gatcggcgtt ttcgttcgac 2460
tacgccatgg acctctgggg ccagggaacc ctggtcaccg tgtcgagcgg tggaggcgga 2520
tctggcggag gtggttccgg cggtggcggc tccggtggag gcggctctga catccagatg 2580
acccagtctc cttccaccct gtctgcatct gtaggagaca gagtcaccat cacttgccag 2640
gccagtcaga gcattagttc ccacttaaac tggtatcagc agaaaccagg gaaagcccct 2700
aagctcctga tctataaggc atccactctg gcatctgggg tcccatcaag gttcagcggc 2760
agtggatctg ggacagaatt tactctcacc atcagcagcc tgcagcctga tgattttgca 2820
acttattact gccaacaggg ttatagttgg ggtaatgttg ataatgtttt cggcggaggg 2880
accaaggtgg agatcaaagg cggtggaggg tccggcggtg gtggctccgg acggtcgctg 2940
gtggagtctg ggggaggctt ggtccagcct ggggggtccc tgagactctc ctgtactgcc 3000
tctggattca ccatcagtag ctaccacatg cagtgggtcc gccaggctcc agggaagggg 3060
ctggagtaca tcggaaccat tagtagtggt ggtaatgtat actacgcaag ctccgctaga 3120
ggcagattca ccatctccag accctcgtcc aagaacacgg tggatcttca aatgaacagc 3180
ctgagagccg aggacacggc tgtgtattac tgtgcgagag actctggtta tagtgatcct 3240
atgtggggcc agggaaccct ggtcaccgtc tcttcaggcg gtggcggtag tgggggaggc 3300
ggttctggcg gcggagggtc cggcggtgga ggatcagacg ttgtgatgac ccagtctcca 3360
tcttccgtgt ctgcatctgt aggagacaga gtcaccatca cctgtcaggc cagtcagaac 3420
attaggactt acttatcctg gtatcagcag aaaccaggga aagcccctaa gctcctgatc 3480
tatgctgcag ccaatctggc atctggggtc ccatcaaggt tcagcggcag tggatctggg 3540
acagatttca ctctcaccat cagcgacctg gagcctggcg atgctgcaac ttactattgt 3600
cagtctacct atcttggtac tgattatgtt ggcggtgctt tcggcggagg gaccaaggtg 3660
gagatcaaat ga 3672
<210> 69
<211> 740
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 69
Glu Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Ile Ile Thr Cys Gln Ala Ser Glu Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Tyr Phe Tyr Phe Ile Ser
85 90 95
Arg Thr Tyr Val Asn Ser Phe Gly Gln Gly Thr Lys Leu Thr Val Leu
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val
130 135 140
Gln Pro Gly Gly Ser Leu Ser Leu Ser Cys Ala Ala Ser Gly Phe Thr
145 150 155 160
Ile Ser Thr Asn Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly
165 170 175
Leu Glu Trp Val Gly Val Ile Thr Gly Arg Asp Ile Thr Tyr Tyr Ala
180 185 190
Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn
195 200 205
Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
210 215 220
Tyr Tyr Cys Ala Arg Asp Gly Gly Ser Ser Ala Ile Thr Ser Asn Asn
225 230 235 240
Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly
245 250 255
Ser Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Ser Thr
260 265 270
Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Phe Ser Cys Arg Ala Ser
275 280 285
Gln Ser Ile Gly Thr Asn Ile His Trp Tyr Gln Gln Lys Pro Gly Lys
290 295 300
Pro Pro Arg Leu Leu Ile Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile
305 310 315 320
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr
325 330 335
Ile Ser Ser Val Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln
340 345 350
Asn Asn Asn Trp Pro Thr Thr Phe Gly Cys Gly Thr Lys Leu Thr Val
355 360 365
Leu Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp
370 375 380
Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn
385 390 395 400
Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu
405 410 415
Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp
420 425 430
Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr
435 440 445
Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser
450 455 460
Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly
465 470 475 480
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Ser Ala Leu Thr
485 490 495
Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser
500 505 510
Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Phe Val Ser Trp
515 520 525
Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val
530 535 540
Ser Asp Arg Pro Ser Gly Val Ser Asp Arg Phe Ser Gly Ser Lys Ser
545 550 555 560
Gly Asn Thr Ala Ser Leu Ile Ile Ser Gly Leu Gln Ala Asp Asp Glu
565 570 575
Ala Asp Tyr Tyr Cys Ser Ser Tyr Gly Ser Ser Ser Thr His Val Ile
580 585 590
Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gly Gly Gly Ser Gly
595 600 605
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
610 615 620
Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu
625 630 635 640
Ser Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met
645 650 655
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn
660 665 670
Ile Asn Arg Asp Gly Ser Ala Ser Tyr Tyr Val Asp Ser Val Lys Gly
675 680 685
Arg Phe Thr Ile Ser Arg Asp Asp Ala Lys Asn Ser Leu Tyr Leu Gln
690 695 700
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
705 710 715 720
Asp Arg Gly Val Gly Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val
725 730 735
Thr Val Ser Ser
740
<210> 70
<211> 2220
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 70
gaaatcgtta tgacgcagag tccctccacg ctctccgcta gtgtcgggga tcgcgtcatt 60
atcacatgcc aggcctccga gtcaatcagc agctggcttg catggtatca acagaagccg 120
ggaaaagctc ctaaattgct gatctatgaa gcgtcaaaat tggcgtctgg tgtcccatct 180
aggttctccg gctctgggtc tggtgcggaa tttactttga caatctccag tcttcaacca 240
gacgatttcg ctacctacta ctgccaaggg tatttctatt ttataagccg gacatatgta 300
aactccttcg gccaaggaac aaagttgact gttcttggtg gcggaggcag tggtggcggg 360
ggcagcggag gtggtggttc agggggtggt gggagcgaag tccaattggt agaaagtggc 420
ggtggtctgg tgcaacctgg tggatctctt agcctctcat gcgccgctag tggctttact 480
atttcaacta atgcgatgag ctgggttcgc caggcccccg gcaaaggact tgagtgggtc 540
ggcgtcatca ccggcaggga cattacatac tatgcgagtt gggcaaaggg caggttcacg 600
attagccgcg atacttcaaa gaataccgtt taccttcaaa tgaatagctt gagggcggaa 660
gacacagctg tgtattactg cgcgagggat ggaggtagtt ccgccataac ttccaacaac 720
atatggggac aaggcacgct ggttactgtc tcgagtggcg gtggagggtc cggcggtggt 780
ggatcagaaa tcgtccttac acaatctcct agcacactga gtgtgagccc cggcgaacgc 840
gcgactttct cttgcagggc aagtcaatcc atagggacta atatacattg gtatcaacaa 900
aagccaggta aaccacccag gcttttgatt aagtatgcaa gtgagtctat ttccggtatc 960
cctgaccgct tctctggatc aggcagtggc acagagttca cactcaccat atctagtgtg 1020
caatcagagg acttcgccgt gtattactgc caacagaata ataactggcc gactaccttc 1080
ggatgcggta caaagctgac cgttttacgt acggtggctg caccatctgt cttcatcttc 1140
ccgccatctg atgagcagtt gaaatctgga actgcctctg ttgtgtgcct gctgaataac 1200
ttctatccca gagaggccaa agtacagtgg aaggtggata acgccctcca atcgggtaac 1260
tcccaggaga gtgtcacaga gcaggacagc aaggacagca cctacagcct cagcagcacc 1320
ctgacgctga gcaaagcaga ctacgagaaa cacaaagtct acgcctgcga agtcacccat 1380
cagggcctga gctcgcccgt cacaaagagc ttcaacaggg gagagtgtgg cggtggcggt 1440
agcggtggcg gcggaagtgg tggcggagga tcccagtctg ccctgactca gcctgcctcc 1500
gtgtctgggt ctcctggaca gtcgatcacc atctcctgca ctggaaccag cagtgacgtt 1560
ggtggttata actttgtctc ctggtaccaa caacacccag gcaaagcccc caaactcatg 1620
atctatgatg tcagtgatcg gccctcaggg gtgtctgatc gcttctccgg ctccaagtct 1680
ggcaacacgg cctccctgat catctctggc ctccaggctg acgacgaggc tgattattac 1740
tgcagctcat atgggagcag cagcactcat gtgattttcg gcggagggac caaggtgacc 1800
gtcctaggtg gaggcggttc aggcggaggt ggttccggcg gtggcggctc cggtggaggc 1860
ggctctcagg tgcaattgca ggagtcgggg ggaggcctgg tcaagcctgg agggtccctg 1920
agtctctcct gtgcagcctc tggattcacc tttagtagtt attggatgag ctgggtccgc 1980
caggctccag ggaaggggct ggagtgggtg gccaacataa accgcgatgg aagtgcgagt 2040
tactatgtgg actctgtgaa gggccgattc accatctcca gagacgacgc caagaactca 2100
ctgtatctgc aaatgaacag cctgagagct gaggacacgg ctgtgtatta ctgtgcgaga 2160
gatcgtgggg tgggctactt cgatctctgg ggccgtggca ccctggtcac cgtctctagc 2220
<210> 71
<211> 1224
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 71
Glu Ile Val Leu Thr Gln Ser Pro Ser Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn
20 25 30
Ile His Trp Tyr Gln Gln Lys Pro Gly Lys Pro Pro Arg Leu Leu Ile
35 40 45
Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Asp Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Val Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr
85 90 95
Thr Phe Gly Pro Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln
115 120 125
Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr
130 135 140
Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr Gly
145 150 155 160
Val His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu Gly
165 170 175
Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr Ser
180 185 190
Arg Phe Thr Ile Thr Lys Asp Asn Ser Lys Asn Gln Val Tyr Phe Lys
195 200 205
Leu Arg Ser Val Arg Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Arg
210 215 220
Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly Thr
225 230 235 240
Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
245 250 255
Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln
260 265 270
Thr Leu Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser
275 280 285
Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Cys Leu Glu
290 295 300
Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala
305 310 315 320
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
325 330 335
Tyr Leu Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr
340 345 350
Cys Ala Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln
355 360 365
Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
370 375 380
Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
385 390 395 400
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
405 410 415
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
420 425 430
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
435 440 445
Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
450 455 460
Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp
465 470 475 480
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala
485 490 495
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
500 505 510
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
515 520 525
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
530 535 540
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
545 550 555 560
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
565 570 575
Glu Tyr Lys Cys Ala Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
580 585 590
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
595 600 605
Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu
610 615 620
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
625 630 635 640
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
645 650 655
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
660 665 670
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
675 680 685
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
690 695 700
Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Leu
705 710 715 720
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser
725 730 735
Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Gly Tyr Asp Met Cys Trp
740 745 750
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala Cys Ile Ala
755 760 765
Ala Gly Ser Ala Gly Ile Thr Tyr Asp Ala Asn Trp Ala Lys Gly Arg
770 775 780
Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met
785 790 795 800
Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser
805 810 815
Ala Phe Ser Phe Asp Tyr Ala Met Asp Leu Trp Gly Gln Gly Thr Leu
820 825 830
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
835 840 845
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser
850 855 860
Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys
865 870 875 880
Gln Ala Ser Gln Ser Ile Ser Ser His Leu Asn Trp Tyr Gln Gln Lys
885 890 895
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Thr Leu Ala
900 905 910
Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe
915 920 925
Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr
930 935 940
Cys Gln Gln Gly Tyr Ser Trp Gly Asn Val Asp Asn Val Phe Gly Gly
945 950 955 960
Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly
965 970 975
Ser Gly Arg Ser Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
980 985 990
Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Ile Ser Ser
995 1000 1005
Tyr His Met Gln Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr
1010 1015 1020
Ile Gly Thr Ile Ser Ser Gly Gly Asn Val Tyr Tyr Ala Ser Ser Ala
1025 1030 1035 1040
Arg Gly Arg Phe Thr Ile Ser Arg Pro Ser Ser Lys Asn Thr Val Asp
1045 1050 1055
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
1060 1065 1070
Ala Arg Asp Ser Gly Tyr Ser Asp Pro Met Trp Gly Gln Gly Thr Leu
1075 1080 1085
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1090 1095 1100
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser
1105 1110 1115 1120
Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys
1125 1130 1135
Gln Ala Ser Gln Asn Ile Arg Thr Tyr Leu Ser Trp Tyr Gln Gln Lys
1140 1145 1150
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ala Asn Leu Ala
1155 1160 1165
Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
1170 1175 1180
Thr Leu Thr Ile Ser Asp Leu Glu Pro Gly Asp Ala Ala Thr Tyr Tyr
1185 1190 1195 1200
Cys Gln Ser Thr Tyr Leu Gly Thr Asp Tyr Val Gly Gly Ala Phe Gly
1205 1210 1215
Gly Gly Thr Lys Val Glu Ile Lys
1220
<210> 72
<211> 3672
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 72
gaaatcgtcc ttacacaatc tcctagcaca ctgagtgtga gccccggcga acgcgcgact 60
ttctcttgca gggcaagtca atccataggg actaatatac attggtatca acaaaagcca 120
ggtaaaccac ccaggctttt gattaagtat gcaagtgagt ctatttccgg tatccctgac 180
cgcttctctg gatcaggcag tggcacagag ttcacactca ccatatctag tgtgcaatca 240
gaggacttcg ccgtgtatta ctgccaacag aataataact ggccgactac cttcggaccc 300
ggtacaaagc tgaccgtttt aggcggtggc ggtagtgggg gaggcggttc tggcggcgga 360
gggtccggcg gtggaggatc acaagtacag ttgcagcaat ccggtcccgg tctcgtcaaa 420
ccgagtgaga cgcttagtat aacgtgtact gtttcaggct ttagccttac gaactatgga 480
gttcactgga ttcggcaggc acccggcaaa ggtttggaat ggctgggtgt tatttggtca 540
ggtggaaata cagactataa cacccccttt acaagtcggt tcacaattac gaaagataat 600
tccaaaaatc aagtttattt caagttgaga tccgtccgcg cggacgacac tgcgatctac 660
tattgtgcga gggcactgac ctactacgat tacgaatttg cgtattgggg gcaagggact 720
cttgtaacag tctcgagcgg cggtggaggg tccggcggtg gtggatcaca ggtcacattg 780
aaggaatctg gccccggcct tgttcagcca ggacagaccc ttaggctcac ctgtgccttc 840
agtggttttt ctcttagcac tagcggtatg ggggtcggct ggattcggca gcctcccggc 900
aaatgtcttg agtggttggc tcacatttgg tgggacgacg acaaacggta taatcctgcc 960
ttgaaaagtc ggctgaccat tagtaaggat acctcaaaaa atcaagtgta cttgcaaatg 1020
aatagccttg acgccgagga tacggctgta tattattgcg ctcggatgga actctggtct 1080
tactactttg attattgggg gcaggggact ctcgtcacgg tgtcgagtgc tagcaccaag 1140
ggcccatcgg tcttccccct ggcaccctcc tccaagagca cctctggggg cacagcggcc 1200
ctgggctgcc tggtcaagga ctacttcccc gaaccggtga cggtgtcgtg gaactcaggc 1260
gccctgacca gcggcgtgca caccttcccg gctgtcctac agtcctcagg actctactcc 1320
ctcagcagcg tggtgaccgt gccctccagc agcttgggca cccagaccta catctgcaac 1380
gtgaatcaca agcccagcaa caccaaggtg gacaagagag ttgagcccaa atcttgtgac 1440
aaaactcaca catgcccacc gtgcccagca cctgaagccg cgggggcacc gtcagtcttc 1500
ctcttccccc caaaacccaa ggacaccctc atgatctccc ggacccctga ggtcacatgc 1560
gtggtggtgg acgtgagcca cgaagaccct gaggtcaagt tcaactggta cgtggacggc 1620
gtggaggtgc ataatgccaa gacaaagccg cgggaggagc agtacaacag cacgtaccgt 1680
gtggtcagcg tcctcaccgt cctgcaccag gactggctga atggcaagga gtacaagtgc 1740
gcggtctcca acaaagccct cccagccccc atcgagaaaa ccatctccaa agccaaaggg 1800
cagccccgag aaccacaggt gtacaccctg cccccatccc gggatgagct gaccaagaac 1860
caggtcagcc tgacctgcct ggtcaaaggc ttctatccca gcgacatcgc cgtggagtgg 1920
gagagcaatg ggcagccgga gaacaactac aagaccacgc ctcccgtgct ggactccgac 1980
ggctccttct tcctctatag caagctcacc gtggacaaga gcaggtggca gcaggggaac 2040
gtcttctcat gctccgtgat gcatgaggct ctgcacaacc actacacgca gaagagcctc 2100
tccctgtctc cgggtggcgg tggagggtcc ggcggtggtg gatccgaggt gcagctgttg 2160
gagtctgggg gaggcttggt acagcctggg gggtccctga gactctcctg tgcagcctct 2220
ggattctcct tcagtagcgg gtacgacatg tgctgggtcc gccaggctcc agggaagggg 2280
ctggagtgga tcgcatgcat tgctgctggt agtgctggta tcacttacga cgcgaactgg 2340
gcgaaaggcc ggttcaccat ctccagagac aattccaaga acacgctgta tctgcaaatg 2400
aacagcctga gagccgagga cacggccgta tattactgtg cgagatcggc gttttcgttc 2460
gactacgcca tggacctctg gggccaggga accctggtca ccgtgtcgag cggtggaggc 2520
ggatctggcg gaggtggttc cggcggtggc ggctccggtg gaggcggctc tgacatccag 2580
atgacccagt ctccttccac cctgtctgca tctgtaggag acagagtcac catcacttgc 2640
caggccagtc agagcattag ttcccactta aactggtatc agcagaaacc agggaaagcc 2700
cctaagctcc tgatctataa ggcatccact ctggcatctg gggtcccatc aaggttcagc 2760
ggcagtggat ctgggacaga atttactctc accatcagca gcctgcagcc tgatgatttt 2820
gcaacttatt actgccaaca gggttatagt tggggtaatg ttgataatgt tttcggcgga 2880
gggaccaagg tggagatcaa aggcggtgga gggtccggcg gtggtggctc cggacggtcg 2940
ctggtggagt ctgggggagg cttggtccag cctggggggt ccctgagact ctcctgtact 3000
gcctctggat tcaccatcag tagctaccac atgcagtggg tccgccaggc tccagggaag 3060
gggctggagt acatcggaac cattagtagt ggtggtaatg tatactacgc aagctccgct 3120
agaggcagat tcaccatctc cagaccctcg tccaagaaca cggtggatct tcaaatgaac 3180
agcctgagag ccgaggacac ggctgtgtat tactgtgcga gagactctgg ttatagtgat 3240
cctatgtggg gccagggaac cctggtcacc gtctcttcag gcggtggcgg tagtggggga 3300
ggcggttctg gcggcggagg gtccggcggt ggaggatcag acgttgtgat gacccagtct 3360
ccatcttccg tgtctgcatc tgtaggagac agagtcacca tcacctgtca ggccagtcag 3420
aacattagga cttacttatc ctggtatcag cagaaaccag ggaaagcccc taagctcctg 3480
atctatgctg cagccaatct ggcatctggg gtcccatcaa ggttcagcgg cagtggatct 3540
gggacagatt tcactctcac catcagcgac ctggagcctg gcgatgctgc aacttactat 3600
tgtcagtcta cctatcttgg tactgattat gttggcggtg ctttcggcgg agggaccaag 3660
gtggagatca aa 3672
<210> 73
<211> 739
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 73
Glu Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Ile Ile Thr Cys Gln Ala Ser Glu Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Tyr Phe Tyr Phe Ile Ser
85 90 95
Arg Thr Tyr Val Asn Ser Phe Gly Gln Gly Thr Lys Leu Thr Val Leu
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val
130 135 140
Gln Pro Gly Gly Ser Leu Ser Leu Ser Cys Ala Ala Ser Gly Phe Thr
145 150 155 160
Ile Ser Thr Asn Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly
165 170 175
Leu Glu Trp Val Gly Val Ile Thr Gly Arg Asp Ile Thr Tyr Tyr Ala
180 185 190
Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn
195 200 205
Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
210 215 220
Tyr Tyr Cys Ala Arg Asp Gly Gly Ser Ser Ala Ile Thr Ser Asn Asn
225 230 235 240
Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly
245 250 255
Ser Gly Gly Gly Gly Ser Glu Asn Val Leu Thr Gln Ser Pro Ala Ser
260 265 270
Leu Ser Ala Ser Pro Gly Glu Arg Val Thr Ile Thr Cys Ser Ala Ser
275 280 285
Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Ala
290 295 300
Pro Lys Leu Trp Ile Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val Pro
305 310 315 320
Ser Arg Phe Ser Gly Ser Gly Ser Gly Asn Asp His Thr Leu Thr Ile
325 330 335
Ser Ser Met Glu Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly
340 345 350
Ser Val Tyr Pro Phe Thr Phe Gly Cys Gly Thr Lys Val Glu Ile Lys
355 360 365
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
370 375 380
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
385 390 395 400
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
405 410 415
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
420 425 430
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
435 440 445
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
450 455 460
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser
465 470 475 480
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Ser Ala Leu Thr Gln
485 490 495
Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys
500 505 510
Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Phe Val Ser Trp Tyr
515 520 525
Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser
530 535 540
Asp Arg Pro Ser Gly Val Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly
545 550 555 560
Asn Thr Ala Ser Leu Ile Ile Ser Gly Leu Gln Ala Asp Asp Glu Ala
565 570 575
Asp Tyr Tyr Cys Ser Ser Tyr Gly Ser Ser Ser Thr His Val Ile Phe
580 585 590
Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gly Gly Gly Ser Gly Gly
595 600 605
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln
610 615 620
Leu Gln Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Ser
625 630 635 640
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser
645 650 655
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile
660 665 670
Asn Arg Asp Gly Ser Ala Ser Tyr Tyr Val Asp Ser Val Lys Gly Arg
675 680 685
Phe Thr Ile Ser Arg Asp Asp Ala Lys Asn Ser Leu Tyr Leu Gln Met
690 695 700
Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp
705 710 715 720
Arg Gly Val Gly Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr
725 730 735
Val Ser Ser
<210> 74
<211> 2217
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 74
gaaatcgtta tgacgcagag tccctccacg ctctccgcta gtgtcgggga tcgcgtcatt 60
atcacatgcc aggcctccga gtcaatcagc agctggcttg catggtatca acagaagccg 120
ggaaaagctc ctaaattgct gatctatgaa gcgtcaaaat tggcgtctgg tgtcccatct 180
aggttctccg gctctgggtc tggtgcggaa tttactttga caatctccag tcttcaacca 240
gacgatttcg ctacctacta ctgccaaggg tatttctatt ttataagccg gacatatgta 300
aactccttcg gccaaggaac aaagttgact gttcttggtg gcggaggcag tggtggcggg 360
ggcagcggag gtggtggttc agggggtggt gggagcgaag tccaattggt agaaagtggc 420
ggtggtctgg tgcaacctgg tggatctctt agcctctcat gcgccgctag tggctttact 480
atttcaacta atgcgatgag ctgggttcgc caggcccccg gcaaaggact tgagtgggtc 540
ggcgtcatca ccggcaggga cattacatac tatgcgagtt gggcaaaggg caggttcacg 600
attagccgcg atacttcaaa gaataccgtt taccttcaaa tgaatagctt gagggcggaa 660
gacacagctg tgtattactg cgcgagggat ggaggtagtt ccgccataac ttccaacaac 720
atatggggac aaggcacgct ggttactgtc tcgagcggcg gtggagggtc cggcggtggt 780
ggatcagaaa atgtattgac acagagcccc gcctccctca gtgcctcacc tggggaaagg 840
gtaactatca cttgctctgc atcaagcagc gtctcataca tgcattggta tcaacaaaag 900
cctggacagg cccccaagct ctggatatac gatacgagca agctggcttc cggcgtacct 960
agccgcttca gtggttccgg ctcaggcaac gatcacaccc ttacgatttc cagtatggaa 1020
cccgaagatt ttgcaactta ttattgtttc caggggagcg tgtacccatt cactttcggg 1080
tgtgggacaa aagtggagat caagcgtacg gtggctgcac catctgtctt catcttcccg 1140
ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc 1200
tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc 1260
caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg 1320
acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag 1380
ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgtggcgg tggcggtagc 1440
ggtggcggcg gaagtggtgg cggaggatcc cagtctgccc tgactcagcc tgcctccgtg 1500
tctgggtctc ctggacagtc gatcaccatc tcctgcactg gaaccagcag tgacgttggt 1560
ggttataact ttgtctcctg gtaccaacaa cacccaggca aagcccccaa actcatgatc 1620
tatgatgtca gtgatcggcc ctcaggggtg tctgatcgct tctccggctc caagtctggc 1680
aacacggcct ccctgatcat ctctggcctc caggctgacg acgaggctga ttattactgc 1740
agctcatatg ggagcagcag cactcatgtg attttcggcg gagggaccaa ggtgaccgtc 1800
ctaggtggag gcggttcagg cggaggtggt tccggcggtg gcggctccgg tggaggcggc 1860
tctcaggtgc aattgcagga gtcgggggga ggcctggtca agcctggagg gtccctgagt 1920
ctctcctgtg cagcctctgg attcaccttt agtagttatt ggatgagctg ggtccgccag 1980
gctccaggga aggggctgga gtgggtggcc aacataaacc gcgatggaag tgcgagttac 2040
tatgtggact ctgtgaaggg ccgattcacc atctccagag acgacgccaa gaactcactg 2100
tatctgcaaa tgaacagcct gagagctgag gacacggctg tgtattactg tgcgagagat 2160
cgtggggtgg gctacttcga tctctggggc cgtggcaccc tggtcaccgt ctctagc 2217
<210> 75
<211> 1234
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 75
Glu Ile Val Leu Thr Gln Ser Pro Ser Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn
20 25 30
Ile His Trp Tyr Gln Gln Lys Pro Gly Lys Pro Pro Arg Leu Leu Ile
35 40 45
Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Asp Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Val Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr
85 90 95
Thr Phe Gly Pro Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln
115 120 125
Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr
130 135 140
Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr Gly
145 150 155 160
Val His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu Gly
165 170 175
Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr Ser
180 185 190
Arg Phe Thr Ile Thr Lys Asp Asn Ser Lys Asn Gln Val Tyr Phe Lys
195 200 205
Leu Arg Ser Val Arg Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Arg
210 215 220
Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly Thr
225 230 235 240
Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
245 250 255
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu
260 265 270
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys
275 280 285
Ala Ala Ser Gly Phe Thr Ile Ser Thr Asn Ala Met Ser Trp Val Arg
290 295 300
Gln Ala Pro Gly Lys Cys Leu Glu Trp Ile Gly Val Ile Thr Gly Arg
305 310 315 320
Asp Ile Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser
325 330 335
Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg
340 345 350
Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Gly Ser Ser
355 360 365
Ala Ile Thr Ser Asn Asn Ile Trp Gly Gln Gly Thr Leu Val Thr Val
370 375 380
Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser
385 390 395 400
Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys
405 410 415
Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
420 425 430
Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu
435 440 445
Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr
450 455 460
Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val
465 470 475 480
Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro
485 490 495
Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala Pro Ser Val Phe Leu Phe
500 505 510
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
515 520 525
Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe
530 535 540
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
545 550 555 560
Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
565 570 575
Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Ala Val
580 585 590
Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
595 600 605
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
610 615 620
Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
625 630 635 640
Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
645 650 655
Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
660 665 670
Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
675 680 685
Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
690 695 700
Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser
705 710 715 720
Gly Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
725 730 735
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
740 745 750
Ser Phe Ser Ser Gly Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly
755 760 765
Lys Gly Leu Glu Trp Ile Ala Cys Ile Ala Ala Gly Ser Ala Gly Ile
770 775 780
Thr Tyr Asp Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp
785 790 795 800
Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu
805 810 815
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Ala Phe Ser Phe Asp Tyr
820 825 830
Ala Met Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly
835 840 845
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
850 855 860
Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala
865 870 875 880
Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile
885 890 895
Ser Ser His Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
900 905 910
Leu Leu Ile Tyr Lys Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg
915 920 925
Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser
930 935 940
Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser
945 950 955 960
Trp Gly Asn Val Asp Asn Val Phe Gly Gly Gly Thr Lys Val Glu Ile
965 970 975
Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Arg Ser Leu Val
980 985 990
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser
995 1000 1005
Cys Thr Ala Ser Gly Phe Thr Ile Ser Ser Tyr His Met Gln Trp Val
1010 1015 1020
Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Ile Gly Thr Ile Ser Ser
1025 1030 1035 1040
Gly Gly Asn Val Tyr Tyr Ala Ser Ser Ala Arg Gly Arg Phe Thr Ile
1045 1050 1055
Ser Arg Pro Ser Ser Lys Asn Thr Val Asp Leu Gln Met Asn Ser Leu
1060 1065 1070
Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Gly Tyr
1075 1080 1085
Ser Asp Pro Met Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly
1090 1095 1100
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
1105 1110 1115 1120
Gly Gly Ser Asp Val Val Met Thr Gln Ser Pro Ser Ser Val Ser Ala
1125 1130 1135
Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asn Ile
1140 1145 1150
Arg Thr Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
1155 1160 1165
Leu Leu Ile Tyr Ala Ala Ala Asn Leu Ala Ser Gly Val Pro Ser Arg
1170 1175 1180
Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asp
1185 1190 1195 1200
Leu Glu Pro Gly Asp Ala Ala Thr Tyr Tyr Cys Gln Ser Thr Tyr Leu
1205 1210 1215
Gly Thr Asp Tyr Val Gly Gly Ala Phe Gly Gly Gly Thr Lys Val Glu
1220 1225 1230
Ile Lys
<210> 76
<211> 3702
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 76
gaaatcgtcc ttacacaatc tcctagcaca ctgagtgtga gccccggcga acgcgcgact 60
ttctcttgca gggcaagtca atccataggg actaatatac attggtatca acaaaagcca 120
ggtaaaccac ccaggctttt gattaagtat gcaagtgagt ctatttccgg tatccctgac 180
cgcttctctg gatcaggcag tggcacagag ttcacactca ccatatctag tgtgcaatca 240
gaggacttcg ccgtgtatta ctgccaacag aataataact ggccgactac cttcggaccc 300
ggtacaaagc tgaccgtttt aggcggtggc ggtagtgggg gaggcggttc tggcggcgga 360
gggtccggcg gtggaggatc acaagtacag ttgcagcaat ccggtcccgg tctcgtcaaa 420
ccgagtgaga cgcttagtat aacgtgtact gtttcaggct ttagccttac gaactatgga 480
gttcactgga ttcggcaggc acccggcaaa ggtttggaat ggctgggtgt tatttggtca 540
ggtggaaata cagactataa cacccccttt acaagtcggt tcacaattac gaaagataat 600
tccaaaaatc aagtttattt caagttgaga tccgtccgcg cggacgacac tgcgatctac 660
tattgtgcga gggcactgac ctactacgat tacgaatttg cgtattgggg gcaagggact 720
cttgtaacag tctcgagcgg tggaggcgga tctggcggag gtggttccgg cggtggcggc 780
tccggtggag gcggctctga ggtgcagctg gtggagtctg ggggaggctt ggtccagcct 840
ggggggtccc tgagactctc ctgtgcagcc tctggattca ccatcagtac caatgcaatg 900
agctgggtcc gccaggctcc agggaagtgt ctggagtgga tcggagtcat tactggtcgt 960
gatatcacat actacgcgag ctgggcgaaa ggcagattca ccatctccag agacaattcc 1020
aagaacacgc tgtatcttca aatgaacagc ctgagagccg aggacacggc tgtgtattac 1080
tgtgcgagag acggtggttc ttctgctatt actagtaaca acatttgggg ccagggaacc 1140
ctggtcaccg tgtcctcagc tagcaccaag ggcccatcgg tcttccccct ggcaccctcc 1200
tccaagagca cctctggggg cacagcggcc ctgggctgcc tggtcaagga ctacttcccc 1260
gaaccggtga cggtgtcgtg gaactcaggc gccctgacca gcggcgtgca caccttcccg 1320
gctgtcctac agtcctcagg actctactcc ctcagcagcg tggtgaccgt gccctccagc 1380
agcttgggca cccagaccta catctgcaac gtgaatcaca agcccagcaa caccaaggtg 1440
gacaagagag ttgagcccaa atcttgtgac aaaactcaca catgcccacc gtgcccagca 1500
cctgaagccg cgggggcacc gtcagtcttc ctcttccccc caaaacccaa ggacaccctc 1560
atgatctccc ggacccctga ggtcacatgc gtggtggtgg acgtgagcca cgaagaccct 1620
gaggtcaagt tcaactggta cgtggacggc gtggaggtgc ataatgccaa gacaaagccg 1680
cgggaggagc agtacaacag cacgtaccgt gtggtcagcg tcctcaccgt cctgcaccag 1740
gactggctga atggcaagga gtacaagtgc gcggtctcca acaaagccct cccagccccc 1800
atcgagaaaa ccatctccaa agccaaaggg cagccccgag aaccacaggt gtacaccctg 1860
cccccatccc gggatgagct gaccaagaac caggtcagcc tgacctgcct ggtcaaaggc 1920
ttctatccca gcgacatcgc cgtggagtgg gagagcaatg ggcagccgga gaacaactac 1980
aagaccacgc ctcccgtgct ggactccgac ggctccttct tcctctatag caagctcacc 2040
gtggacaaga gcaggtggca gcaggggaac gtcttctcat gctccgtgat gcatgaggct 2100
ctgcacaacc actacacgca gaagagcctc tccctgtctc cgggtggcgg tggagggtcc 2160
ggcggtggtg gatccgaggt gcagctgttg gagtctgggg gaggcttggt acagcctggg 2220
gggtccctga gactctcctg tgcagcctct ggattctcct tcagtagcgg gtacgacatg 2280
tgctgggtcc gccaggctcc agggaagggg ctggagtgga tcgcatgcat tgctgctggt 2340
agtgctggta tcacttacga cgcgaactgg gcgaaaggcc ggttcaccat ctccagagac 2400
aattccaaga acacgctgta tctgcaaatg aacagcctga gagccgagga cacggccgta 2460
tattactgtg cgagatcggc gttttcgttc gactacgcca tggacctctg gggccaggga 2520
accctggtca ccgtgtcgag cggtggaggc ggatctggcg gaggtggttc cggcggtggc 2580
ggctccggtg gaggcggctc tgacatccag atgacccagt ctccttccac cctgtctgca 2640
tctgtaggag acagagtcac catcacttgc caggccagtc agagcattag ttcccactta 2700
aactggtatc agcagaaacc agggaaagcc cctaagctcc tgatctataa ggcatccact 2760
ctggcatctg gggtcccatc aaggttcagc ggcagtggat ctgggacaga atttactctc 2820
accatcagca gcctgcagcc tgatgatttt gcaacttatt actgccaaca gggttatagt 2880
tggggtaatg ttgataatgt tttcggcgga gggaccaagg tggagatcaa aggcggtgga 2940
gggtccggcg gtggtggctc cggacggtcg ctggtggagt ctgggggagg cttggtccag 3000
cctggggggt ccctgagact ctcctgtact gcctctggat tcaccatcag tagctaccac 3060
atgcagtggg tccgccaggc tccagggaag gggctggagt acatcggaac cattagtagt 3120
ggtggtaatg tatactacgc aagctccgct agaggcagat tcaccatctc cagaccctcg 3180
tccaagaaca cggtggatct tcaaatgaac agcctgagag ccgaggacac ggctgtgtat 3240
tactgtgcga gagactctgg ttatagtgat cctatgtggg gccagggaac cctggtcacc 3300
gtctcttcag gcggtggcgg tagtggggga ggcggttctg gcggcggagg gtccggcggt 3360
ggaggatcag acgttgtgat gacccagtct ccatcttccg tgtctgcatc tgtaggagac 3420
agagtcacca tcacctgtca ggccagtcag aacattagga cttacttatc ctggtatcag 3480
cagaaaccag ggaaagcccc taagctcctg atctatgctg cagccaatct ggcatctggg 3540
gtcccatcaa ggttcagcgg cagtggatct gggacagatt tcactctcac catcagcgac 3600
ctggagcctg gcgatgctgc aacttactat tgtcagtcta cctatcttgg tactgattat 3660
gttggcggtg ctttcggcgg agggaccaag gtggagatca aa 3702
<210> 77
<211> 739
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 77
Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly
1 5 10 15
Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Gln Gly Thr Lys Val Thr Val Leu Gly Gly Gly Gly Ser Gly
100 105 110
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
115 120 125
Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu
130 135 140
Ser Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met
145 150 155 160
Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
165 170 175
Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys
180 185 190
Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu
195 200 205
Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
210 215 220
Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
225 230 235 240
Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
245 250 255
Asp Val Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
260 265 270
Asp Arg Val Thr Ile Asn Cys Gln Ala Ser Glu Ser Ile Ser Ser Trp
275 280 285
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
290 295 300
Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
305 310 315 320
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
325 330 335
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Tyr Phe Tyr Phe Ile Ser
340 345 350
Arg Thr Tyr Val Asn Ser Phe Gly Cys Gly Thr Lys Val Glu Ile Lys
355 360 365
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
370 375 380
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
385 390 395 400
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
405 410 415
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
420 425 430
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
435 440 445
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
450 455 460
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser
465 470 475 480
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Ser Ala Leu Thr Gln
485 490 495
Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys
500 505 510
Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Phe Val Ser Trp Tyr
515 520 525
Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser
530 535 540
Asp Arg Pro Ser Gly Val Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly
545 550 555 560
Asn Thr Ala Ser Leu Ile Ile Ser Gly Leu Gln Ala Asp Asp Glu Ala
565 570 575
Asp Tyr Tyr Cys Ser Ser Tyr Gly Ser Ser Ser Thr His Val Ile Phe
580 585 590
Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gly Gly Gly Ser Gly Gly
595 600 605
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln
610 615 620
Leu Gln Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Ser
625 630 635 640
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser
645 650 655
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile
660 665 670
Asn Arg Asp Gly Ser Ala Ser Tyr Tyr Val Asp Ser Val Lys Gly Arg
675 680 685
Phe Thr Ile Ser Arg Asp Asp Ala Lys Asn Ser Leu Tyr Leu Gln Met
690 695 700
Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp
705 710 715 720
Arg Gly Val Gly Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr
725 730 735
Val Ser Ser
<210> 78
<211> 2220
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 78
gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact 60
atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga 120
caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc 180
ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa 240
gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg 300
acaaaagtga ccgtcctagg cggtggcggt agtgggggag gcggttctgg cggcggaggg 360
tccggcggtg gaggatcaca ggtcacattg aaggaatctg gccccggcct tgttcagcca 420
ggacagaccc ttagcctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg 480
ggggtcggct ggattcggca gcctcccggc aaaggtcttg agtggttggc tcacatttgg 540
tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat 600
acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta 660
tattattgcg ctcggatgga actctggtct tactactttg attattgggg gcaggggact 720
ctcgtcacgg tctcgagtgg cggtggaggg tccggcggtg gtggatcaga cgtcgtgatg 780
acccagtctc cttccaccct gtctgcatct gtaggagaca gagtcaccat caattgccaa 840
gccagtgaga gcattagcag ttggttagcc tggtatcagc agaaaccagg gaaagcccct 900
aagctcctga tctatgaagc atccaaactg gcatctgggg tcccatcaag gttcagcggc 960
agtggatctg ggacagaatt tactctcacc atcagcagcc tgcagcctga tgattttgca 1020
acttattact gccaaggcta tttttatttt attagtcgta cttatgtaaa ttctttcggc 1080
tgtgggacca aggtggagat caaacgtacg gtggctgcac catctgtctt catcttcccg 1140
ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc 1200
tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc 1260
caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg 1320
acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag 1380
ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgtggcgg tggcggtagc 1440
ggtggcggcg gaagtggtgg cggaggatcc cagtctgccc tgactcagcc tgcctccgtg 1500
tctgggtctc ctggacagtc gatcaccatc tcctgcactg gaaccagcag tgacgttggt 1560
ggttataact ttgtctcctg gtaccaacaa cacccaggca aagcccccaa actcatgatc 1620
tatgatgtca gtgatcggcc ctcaggggtg tctgatcgct tctccggctc caagtctggc 1680
aacacggcct ccctgatcat ctctggcctc caggctgacg acgaggctga ttattactgc 1740
agctcatatg ggagcagcag cactcatgtg attttcggcg gagggaccaa ggtgaccgtc 1800
ctaggtggag gcggttcagg cggaggtggt tccggcggtg gcggctccgg tggaggcggc 1860
tctcaggtgc aattgcagga gtcgggggga ggcctggtca agcctggagg gtccctgagt 1920
ctctcctgtg cagcctctgg attcaccttt agtagttatt ggatgagctg ggtccgccag 1980
gctccaggga aggggctgga gtgggtggcc aacataaacc gcgatggaag tgcgagttac 2040
tatgtggact ctgtgaaggg ccgattcacc atctccagag acgacgccaa gaactcactg 2100
tatctgcaaa tgaacagcct gagagctgag gacacggctg tgtattactg tgcgagagat 2160
cgtggggtgg gctacttcga tctctggggc cgtggcaccc tggtcaccgt ctctagctga 2220
<210> 79
<211> 1230
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 79
Asp Val Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Asn Cys Gln Ala Ser Glu Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Tyr Phe Tyr Phe Ile Ser
85 90 95
Arg Thr Tyr Val Asn Ser Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val
130 135 140
Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr
145 150 155 160
Ile Ser Thr Asn Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly
165 170 175
Leu Glu Trp Ile Gly Val Ile Thr Gly Arg Asp Ile Thr Tyr Tyr Ala
180 185 190
Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
195 200 205
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
210 215 220
Tyr Tyr Cys Ala Arg Asp Gly Gly Ser Ser Ala Ile Thr Ser Asn Asn
225 230 235 240
Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly
245 250 255
Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Gln Ser Gly Ala Glu
260 265 270
Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly
275 280 285
Tyr Ser Phe Ser Ser Ser Trp Ile Gly Trp Val Arg Gln Ala Pro Gly
290 295 300
Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Asp Asp Ser Asp Thr
305 310 315 320
Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys
325 330 335
Ser Ile Arg Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp
340 345 350
Thr Ala Met Tyr Tyr Cys Ala Arg His Val Thr Met Ile Trp Gly Val
355 360 365
Ile Ile Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala
370 375 380
Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser
385 390 395 400
Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
405 410 415
Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly
420 425 430
Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu
435 440 445
Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr
450 455 460
Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg
465 470 475 480
Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
485 490 495
Ala Pro Glu Ala Ala Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys
500 505 510
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
515 520 525
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
530 535 540
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
545 550 555 560
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
565 570 575
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Ala Val Ser Asn Lys
580 585 590
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
595 600 605
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
610 615 620
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
625 630 635 640
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
645 650 655
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
660 665 670
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
675 680 685
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
690 695 700
Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly
705 710 715 720
Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro
725 730 735
Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser
740 745 750
Ser Gly Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
755 760 765
Glu Trp Ile Ala Cys Ile Ala Ala Gly Ser Ala Gly Ile Thr Tyr Asp
770 775 780
Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
785 790 795 800
Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
805 810 815
Val Tyr Tyr Cys Ala Arg Ser Ala Phe Ser Phe Asp Tyr Ala Met Asp
820 825 830
Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly
835 840 845
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
850 855 860
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
865 870 875 880
Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Ser His
885 890 895
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
900 905 910
Tyr Lys Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
915 920 925
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
930 935 940
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Trp Gly Asn
945 950 955 960
Val Asp Asn Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Gly Gly
965 970 975
Gly Gly Ser Gly Gly Gly Gly Ser Arg Ser Leu Val Glu Ser Gly Gly
980 985 990
Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser
995 1000 1005
Gly Phe Thr Ile Ser Ser Tyr His Met Gln Trp Val Arg Gln Ala Pro
1010 1015 1020
Gly Lys Gly Leu Glu Tyr Ile Gly Thr Ile Ser Ser Gly Gly Asn Val
1025 1030 1035 1040
Tyr Tyr Ala Ser Ser Ala Arg Gly Arg Phe Thr Ile Ser Arg Pro Ser
1045 1050 1055
Ser Lys Asn Thr Val Asp Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
1060 1065 1070
Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Gly Tyr Ser Asp Pro Met
1075 1080 1085
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
1090 1095 1100
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp
1105 1110 1115 1120
Val Val Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp
1125 1130 1135
Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asn Ile Arg Thr Tyr Leu
1140 1145 1150
Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
1155 1160 1165
Ala Ala Ala Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
1170 1175 1180
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asp Leu Glu Pro Gly
1185 1190 1195 1200
Asp Ala Ala Thr Tyr Tyr Cys Gln Ser Thr Tyr Leu Gly Thr Asp Tyr
1205 1210 1215
Val Gly Gly Ala Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
1220 1225 1230
<210> 80
<211> 3690
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 80
gacgtcgtga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcaattgcc aagccagtga gagcattagc agttggttag cctggtatca gcagaaacca 120
gggaaagccc ctaagctcct gatctatgaa gcatccaaac tggcatctgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagag ttcactctca ccatcagcag cctgcagcct 240
gatgattttg caacttatta ctgccaaggc tatttttatt ttattagtcg tacttatgta 300
aattctttcg gcggagggac caaggtggag atcaaaggcg gtggcggtag tgggggaggc 360
ggttctggcg gcggagggtc cggcggtgga ggatcagagg tgcagctggt ggagtctggg 420
ggaggcttgg tccagcctgg ggggtccctg agactctcct gtgcagcctc tggattcacc 480
atcagtacca atgcaatgag ctgggtccgc caggctccag ggaaggggct ggagtggatc 540
ggagtcatta ctggtcgtga tatcacatac tacgcgagct gggcgaaagg cagattcacc 600
atctccagag acaattccaa gaacacgctg tatcttcaaa tgaacagcct gagagccgag 660
gacacggctg tgtattactg tgcgcgcgac ggtggatcat ctgctattac tagtaacaac 720
atttggggcc aaggaactct ggtcaccgtt tcttcaggcg gtggagggtc cggcggtggt 780
ggatccgagg tgcagctggt gcagtctgga gcagaggtga agaaaccagg agagtctctg 840
aagatctcct gtaagggttc tggatacagc tttagcagtt catggatcgg ctgggtgcgc 900
caggcacctg ggaaaggcct ggaatggatg gggatcatct atcctgatga ctctgatacc 960
agatacagtc catccttcca aggccaggtc accatctcag ccgacaagtc catcaggact 1020
gcctacctgc agtggagtag cctgaaggcc tcggacaccg ctatgtatta ctgtgcgaga 1080
catgttacta tgatttgggg agttattatt gacttctggg gccagggaac cctggtcacc 1140
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc 1200
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg 1260
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta 1320
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc 1380
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga 1440
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc 1500
gcgggggcac cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc 1560
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag 1620
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag 1680
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg 1740
aatggcaagg agtacaagtg cgcggtctcc aacaaagccc tcccagcccc catcgagaaa 1800
accatctcca aagccaaagg gcagccccga gaaccacagg tgtataccct gcccccatcc 1860
cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc 1920
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg 1980
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag 2040
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac 2100
cactacacgc agaagagcct ctccctgtct ccgggtggcg gtggagggtc cggcggtggt 2160
ggatccgagg tgcagctgtt ggagtctggg ggaggcttgg tacagcctgg ggggtccctg 2220
agactctcct gtgcagcctc tggattctcc ttcagtagcg ggtacgacat gtgctgggtc 2280
cgccaggctc cagggaaggg gctggagtgg atcgcatgca ttgctgctgg tagtgctggt 2340
atcacttacg acgcgaactg ggcgaaaggc cggttcacca tctccagaga caattccaag 2400
aacacgctgt atctgcaaat gaacagcctg agagccgagg acacggccgt atattactgt 2460
gcgagatcgg cgttttcgtt cgactacgcc atggacctct ggggccaggg aaccctggtc 2520
accgtctcga gcggtggagg cggatctggc ggaggtggtt ccggcggtgg cggctccggt 2580
ggaggcggct ctgacatcca gatgacccag tctccttcca ccctgtctgc atctgtagga 2640
gacagagtca ccatcacttg ccaggccagt cagagcatta gttcccactt aaactggtat 2700
cagcagaaac cagggaaagc ccctaagctc ctgatctata aggcatccac tctggcatct 2760
ggggtcccat caaggttcag cggcagtgga tctgggacag aatttactct caccatcagc 2820
agcctgcagc ctgatgattt tgcaacttat tactgccaac agggttatag ttggggtaat 2880
gttgataatg ttttcggcgg agggaccaag gtggagatca aaggcggtgg agggtccggc 2940
ggtggtggat cccggtcgct ggtggagtct gggggaggct tggtccagcc tggggggtcc 3000
ctgagactct cctgtacagc ctctggattc accatcagta gctaccacat gcagtgggtc 3060
cgccaggctc cagggaaggg gctggagtac atcggaacca ttagtagtgg tggtaatgta 3120
tactacgcga gctccgcgag aggcagattc accatctcca gaccctcgtc caagaacacg 3180
gtggatcttc aaatgaacag cctgagagcc gaggacacgg ctgtgtatta ctgtgcgaga 3240
gactctggtt atagtgatcc tatgtggggc cagggaaccc tggtcaccgt ctcgagcggc 3300
ggtggcggta gtgggggagg cggttctggc ggcggagggt ccggcggtgg aggatcagac 3360
gttgtgatga cccagtctcc atcttccgtg tctgcatctg taggagacag agtcaccatc 3420
acctgtcagg ccagtcagaa cattaggact tacttatcct ggtatcagca gaaaccaggg 3480
aaagccccta agctcctgat ctatgctgca gccaatctgg catctggggt cccatcaagg 3540
ttcagcggca gtggatctgg gacagatttc actctcacca tcagcgacct ggagcctggc 3600
gatgctgcaa cttactattg tcagtctacc tatcttggta ctgattatgt tggcggtgct 3660
ttcggcggag ggaccaaggt ggagatcaaa 3690
<210> 81
<211> 214
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 81
Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Ala
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 82
<211> 642
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 82
gccatccagt tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggcaagtca gggcattagc agtgctttag cctggtatca gcagaaacca 120
gggaaagctc ctaagctcct gatctatgat gcctccagtt tggaaagtgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcagcct 240
gaagattttg caacttatta ctgtcaacag tttaatagtt acccattcac tttcggccct 300
gggaccaaag tggatatcaa acgtacggtg gctgcaccat ctgtcttcat cttcccgcca 360
tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat 420
cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag 480
gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 540
ctgagcaaag cagactacga gaaacacaaa gtctacgcct gcgaagtcac ccatcagggc 600
ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gt 642
<210> 83
<211> 450
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 83
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ser Ser Ser
20 25 30
Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Tyr Pro Asp Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
50 55 60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Arg Thr Ala Tyr
65 70 75 80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg His Val Thr Met Ile Trp Gly Val Ile Ile Asp Phe Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly
450
<210> 84
<211> 1350
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 84
gaggtgcagc tggtgcagtc tggagcagag gtgaagaaac caggagagtc tctgaagatc 60
tcctgtaagg gttctggata cagctttagc agttcatgga tcggctgggt gcgccaggca 120
cctgggaaag gcctggaatg gatggggatc atctatcctg atgactctga taccagatac 180
agtccatcct tccaaggcca ggtcaccatc tcagccgaca agtccatcag gactgcctac 240
ctgcagtgga gtagcctgaa ggcctcggac accgctatgt attactgtgc gagacatgtt 300
actatgattt ggggagttat tattgacttc tggggccagg gaaccctggt caccgtctcc 360
tcagctagca ccaagggccc atcggtcttc cccctggcac cctcctccaa gagcacctct 420
gggggcacag cggccctggg ctgcctggtc aaggactact tccccgaacc ggtgacggtg 480
tcgtggaact caggcgccct gaccagcggc gtgcacacct tcccggctgt cctacagtcc 540
tcaggactct actccctcag cagcgtggtg accgtgccct ccagcagctt gggcacccag 600
acctacatct gcaacgtgaa tcacaagccc agcaacacca aggtggacaa gagagttgag 660
cccaaatctt gtgacaaaac tcacacatgc ccaccgtgcc cagcacctga actcctgggg 720
ggaccgtcag tcttcctctt ccccccaaaa cccaaggaca ccctcatgat ctcccggacc 780
cctgaggtca catgcgtggt ggtggacgtg agccacgaag accctgaggt caagttcaac 840
tggtacgtgg acggcgtgga ggtgcataat gccaagacaa agccgcggga ggagcagtac 900
aacagcacgt accgtgtggt cagcgtcctc accgtcctgc accaggactg gctgaatggc 960
aaggagtaca agtgcaaggt ctccaacaaa gccctcccag cccccatcga gaaaaccatc 1020
tccaaagcca aagggcagcc ccgagaacca caggtgtaca ccctgccccc atcccgggat 1080
gagctgacca agaaccaggt cagcctgacc tgcctggtca aaggcttcta tcccagcgac 1140
atcgccgtgg agtgggagag caatgggcag ccggagaaca actacaagac cacgcctccc 1200
gtgctggact ccgacggctc cttcttcctc tatagcaagc tcaccgtgga caagagcagg 1260
tggcagcagg ggaacgtctt ctcatgctcc gtgatgcatg aggctctgca caaccactac 1320
acgcagaaga gcctctccct gtctccgggt 1350
<210> 85
<211> 214
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 85
Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Ala
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 86
<211> 642
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 86
gccatccagt tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggcaagtca gggcattagc agtgctttag cctggtatca gcagaaacca 120
gggaaagctc ctaagctcct gatctatgat gcctccagtt tggaaagtgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcagcct 240
gaagattttg caacttatta ctgtcaacag tttaatagtt acccattcac tttcggccct 300
gggaccaaag tggatatcaa acgtacggtg gctgcaccat ctgtcttcat cttcccgcca 360
tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat 420
cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag 480
gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 540
ctgagcaaag cagactacga gaaacacaaa gtctacgcct gcgaagtcac ccatcagggc 600
ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gt 642
<210> 87
<211> 1225
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 87
Gln Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly
1 5 10 15
Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Ile
20 25 30
His Trp Phe Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr
35 40 45
Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu
65 70 75 80
Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Thr Ser Asn Pro Pro Thr
85 90 95
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Ser Gly
100 105 110
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
115 120 125
Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val
130 135 140
Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asn Met
145 150 155 160
His Trp Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile Gly Ala
165 170 175
Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly
180 185 190
Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln
195 200 205
Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg
210 215 220
Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly Ala Gly
225 230 235 240
Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
245 250 255
Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
260 265 270
Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ile Ser Thr
275 280 285
Asn Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
290 295 300
Ile Gly Val Ile Thr Gly Arg Asp Ile Thr Tyr Tyr Ala Ser Trp Ala
305 310 315 320
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
325 330 335
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
340 345 350
Ala Arg Asp Gly Gly Ser Ser Ala Ile Thr Ser Asn Asn Ile Trp Gly
355 360 365
Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
370 375 380
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
385 390 395 400
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
405 410 415
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
420 425 430
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
435 440 445
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
450 455 460
Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys
465 470 475 480
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly
485 490 495
Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
500 505 510
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
515 520 525
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
530 535 540
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
545 550 555 560
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
565 570 575
Lys Glu Tyr Lys Cys Ala Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
580 585 590
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
595 600 605
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
610 615 620
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
625 630 635 640
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
645 650 655
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
660 665 670
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
675 680 685
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
690 695 700
Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu
705 710 715 720
Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu
725 730 735
Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Gly Tyr Asp Met Cys
740 745 750
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala Cys Ile
755 760 765
Ala Ala Gly Ser Ala Gly Ile Thr Tyr Asp Ala Asn Trp Ala Lys Gly
770 775 780
Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
785 790 795 800
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
805 810 815
Ser Ala Phe Ser Phe Asp Tyr Ala Met Asp Leu Trp Gly Gln Gly Thr
820 825 830
Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
835 840 845
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln
850 855 860
Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr
865 870 875 880
Cys Gln Ala Ser Gln Ser Ile Ser Ser His Leu Asn Trp Tyr Gln Gln
885 890 895
Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Thr Leu
900 905 910
Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu
915 920 925
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr
930 935 940
Tyr Cys Gln Gln Gly Tyr Ser Trp Gly Asn Val Asp Asn Val Phe Gly
945 950 955 960
Gly Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly Ser Gly Gly Gly
965 970 975
Gly Ser Gly Arg Ser Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro
980 985 990
Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Ile Ser
995 1000 1005
Ser Tyr His Met Gln Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
1010 1015 1020
Tyr Ile Gly Thr Ile Ser Ser Gly Gly Asn Val Tyr Tyr Ala Ser Ser
1025 1030 1035 1040
Ala Arg Gly Arg Phe Thr Ile Ser Arg Pro Ser Ser Lys Asn Thr Val
1045 1050 1055
Asp Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
1060 1065 1070
Cys Ala Arg Asp Ser Gly Tyr Ser Asp Pro Met Trp Gly Gln Gly Thr
1075 1080 1085
Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1090 1095 1100
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln
1105 1110 1115 1120
Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr
1125 1130 1135
Cys Gln Ala Ser Gln Asn Ile Arg Thr Tyr Leu Ser Trp Tyr Gln Gln
1140 1145 1150
Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ala Asn Leu
1155 1160 1165
Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
1170 1175 1180
Phe Thr Leu Thr Ile Ser Asp Leu Glu Pro Gly Asp Ala Ala Thr Tyr
1185 1190 1195 1200
Tyr Cys Gln Ser Thr Tyr Leu Gly Thr Asp Tyr Val Gly Gly Ala Phe
1205 1210 1215
Gly Gly Gly Thr Lys Val Glu Ile Lys
1220 1225
<210> 88
<211> 3678
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 88
cagatcgtgc tgagccagag ccccgccatc ctgagcgcca gccccggcga gaaggtgacc 60
atgacctgcc gggccagcag cagcgtgagc tacatccact ggttccagca gaagcccggc 120
agcagcccca agccctggat ctacgccacc agcaacctgg ccagcggcgt gcccgtgcgg 180
ttcagcggca gcggcagcgg caccagctac agcctgacca tcagccgggt ggaggccgag 240
gacgccgcca cctactactg ccagcagtgg accagcaacc cccccacctt cggcggcggc 300
accaagctga ccgtgctggg tggtggtggc tctggaggag gcgggagcgg gggtggtggc 360
tcaggtggtg gaggttccca ggtgcagctg cagcagcccg gcgccgagct ggtgaagccc 420
ggcgccagcg tgaagatgag ctgcaaggcc agcggctaca ccttcaccag ctacaacatg 480
cactgggtga agcagacccc cggccggggc ctggagtgga tcggcgccat ctaccccggc 540
aacggcgaca ccagctacaa ccagaagttc aagggcaagg ccaccctgac cgccgacaag 600
agcagcagca ccgcctacat gcagctgagc agcctgacca gcgaggacag cgccgtgtac 660
tactgcgccc ggagcaccta ctacggcggc gactggtact tcaacgtgtg gggcgccggc 720
accaccgtga ccgtctcgag tggcggtgga gggtccggcg gtggtggatc agaggtgcag 780
ctggtggagt ctgggggagg cttggtccag cctggggggt ccctgagact ctcctgtgca 840
gcctctggat tcaccatcag taccaatgca atgagctggg tccgccaggc tccagggaag 900
gggctggagt ggatcggagt cattactggt cgtgatatca catactacgc gagctgggcg 960
aaaggcagat tcaccatctc cagagacaat tccaagaaca cgctgtatct tcaaatgaac 1020
agcctgagag ccgaggacac ggctgtgtat tactgtgcga gagacggtgg ttcttctgct 1080
attactagta acaacatttg gggccaggga accctggtca ccgtgtcctc agctagcacc 1140
aagggcccat cggtcttccc cctggcaccc tcctccaaga gcacctctgg gggcacagcg 1200
gccctgggct gcctggtcaa ggactacttc cccgaaccgg tgacggtgtc gtggaactca 1260
ggcgccctga ccagcggcgt gcacaccttc ccggctgtcc tacagtcctc aggactctac 1320
tccctcagca gcgtggtgac cgtgccctcc agcagcttgg gcacccagac ctacatctgc 1380
aacgtgaatc acaagcccag caacaccaag gtggacaaga gagttgagcc caaatcttgt 1440
gacaaaactc acacatgccc accgtgccca gcacctgaag ccgcgggggc accgtcagtc 1500
ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca 1560
tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac 1620
ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa cagcacgtac 1680
cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag 1740
tgcgcggtct ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa 1800
gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggatga gctgaccaag 1860
aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag 1920
tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc 1980
gacggctcct tcttcctcta tagcaagctc accgtggaca agagcaggtg gcagcagggg 2040
aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc 2100
ctctccctgt ctccgggtgg cggtggaggg tccggcggtg gtggatccga ggtgcagctg 2160
ttggagtctg ggggaggctt ggtacagcct ggggggtccc tgagactctc ctgtgcagcc 2220
tctggattct ccttcagtag cgggtacgac atgtgctggg tccgccaggc tccagggaag 2280
gggctggagt ggatcgcatg cattgctgct ggtagtgctg gtatcactta cgacgcgaac 2340
tgggcgaaag gccggttcac catctccaga gacaattcca agaacacgct gtatctgcaa 2400
atgaacagcc tgagagccga ggacacggcc gtatattact gtgcgagatc ggcgttttcg 2460
ttcgactacg ccatggacct ctggggccag ggaaccctgg tcaccgtgtc gagcggtgga 2520
ggcggatctg gcggaggtgg ttccggcggt ggcggctccg gtggaggcgg ctctgacatc 2580
cagatgaccc agtctccttc caccctgtct gcatctgtag gagacagagt caccatcact 2640
tgccaggcca gtcagagcat tagttcccac ttaaactggt atcagcagaa accagggaaa 2700
gcccctaagc tcctgatcta taaggcatcc actctggcat ctggggtccc atcaaggttc 2760
agcggcagtg gatctgggac agaatttact ctcaccatca gcagcctgca gcctgatgat 2820
tttgcaactt attactgcca acagggttat agttggggta atgttgataa tgttttcggc 2880
ggagggacca aggtggagat caaaggcggt ggagggtccg gcggtggtgg ctccggacgg 2940
tcgctggtgg agtctggggg aggcttggtc cagcctgggg ggtccctgag actctcctgt 3000
actgcctctg gattcaccat cagtagctac cacatgcagt gggtccgcca ggctccaggg 3060
aaggggctgg agtacatcgg aaccattagt agtggtggta atgtatacta cgcaagctcc 3120
gctagaggca gattcaccat ctccagaccc tcgtccaaga acacggtgga tcttcaaatg 3180
aacagcctga gagccgagga cacggctgtg tattactgtg cgagagactc tggttatagt 3240
gatcctatgt ggggccaggg aaccctggtc accgtctctt caggcggtgg cggtagtggg 3300
ggaggcggtt ctggcggcgg agggtccggc ggtggaggat cagacgttgt gatgacccag 3360
tctccatctt ccgtgtctgc atctgtagga gacagagtca ccatcacctg tcaggccagt 3420
cagaacatta ggacttactt atcctggtat cagcagaaac cagggaaagc ccctaagctc 3480
ctgatctatg ctgcagccaa tctggcatct ggggtcccat caaggttcag cggcagtgga 3540
tctgggacag atttcactct caccatcagc gacctggagc ctggcgatgc tgcaacttac 3600
tattgtcagt ctacctatct tggtactgat tatgttggcg gtgctttcgg cggagggacc 3660
aaggtggaga tcaaatga 3678
<210> 89
<211> 475
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 89
Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly
1 5 10 15
Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Gln Gly Thr Lys Val Thr Val Leu Gly Gly Gly Gly Ser Gly
100 105 110
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
115 120 125
Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu
130 135 140
Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met
145 150 155 160
Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
165 170 175
Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys
180 185 190
Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu
195 200 205
Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
210 215 220
Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
225 230 235 240
Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
245 250 255
Asp Val Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
260 265 270
Asp Arg Val Thr Ile Asn Cys Gln Ala Ser Glu Ser Ile Ser Ser Trp
275 280 285
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
290 295 300
Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
305 310 315 320
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
325 330 335
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Tyr Phe Tyr Phe Ile Ser
340 345 350
Arg Thr Tyr Val Asn Ser Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
355 360 365
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
370 375 380
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
385 390 395 400
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
405 410 415
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
420 425 430
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
435 440 445
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
450 455 460
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
465 470 475
<210> 90
<211> 1425
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 90
gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact 60
atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga 120
caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc 180
ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa 240
gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg 300
acaaaagtga cggtactggg tggaggcggt tcaggcggag gtggttccgg cggtggcggc 360
tccggtggag gcggctctca ggtcacattg aaggaatctg gccccggcct tgttcagcca 420
ggacagaccc ttaggctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg 480
ggggtcggct ggattcggca gcctcccggc aaaggtcttg agtggttggc tcacatttgg 540
tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat 600
acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta 660
tattattgcg cgcggatgga actctggtct tactactttg attattgggg gcaggggact 720
ctcgtcacgg tctcgagcgg cggtggaggg tccggcggtg gtggatcaga cgtcgtgatg 780
acccagtctc cttccaccct gtctgcatct gtaggagaca gagtcaccat caattgccaa 840
gccagtgaga gcattagcag ttggttagcc tggtatcagc agaaaccagg gaaagcccct 900
aagctcctga tctatgaagc atccaaactg gcatctgggg tcccatcaag gttcagcggc 960
agtggatctg ggacagaatt cactctcacc atcagcagcc tgcagcctga tgattttgca 1020
acttattact gccaaggcta tttttatttt attagtcgta cttatgtaaa ttctttcggc 1080
ggagggacca aggtggagat caaacgtacg gtggctgcac catctgtctt catcttcccg 1140
ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc 1200
tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc 1260
caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg 1320
acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag 1380
ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgt 1425
<210> 91
<211> 120
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 91
Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln
1 5 10 15
Thr Leu Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Cys Leu Glu
35 40 45
Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80
Tyr Leu Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 92
<211> 360
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 92
caggtcacat tgaaggaatc tggccccggc cttgttcagc caggacagac ccttaggctc 60
acctgtgcct tcagtggttt ttctcttagc actagcggta tgggggtcgg ctggattcgg 120
cagcctcccg gcaaatgtct tgagtggttg gctcacattt ggtgggacga cgacaaacgg 180
tataatcctg ccttgaaaag tcggctgacc attagtaagg atacctcaaa aaatcaagtg 240
tacttgcaaa tgaatagcct tgacgccgag gatacggctg tatattattg cgctcggatg 300
gaactctggt cttactactt tgattattgg gggcagggga ctctcgtcac ggtgtcgagt 360
<210> 93
<211> 106
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 93
Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly
1 5 10 15
Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Cys Gly Thr Lys Val Glu Ile Lys
100 105
<210> 94
<211> 318
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 94
gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact 60
atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga 120
caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc 180
ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa 240
gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggtgtggg 300
acaaaagtgg agatcaag 318
<210> 95
<211> 246
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 95
Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly
1 5 10 15
Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr
85 90 95
Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly Ser Gly
100 105 110
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
115 120 125
Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu
130 135 140
Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met
145 150 155 160
Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Cys Leu Glu Trp Leu
165 170 175
Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys
180 185 190
Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu
195 200 205
Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
210 215 220
Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
225 230 235 240
Leu Val Thr Val Ser Ser
245
<210> 96
<211> 738
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized
<400> 96
gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact 60
atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga 120
caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc 180
ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa 240
gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggtgtggg 300
acaaaagtgg agatcaaggg tggcggaggc agtggtggcg ggggcagcgg aggtggtggt 360
tcagggggtg gtgggagcca ggtcacattg aaggaatctg gccccggcct tgttcagcca 420
ggacagaccc ttaggctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg 480
ggggtcggct ggattcggca gcctcccggc aaatgtcttg agtggttggc tcacatttgg 540
tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat 600
acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta 660
tattattgcg ctcggatgga actctggtct tactactttg attattgggg gcaggggact 720
ctcgtcacgg tgtcgagt 738

Claims (35)

1.一种对人CD19具有结合特异性的肽，包含与SEQ ID NO.1、3、5、7、9、11、13、15、17、19、21、23、91或93具有至少98％的序列同一性的氨基酸序列。
2.一种scFv肽，其包含权利要求1所述的肽。
3.根据权利要求2所述的scFv肽，其对人CD19的结合亲和力的KD不大于10nM。
4.一种对人CD19具有结合特异性的抗体，其中所述抗体包含权利要求1所述的肽。
5.根据权利要求4所述的抗体，其中所述抗体是多特异性抗体。
6.根据权利要求4所述的抗体，其包含scFv，其中所述scFv包含权利要求1所述的肽。
7.根据权利要求4所述的抗体，其包含Fab，其中所述Fab包含权利要求1所述的肽。
8.一种包含权利要求1所述的肽的多特异性抗体样蛋白，其中所述多特异性抗体样蛋白具有N-末端和C-末端，所述多特异性抗体样蛋白从N-末端到C-末端依次包含所述N-末端的第一结合结构域(D1)、包含轻链部分的第二结合结构域(D2)、Fc区、第三结合结构域(D3)和所述C-末端的第四结合结构域(D4)，
其中所述轻链部分包含共价连接到所述C-末端的第五结合结构域(D5)、共价连接到所述N-末端的第六结合结构域(D6)或两者，以及
其中D1、D2、D3、D4、D5和D6各自对肿瘤抗原、免疫信号抗原或其组合具有结合特异性。
9.根据权利要求8所述的多特异性抗体样蛋白，其中D1包含权利要求1所述的肽。
10.根据权利要求8所述的多特异性抗体样蛋白，其中D1包含肽，所述肽具有与SEQ IDNO.7或19具有95％的序列同一性的氨基酸序列。
11.根据权利要求8所述的多特异性抗体样蛋白，其中D2包含权利要求1所述的肽。
12.根据权利要求8所述的多特异性抗体样蛋白，其中D2包含肽，所述肽具有与SEQ IDNO.91或93具有95％的序列同一性的氨基酸序列。
13.根据权利要求8所述的多特异性抗体样蛋白，其中D6包含权利要求1所述的肽。
14.根据权利要求8所述的多特异性抗体样蛋白，其中D6包含肽，所述肽具有与SEQ IDNO.7或19具有95％的序列同一性的氨基酸序列。
15.一种多特异性单克隆抗体，包含权利要求8所述的多特异性抗体样蛋白。
16.根据权利要求15所述的多特异性单克隆抗体，其对人CD19的结合亲和力的Kd不大于10nM。
17.根据权利要求15所述的多特异性抗体，其中所述抗体是人源化抗体。
18.根据权利要求15所述的多特异性样蛋白，其中所述抗体为IgG。
19.一种分离的核酸序列，其编码权利要求15所述的多特异性单克隆抗体的氨基酸序列。
20.一种表达载体，其包含权利要求19所述的分离的核酸。
21.一种宿主细胞，其包含权利要求19所述的核酸，其中所述宿主细胞为原核细胞或真核细胞。
22.一种产生抗体的方法，包括培养权利要求21所述的宿主细胞以产生所述抗体。
23.一种免疫缀合物，其包含权利要求15所述的多特异性单克隆抗体和药物单元，其中所述药物单元通过接头与所述多特异性单克隆抗体连接，并且其中所述接头包含选自酯键、醚键、胺键、酰胺键、二硫键、酰亚胺键、砜键、磷酸酯键、磷酯键、肽键、腙键或其组合的共价键。
24.根据权利要求23所述的免疫缀合物，其中所述药物单元包含细胞毒性剂、免疫调节试剂、显像剂或其组合。
25.根据权利要求24所述的免疫缀合物，其中所述细胞毒性剂选自生长抑制剂或来自一类微管蛋白结合剂、DNA嵌入剂、DNA烷化剂、酶抑制剂、免疫调节剂、抗代谢剂、放射性同位素或其组合的化学治疗剂。
26.根据权利要求24所述的免疫缀合物，其中所述细胞毒性剂选自卡奇霉素、喜树碱、奥唑米星、一甲基澳瑞他汀E、曲妥珠单抗、其衍生物或组合。
27.根据权利要求24所述的免疫缀合物，其中所述免疫调节试剂激活或抑制免疫细胞、T细胞、NK细胞、B细胞、巨噬细胞或树突细胞。
28.根据权利要求24所述的免疫缀合物，其中所述显像剂可以是放射性核素、荧光剂、量子点或其组合。
29.一种药物组合物，其包含权利要求15所述的多特异性单克隆抗体和药学上可接受的载体。
30.根据权利要求29所述的药物组合物，还可包含化学治疗剂、生长抑制剂、来自一类卡奇霉素、抗有丝分裂剂、毒素、放射性同位素、治疗剂或其组合的细胞毒性剂。
31.一种药物组合物，其包含权利要求24所述的免疫缀合物和药学上可接受的载体。
32.一种治疗患有癌症的受试者的方法，其包括向所述受试者施用有效量的权利要求15所述的多特异性单克隆抗体。
33.根据权利要求32所述的方法，其还包括共施用有效量的治疗剂，其中所述治疗剂包括抗体、化学治疗剂、酶或其组合。
34.根据权利要求33所述的方法，其中所述受试者是人。
35.一种包含有效浓度的权利要求15所述的多特异性单克隆抗体的溶液，其中所述溶液是受试者的血浆。
CN202180005432.XA 2020-03-03 2021-02-27 抗cd19抗体及其使用和制备方法 Active CN114502151B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062984731P 2020-03-03 2020-03-03
US62/984,731 2020-03-03
PCT/US2021/020145 WO2021178253A1 (en) 2020-03-03 2021-02-27 Anti-cd19 antibodies and methods of using and making thereof

Publications (2)

Publication Number Publication Date
CN114502151A true CN114502151A (zh) 2022-05-13
CN114502151B CN114502151B (zh) 2024-10-25

Family

ID=

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996036360A1 (en) * 1995-05-17 1996-11-21 Regents Of The University Of Minnesota Immunoconjugates comprising single-chain variable region fragments of anti-cd-19 antibodies
US20050070693A1 (en) * 2003-07-31 2005-03-31 Immunomedics, Inc. Therapy using anti-CD-19 antibodies
US20100068136A1 (en) * 2003-07-31 2010-03-18 Immunomedics, Inc. Anti-CD19 Antibodies
WO2018183494A1 (en) * 2017-03-31 2018-10-04 Immunogen, Inc. Cd19-targeting antibody-drug conjugates
CN110545883A (zh) * 2017-04-24 2019-12-06 凯德药业股份有限公司 针对cd19的人源化抗原结合结构域及其使用方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996036360A1 (en) * 1995-05-17 1996-11-21 Regents Of The University Of Minnesota Immunoconjugates comprising single-chain variable region fragments of anti-cd-19 antibodies
US20050070693A1 (en) * 2003-07-31 2005-03-31 Immunomedics, Inc. Therapy using anti-CD-19 antibodies
US20100068136A1 (en) * 2003-07-31 2010-03-18 Immunomedics, Inc. Anti-CD19 Antibodies
WO2018183494A1 (en) * 2017-03-31 2018-10-04 Immunogen, Inc. Cd19-targeting antibody-drug conjugates
CN110545883A (zh) * 2017-04-24 2019-12-06 凯德药业股份有限公司 针对cd19的人源化抗原结合结构域及其使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
陈森, 饶青, 王建祥, 王敏: "抗人CD19单链抗体基因的构建、表达及功能测定", 生物工程学报, vol. 21, no. 05, pages 686 - 691 *

Also Published As

Publication number Publication date
EP4114373A4 (en) 2024-05-01
JP2023516344A (ja) 2023-04-19
KR20220149573A (ko) 2022-11-08
CA3173980A1 (en) 2021-09-10
US20230086069A1 (en) 2023-03-23
BR112022017595A2 (pt) 2022-10-18
EP4114373A1 (en) 2023-01-11
MX2022010915A (es) 2022-10-07
AU2021231712A1 (en) 2022-10-06
TW202146454A (zh) 2021-12-16
WO2021178253A1 (en) 2021-09-10
IL295993A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
CN110869389B (zh) 抗ror1抗体及其制备和使用方法
AU2021203876A1 (en) Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
KR102182485B1 (ko) 단백질 약물의 불활성화를 위한 항체 로커
KR102361237B1 (ko) 코일드 코일 면역글로불린 융합 단백질 및 이것의 조성물
DK2519543T3 (en) HETERODIMER BINDING PROTEINS AND USE THEREOF
RU2753902C2 (ru) Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
KR20210134300A (ko) 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
CN111954680B (zh) IL2Rβ/共同γ链抗体
KR101459159B1 (ko) Ｏｘ-2/ｃｄ200에 대한 항체 및 이들의 용도
KR20210013156A (ko) 항-cd33 항체, 항-cd33/항-cd3 이중특이성 항체, 및 이의 용도
KR20180099723A (ko) 항-tl1a/항-tnf-알파 이중특이적 항원 결합 단백질 및 그의 용도
CN110845618A (zh) 双特异性t细胞活化抗原结合分子
TW202400655A (zh) 使用胃抑肽受體(gipr)結合蛋白與glp-1促效劑之組合來治療或改善代謝病症之方法
CN112210000A (zh) 突变体白介素-2多肽
KR20220040483A (ko) 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는 단백질 및 이의 용도
CN110869392A (zh) 用抗gitr激动性抗体治疗癌症
CN111448323B (zh) 精确制导的多功能治疗抗体
KR20230017841A (ko) Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
CN113493506A (zh) 新型冠状病毒抗体及其应用
CN107949575B (zh) Cys80缀合型免疫球蛋白
KR20220154710A (ko) 소형 유도 및 항법 제어(miniGNC) 항체-유사 단백질 및 이의 제조 및 사용 방법
KR20230142482A (ko) 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는면역접합체 및 이의 용도
KR20230017815A (ko) 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
TW202216743A (zh) Ｉｌ－１０突變蛋白及其融合蛋白
CN114502151B (zh) 抗cd19抗体及其使用和制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220601

Address after: No. 15318, 95 Street northeast, Redmond, Washington, U. S.

Applicant after: Seattle Immunization Co.

Applicant after: Chengdu bailidote Biological Pharmaceutical Co.,Ltd.

Address before: No. 15318, 95 Street northeast, Redmond, Washington, U. S.

Applicant before: Seattle Immunization Co.

Applicant before: SICHUAN BAILI PHARM Co.,Ltd.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40065811

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240625

Address after: No. 139 Baili Road, Chengdu Cross Strait Science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province, 611130

Applicant after: Chengdu bailidote Biological Pharmaceutical Co.,Ltd.

Country or region after: China

Address before: 15318 Northeast 95th Street, Redmond, Washington, USA

Applicant before: Seattle Immunization Co.

Country or region before: U.S.A.

Applicant before: Chengdu bailidote Biological Pharmaceutical Co.,Ltd.

Country or region before: China

GR01 Patent grant